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ABSTRACT 
 
A SYSTEMS APPROACH TO HEMOSTASIS: HOW THE FEEDBACK BETWEEN 
THROMBUS STRUCTURE AND MOLECULAR TRANSPORT REGULATES THE 
HEMOSTATIC RESPONSE 
John Douglas Welsh 
Dr. Lawrence Brass 
Dr. Scott Diamond 
 
After vascular injury numerous chemical signals are released to induce platelet 
activation, coagulation, and post-hemostatic events. This thesis aims to investigate the 
interplay between thrombus structure and the spatiotemporal distribution and transport 
of biologically relevant solutes, and how this impacts thrombus formation in vivo. Using 
intravital microscopy we have previously described a characteristic architecture of 
thrombi formed in vivo. The architecture consists of a core of highly-activated and tightly 
packed platelets covered by a loose shell of less activated platelets. Initially, we 
developed a novel platelet-targeted sensor capable of reporting on thrombin activity, a 
potent platelet agonist, within thrombi formed ex vivo or in vivo. We found that thrombin 
activity was high in the core region, but restricted from the shell. We then designed 
another sensor capable of tracking soluble protein transport within thrombi formed in 
vivo, and found significant retention of soluble proteins within the platelets that would go 
on to form the core region. Using computational methods we found that the platelet 
packing density between the platelets restricted the diffusion of proteins within the core 
region, and allowed for rapid elution of proteins that made it to the shell. To test this in 
vivo we used mice with a defect in platelet retraction, but not platelet sensitivity to 
vi	  
	  
agonists. The mutant mice showed a much faster rate of solute elution using our 
transport sensor, and we also observed decreased platelet activation and thrombin 
activity within the thrombus. Next, we extended this model of thrombi as regulators of 
protein transport by examining how thrombus architecture altered the leakage of plasma 
proteins into the surrounding tissue. We found that extravascular solute gradients were 
sensitive to commonly used anti-platelet agents as well as small changes in platelet 
packing densities. Finally, we developed a new intravital imaging technique to visualize 
thrombus architecture formation in the mouse femoral artery and vein to extend our 
observations into the macrocirculation. Together, this thesis proposes a novel 
mechanism of thrombus regulation, which is dependent upon molecular transport 
properties shaped by the local hemodynamics and the intrathrombus microenvironment. 
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CHAPTER 1: The biochemistry and biophysics of thrombus formation 
	  
1.1 Thrombus formation and architectural differentiation 
 
In response to vascular damage, circulating platelets become activated and aggregate at 
the site of injury. Reinforced by fibrin, the platelet mass forms a hemostatic plug capable 
of preventing blood loss and restoring local hemodynamics. Disruption of this process 
can result in either continued blood loss from the injury site, or excessive thrombus 
formation that occludes the vessel and causes ischemic injury to the surrounding tissue.   
 
Circulating platelets remain quiescent and free from adhesion and aggregation due to 
endothelial signaling, and a lack of activating signals. However, upon vessel damage 
platelet activation is initiated by a variety of agonists. Extensive studies 1-6 have 
produced a general model of how agonists induce thrombus formation. Vessel wall 
damage exposes subendothelial matrix proteins, such as collagen, inducing platelet 
adhesion and subsequent activation. Von Willebrand Factor (vWF), released from 
damaged endothelial cells or circulating in the plasma, binds to both collagen and 
platelets facilitating further platelet accumulation and activation. In response to sufficient 
activation platelet δ-granules are secreted releasing small molecule agonists, namely 
ADP and thromboxane A2 (TxA2), which further drive local platelet activation. 
Concurrently, thrombin generation is initiated on the surface of the damaged endothelial 
cells and platelet membranes exposing phosphotidylserine (PS). Thrombin production 
drives both potent platelet activation and fibrin deposition, which helps to increase 
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thrombus stability. These various activating signals are then integrated by the adherent 
platelets, resulting in a mass of activated platelets and fibrin covering the injury site.  
 
Numerous studies have found that platelet activation, granule release, platelet packing 
density, and fibrin distribution are heterogeneous within thrombi formed both in vivo and 
ex vivo 7-12. Our recent studies, using in vivo models of hemostatic thrombus formation, 
in the mouse microvasculature, have revealed that this heterogeneity can be classified 
into a hierarchical architecture. This architecture consists of a core of highly-activated 
platelets covered by a shell of less-activated platelets. The core is differentiated from the 
shell by surface P-selectin expression, indicating sufficient activation to induce α-granule 
exocytosis. Also the platelets within the core region have an increased packing density 
and stability compared to the shell 12. Finally, the core region is also enriched with fibrin 
deposition compared to the shell, due to increased local thrombin activity.  This 
architecture consistently forms in response to mechanical or laser induced penetrating 
injuries in the mouse microcirculation, and is reproduced in microfluidic models of 
thrombus formation using human blood 13. Despite the consistency of the observation of 
the core/shell architecture, it is unclear what role it has in regulating hemostasis or 
thrombosis.  
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Figure 1- 1 Architecture of a hemostatic thrombus formed in a mouse cremaster 
arteriole after laser injury. 
A representative image of a thrombus formed 10 minutes after laser injury of a mouse 
cremaster arteriole (bright field). Platelets are labeled with anti-CD41 antibody (blue), 
and surface P-selectin is visualized with anti-CD62P antibody (red). Thus the core of P-
selectin positive platelets is pink, and the shell is the P-selectin negative blue region. 
 
1.2 Pathological thrombus architecture in humans. 
 
While the core-shell architecture observed in the mouse is reproduced with human blood 
in microfluidic devices, the architecture of thrombi formed under pathological conditions 
in humans is difficult to ascertain. Microvascular thrombi are difficult to study in human 
patients as they are not typically removed from the patient, and are too small for 
structural analysis. The mechanism behind microvascular thrombosis is also quite 
different from analysis of hemostatic thrombi formed in vivo. Microvascular thrombosis is 
often induced by systemic defects such as - sepsis, disseminated intravascular 
coagulation, heparin induced thrombocytopenia – which present several key differences 
compared to discrete vascular injuries. These disorders lead to circulating agonists such 
as lipopolysaccharide (LPS), thrombin, and high molecular weight vWF driving systemic 
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platelet activation 14-18. Also local inflammation and circulating thrombin drive extensive 
endothelial cell activation leading to multiple sites of platelet adhesion and nucleation 
points for thrombus formation 14-16,19-21. This is in stark contrast to hemostatic thrombus 
formation in which a discrete injury induces local agonist production and thrombin 
generation, and at least during initial thrombus formation, appears to be largely 
independent of inflammatory pathways or cells. 
 
Venous macrovascular thrombi, resulting from deep vein thrombosis (DVT), are able to 
be isolated and the structure analyzed. DVT results in formation of red clots consisting of 
a mix of platelets, inflammatory cells, red cells, fibrin, and DNA (NETs). This structure is 
quite different from the white clots formed ex vivo with human blood and in vivo with 
mice using hemostatic models, which consist mainly of platelets with fibrin deposited at 
the injury site and within the core region 12,13,22. These differences in thrombus structure 
are likely due to the different mechanisms of thrombus initiation and local 
hemodynamics. DVT is initiated by activated inflammatory cells and endothelial cells in 
the presences of very low blood flow, leading to the release of vWF from endothelium, 
and initiation of thrombin production on the surface of inflammatory cells and NETs 
released from neutrophils. Together, these events activate platelets, drive fibrin 
deposition 23-25, which along with NETs and inflammatory cells are all capable of trapping 
red cells under low flow conditions 23,26,27.   
 
Similarly, studies of the composition of coronary thrombi showed that they had a much 
more heterogeneous structure than observed ex vivo or in vivo. Thrombi removed from 
patients after coronary plaque rupture consisted mostly of fibrin with almost equal parts 
of red cells and platelets, and a large component of cholesterol crystals 28. Also 
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observed in coronary thrombosis is the formation of the Lines of Zahn, which are formed 
by overlaying regions of platelets/fibrin and red cells forming distinct regions 29. Also of 
note is the difference in fibrin deposition, which is in close proximity to the injury site in 
the mouse model, but is deposited throughout the thrombi formed in human coronary 
arteries 28,30.  
 
However, it is possible that initial pathological thrombus growth in both DVT and arterial 
plaque rupture is similar to events we observe during hemostatic thrombus formation in 
mice and human blood ex vivo. It has been noted that at the site of plaque rupture a 
platelet head is commonly formed, suggesting that initial thrombus formation is a platelet 
driven response as we see in the mouse 30. Similarly, the initiation of DVT thrombus 
formation is dependent upon circulating platelet accumulation 23-25. This suggests that in 
both of these pathologies canonical thrombus formation is platelet dependent, and may 
mirror platelet recruitment events observed in laboratory models. The disparities in 
thrombus structure, such as increased fibrin deposition and red cell incorporation, is 
correlated with increased times of ischemia after plaque rupture or low flow conditions 
during DVT, suggesting that these thrombus growth events are dependent upon low flow 
conditions 28,31. Therefore the events we observe in vivo and ex vivo, under flow 
conditions, may mirror the initial thrombus formation during pathological thrombus 
formation, but in the healthy mouse vasculature thrombus formation fails to occlude the 
vessel preventing increased local thrombin activity driving fibrin deposition and red cell 
entrapment.  
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Figure 1- 2  Model of hemostatic and pathological thrombus formation 
(A) A model of hemostatic thrombus formation. Rapid platelet accumulation is followed 
by local thrombin activity that drives further platelet activation and fibrin deposition at the 
injury site. Continued flow delivers anti-thrombotic compounds and elutes thrombin from 
the thrombus. (B) A model of pathological thrombus formation. Initial platelet deposition 
leads to vessel occlusion allowing for continued thrombin activity driving extensive fibrin 
deposition and red cell entrapment. 
 
1.3 The spatiotemporal distribution of agonists drives thrombus architecture. 
 
The differentiation of the thrombus architecture into the core and shell regions is driven 
by differences in the distributions of the various platelet agonists during thrombus 
formation. In our previous studies of thrombus architecture in the mouse microcirculation 
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we found that inhibition of thrombin activity prevented the formation of the core region, 
while blockade of ADP P2Y12 receptors with cangrelor or TxA2 formation with aspirin led 
to shell depletion without any effect on the core. Therefore we concluded that, in the 
mouse microcirculation, core formation is thrombin driven, and that ADP and TXA2 
recruit the shell 12. However, whether or not this specific pattern of agonist driven 
architecture formation is consistent in other injury models or vasculatures is unknown.  
 
Figure 1- 3  Model of agonist distributions and resulting thrombus architecture 
in the mouse microvasculature injury model. 
After laser induced injury to the mouse microvasculature endothelium thrombin soluble 
agonists are released/formed at the injury site. Thrombin activity is localized to the core 
region and drives α-granule release and fibrin deposition. ADP and TXA2 released from 
activated platelets extend beyond the core and recruit circulating platelets which make 
up the shell region. 
 
Agonist distributions are shaped by the kinetics and location of agonist release or 
generation, as well as the transport properties of the agonist. For example, collagen 
exposed at the injury site is in the vessel wall and immobile, thus adherent platelets 
rapidly cover the exposed collagen limiting the effects of collagen/GPVI signaling. 
Conversely, ADP is released from sufficiently activated platelets at various times and 
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locations during thrombus formation, and is highly diffusible within the intrathrombus 
environment 1. Thrombin generation is dependent upon the accumulation of multiple 
coagulation factors on procoagulant surfaces formed after injury. Formation of the 
membrane-bound prothrombinase complex leads to prothrombin cleavage into thrombin. 
Once released from the prothrombinase complex, thrombin is free to diffuse within the 
thrombus. However, thrombin is less diffusible than small molecule agonists, and is 
capable of being sequestered by multiple binding partners including: fibrin, 
thrombomodulin on endothelial cells, GPIb, PAR-1 and -4 on platelets, and antithrombin 
III in plasma 1,32. These various factors all contribute the distribution of agonists, and thus 
platelet activation and fibrin deposition, within the forming thrombus.   
 
Agonist production is also dependent upon the mechanism and extent of injury, and the 
vascular bed which is being injured 33-35. Generally, all injuries create thrombi that are 
sensitive to αIIbβ3 and P2Y12 antagonists, but the contribution of thrombin and collagen 
signaling are dependent upon injury type and severity 36,37. In the cremaster arterioles 
inhibition of thrombin activity reduces thrombus size by 80-90% and abolishes P-
selectin(+) core formation 12. However, it has also been reported that in the mesentery 
arterioles thrombin activity is dependent upon injury severity 36,38,39, with more mild 
penetrating injuries being dependent upon thrombin and collagen induced signaling, and 
severe injuries shifting to more thrombin signaling dependency 36.  In the venous 
macrocirculation, Getz et al., showed that low tissue factor mice had no hemostatic 
defect in response to laser induced vessel rupture 40, suggesting a limited role for 
thrombin. Similar to thrombin, the importance of GPVI signaling during thrombus 
formation is dependent upon the mechanism and extent of injury. In models of injury in 
which there is extensive endothelial cell denudation, exposing subendothelial collagen, 
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GPVI signaling is crucial in driving thrombus formation 39,41-43. In general, increasing the 
severity of penetrating injuries increases the importance of thrombin signaling and 
lessens the impact of GPVI defects 36-39. Endothelial denudation by mechanical pinching 
of the abdominal aorta shows thrombus dependence on GPVI signaling 44, however, a 
similar injury technique used in the carotid artery demonstrated thrombus formation was 
independent of GPVI signaling 37, suggesting that variations in vessel biology also 
impact agonist exposure/production. Similarly, even within the same tissue arteries and 
veins also have different mechanisms underlying thrombus formation 33,34. Therefore 
local agonist concentrations impact thrombus development, but their relative contribution 
appears dependent upon the biology of the injured vessel, the extent and mechanism of 
injury, and the transport properties of the agonists at the site of injury. 
 
Differences in thrombus formation in the macro- and microcirculation are of specific 
interest because clinically relevant thrombosis often occurs in the macrovasculature, but 
current intravital imaging techniques are limited to the microvasculature. Therefore, the 
architecture and dynamics of thrombus formation in these larger vessels are largely 
unknown. The macro- and microcirculation differ in hemodynamics 45-47 and vessel wall 
structure 48, and biology 49,50. Therefore, agonist production and retention may be vastly 
different between the vasculatures, which raises interesting questions about how 
thrombus formation and architecture may vary between the macro- and microcirculation. 
 
1.4 The intrathrombus microenvironment impacts solute transport and 
thrombus formation 
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As described above, agonist distribution is a critical factor responsible for the observed 
differences in the extent of platelet activation, and the distribution of soluble agonists is 
highly dependent on the physical architecture of the platelet mass as it evolves.  The 
microenvironment within the platelet mass consists of aggregated platelets and fibrin 
densely packed together, the structure of which we have only recently been able to be 
interrogate in real time and under physiological conditions. In this regard, the use of 
microfluidic devices has allowed for accurate measurement of the permeability of human 
platelet aggregates formed under flow conditions. Using such an approach, a mature 
platelet mass was found to have a permeability approaching that of an intact endothelial 
cell layer (2 x 10-14 cm2) 51.  This permeability was increased by 3-fold when platelet 
retraction was inhibited and 2-fold when fibrin formation was blocked, highlighting the 
importance of these events in regulating this property of a platelet plug 51. Detailed 
measurements of thrombus permeability in vivo are difficult, so investigators have 
instead used computational modeling based in images of thrombus structure obtained in 
vivo.  One study examining a platelet plug with the core and shell architecture described 
above determined that the core region has greatly reduced permeability (100-fold) and 
greatly increased tortuosity in the paths between platelets compared to the shell 52. 
Taken together, the in vitro, in silico and in vivo findings demonstrate that the 
microenvironment of a hemostatic plug is a dense mesh of platelets and proteins with 
winding and narrow gaps, which restrict solute movement, particularly in the core region. 
 
Computational models of platelet plugs formed in situ, in vitro or in vivo all show that low 
permeability will greatly reduce plasma flow within the intraplug microenvironment 
compared to the lumen 52-55. The reduction of flow also means a reduction in the rate of 
solute transport within the platelet plug 52,53,55,56. Importantly, under low flow conditions 
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within the platelet plug microenvironment the diffusibility of a solute becomes a dominant 
factor in its transport properties 51,52,55. Solute diffusibility is determined in part by size, 
decreasing as size increases. Solute movement is increasingly hindered within the 
growing platelet core as gap sizes decrease and path tortuosity increases 52,55,56. Large 
solutes can even be excluded from the densely packed core region 12. As a result, the 
platelet plug microenvironment becomes a molecular sieve capable of restricting 
movement of solutes dependent upon their size 52,53,55,56. In aggregate, computational 
and in vivo studies show that the platelet mass microenvironment alters plasma velocity 
and solute diffusion to regulate solute transport within the platelet mass. 
 
The formation of this molecular sieve is also important in regulating the transport of 
bioactive molecules into the extravascular tissue plane. The extravascular tissue 
provides a source of tissue factor to initiate coagulation, and local immune cells capable 
of contributing to post-hemostatic inflammation and tissue homeostasis 19,21,57. 
Therefore, thrombus formation regulates the delivery of plasma borne molecules into the 
tissue, and platelet granule release at the site of injury facilitates the delivery of platelet-
borne molecules into the tissue. Also the extravascular tissue provides a sink for 
thrombin produced on the tissue factor surfaces in the vessel wall and extravascular 
tissue. Thrombin in the extravascular tissue is also restricted from diffusion into the 
thrombus and further into the lumen. Therefore, tight platelet packing in the core region 
not only facilitates thrombin retention driving stable thrombus formation, it also reduces 
excessive thrombin transport from the extravascular space into the lumen driving 
continued thrombus growth. In various pathological thrombotic disorders that lack vessel 
rupture, such as DVT and plaque rupture, this sink is unavailable and may contribute to 
occlusive thrombus formation (Figure 1-3). 
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Figure 1- 4  Model of extravascular transport of thrombin during hemostasis and 
thrombosis. 
(A) A schematic of thrombin transport after vessel rupture and hemostasis. Thrombin 
produced in the extravascular tissue is free to diffuse within the tissue or back into the 
restrictive thrombus. (B) A schematic of thrombin transport within a ruptured plaque. 
Thrombin within the plaque is limited in its ability to diffuse away and may be shunted 
back through the thrombus driving futher platelet activation and accumulation. 
 
Transport has long been recognized as important for platelet mass formation as a 
mechanism for delivery of coagulation factors to the injury site, as well as elution of 
platelet agonists from within the platelet mass 58-60. Coagulation is affected by solute 
transport as limited delivery of coagulation factors restrains thrombin generation, while 
limited transport of thrombin out of the platelet mass increases its effective 
concentration. Microfluidic assays have demonstrated that platelets create a physical 
barrier that covers up tissue factor surfaces and exclude plasma-borne coagulation 
factors altering the rate of fibrin deposition 59. These findings suggest that the 
intrathrombus microenvironment impacts agonist retention shaping thrombus 
architecture. 
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1.5 The state of the field  
 
To summarize the information presented above: thrombi formed ex vivo and in vivo form 
a highly conserved architecture consisting of a core and shell region that vary in both 
biological and physical properties, thrombus architecture is regulated by variations in 
agonist gradients formed within the intrathrombus environment, and the physical nature 
of the intrathormbus environment is capable of altering solute transport properties and 
resulting biochemical processes.  
 
These observations raise interesting questions about: how platelet activation and 
retraction shape the physical nature of the intrathrombus environment, the extent to 
which the intrathrombus environment shapes agonist transport and gradient formation, 
and how these two processes feedback to one another to drive core and shell formation. 
Extending these questions is how intrathrombus environment structure impacts solute 
extravasation, shaping solute gradients within the tissue surrounding sites of vascular 
damage, and how these processes are different in different vascular beds that vary in 
biological and physical composition.  
 
The following chapters show work using novel biosensors and intravital imaging 
techniques to address those questions and advance the understanding of how molecular 
physics shape the biology of thrombus formation. Chapter two describes a novel 
biosensor capable of measuring thrombin activity within thrombi formed ex vivo and in 
vivo. Using this sensor we demonstrated that thrombin activity is dependent upon local 
transport conditions in a microfluidic device, and is restricted to the core region in vivo. 
To determine if local transport properties are different within the core and shell regions in 
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vivo we developed a soluble protein transport sensor in chapter three. This sensor 
demonstrated that within the platelets that go on to form the core region soluble proteins 
are retained significantly longer than the platelets that make up the shell region. Chapter 
4 describes computational studies done in order to test how various structural changes 
within the thrombus can impact local protein transport, and demonstrates that 
differences in platelet packing within the core and shell region likely drive the observed 
differences in protein transport. In chapter five we test this hypothesis using mice with a 
defect in platelet retraction causing increased protein transport rates in the core region. 
This alteration of protein transport correlated with decreased thrombin function within the 
thrombus leading to decreased core size and fibrin deposition.  
 
We extended our model of thrombus structure regulating solute distributions in chapter 6 
measuring how thrombus development alters delivery of plasma proteins into the 
surrounding tissue plane. Finally, in chapter 7 we developed a novel technique to 
observe thrombus formation in the mouse femoral artery and vein to compare to our 
observations in the mouse microcirculation. In aggregate, this thesis aims to determine 
how the interplay between thrombus structure and the spatiotemporal distribution and 
transport of biologically relevant solutes impacts thrombus formation in various 
biologically relevant conditions. 
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CHAPTER 2: Platelet-targeting sensor reveals thrombin gradients within blood 
clots forming in microfluidic assays and in mouse 
	  
This research was originally published in the Journal of Thrombosis and Haemostasis. 
Welsh JD, Colace TV, Muthard RW, Stalker TJ, Brass LF, Diamond SL. J Thromb 
Haemost. 2012;10(11):2344-2358. © the International Society of Thrombosis and 
Haemostasis. 
 
2.1 Introduction 
	  
During coagulation, membrane associated prothrombinase (Xa/Va) cleaves prothrombin 
to release active thrombin, a soluble protease that can cleave protease activated 
receptors (PAR1 and PAR4 on human platelets) as well as activate fibrinogen to fibrin 
monomer.  As a soluble species, thrombin is subject to diffusive transport as well as 
convective transport via intrathrombic permeation (if pressure gradients exist 54,61) or via 
blood flow once thrombin leaves the clot 62,63.   Additionally, thrombin can bind platelet 
GPIb to localize its activity on the platelet surface 64,65 or thrombin can be inhibited by 
antithrombin or sequestered into polymerizing fibrin.  The generation and subsequent 
transport of activated Factor X (Xa) and thrombin from tissue factor (TF)-rich sites of Xa 
and activated Factor IX (IXa) formation have an important controlling effect on the rate 
and extent of thrombus growth through platelet activation and fibrin stabilization 59,66.     
Formation of the intrinsic tenase (Factors IXa/VIIIa), as well as feedback pathways such 
as thrombin-mediated production of Factor XIa also may impact the spatiotemporal 
concentration profiles of thrombin within a clot 67.  Thrombin activation of platelets 
induces the release of ADP, thromboxane, as well as pro-inflammatory cytokines and 
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surface display of P-selectin, thus promoting white blood cell recruitment and 
inflammation 16.    
 
Various techniques currently exist to monitor thrombin in closed systems.  These 
techniques measure endogenous end-products like thrombin-antithrombin (TAT) or 
exogenously added reporter substrates 68-71.  Under physiological flow conditions, 
thrombin detection becomes extremely difficult due to the convective removal of 
coagulation products or fluorogenic sensing molecules.  Fibrin deposition can be 
monitored under flow as an important surrogate of thrombin activity.  However, fibrin 
deposition is also subject to convective effects via fibrin monomer dilution and flow-
modulation of fibrin assembly 60,72.  Also, thrombin can affect platelet deposition at 
concentrations below that needed to generate fibrin 62,66.    
 
Despite its central role, thrombin activity has never been visualized in vivo.   We 
developed a thrombin sensitive antibody (ThS-Ab) that binds platelet CD41 (αIIb) to 
ensure its incorporation throughout the growing thrombi.  The sensor consisted of a 
thrombin sensitive peptide (ThS-P) that was linked to an anti-CD41 antibody and was 
rapidly cleaved by thrombin to provide a fluorescent signal.  In this study, we 
characterized this thrombin sensor to provide novel information about thrombin 
localization on activated platelets and within clots. 
 
2.2 Materials and Methods 
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2.2.1 Materials 
	  
Thrombin-sensitive peptide (ThS-P) azidoacetyl alanine-
K(5FAM)GALVPRGSAGK(CPQ2) was custom synthesized (2143 MW, >95% purity; 
CPC scientific, Sunnyale, CA) and dissolved in DMSO (20 mM ThS-P). The cleavage 
site VPR|G was chosen based on the strong preference by thrombin for proline in the P2 
position 60 and the prior use of boc-Val-Pro-Arg-MCA 16. The following reagents were 
stored according to manufacturers’ instructions: dibenzylcyclooctyne-NHS ester (DBCO) 
(Click Chemistry Tools, Scottsdale, Az), mouse monoclonal anti-human CD41 PM6/248 
(azide free; AbD Serotec, Raleigh, NC), PE-mouse monoclonal anti-human CD61, Cy-5 
Annexin V (BD Pharmigen, San Diego, CA), Cy5-anti human fibrin (Gift from Dr. M. 
Poncz, Children’s Hospital of Pennsylvania), anti-collagen type 1 antibody and PE-
mouse monoclonal anti-human CD42b (Ak2; Abcam, Cambridge, MA), anti-mouse CD41 
F(ab)2 fragments (clone MWReg30, BD Bioscience),  anti-mouse fibrin (clone 59D8, gift 
from Dr. H Weiler, Blood Center of Wisconsin),  thrombin, Gly-Pro-Arg-Pro (GPRP), corn 
trypsin inhibitor (CTI; Haematologic Technologies, Essex Junction, VT),  sodium citrate 
(Sigma-Aldrich, St. Louis, MO), HEPES ((N-(2-hydroxyethyl)piperazine-N’-2-
ethanesulfonic acid; Fisher Scientific, Pittsburg, PA), recombinant tissue factor (Sekisui, 
Stamford, CT), phosphatidylcholine (PC), phosphatidylserine (PS), and biotinylated 
phosphoethanolamine (bPE, Avanti Polar Lipids, Alabaster, Al), Streptavidin and Triton 
X-100 (Sigma-Aldrich, St. Louis, MO), and BioGel P-6 gel (Bio-Rad, Hercules, CA).  In 
accordance with University of Pennsylvania Internal Review Board, human blood was 
collected from healthy donors via venipuncture and anticoagulated with CTI (50 µg/mL) 
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or sodium citrate (1:9 by volume) and then recalcified with CaCl2 (15 mM final 
concentration).   
           
2.2.2 Thrombin sensitive antibody (ThS-Ab) synthesis 
 
The thrombin sensitive antibody was used for microfluidic and in vivo studies, but all 
kinetic data was obtained from the peptide alone. Therefore, the exact concentration of 
thrombin sensitive peptide per antibody molecule is unknown limiting the interpretation of 
the resulting signal. A volume of 10 µL of anti-human CD41 (1 mg/mL, azide free) was 
mixed with 5 µL of DBCO-NHS ester (357 µM, 0.7% DMSO by vol. in HEPES Buffered 
Saline (HBS), pH 7.4) and brought to a final volume of 40 µL with HBS.  The DBCO-NHS 
ester labeling reaction was incubated at room temperature for 30 min.  DBCO-NHS ester 
labeling of the anti-human CD41 was then quenched by the addition of 2.5 µL of TRIS-
HCl (1 M, pH 8.0).  After quenching, 4.5 µL of ThS-P (2 mM, 10% DMSO by volume in 
HBS) was added to a final reaction volume of 47 µL.  The ThS-P labeling reaction was 
incubated in the dark at room temperature for 4 hr.  ThS-Ab was isolated by gel filtration 
on P6-Gel maintained in HBS, resulting in 110 µL of purified ThS-Ab (0.05 mg/mL, as 
measured by absorption at 280 and Bradford assays) in HBS (Figure 2-1).   ThS-P and 
ThS-Ab fluorescence was measured in a FluoroSkan Ascent (485 nm excitation/538 nm 
emission).   ThS-Ab fluorescence on platelets was measured by flow cytometry (Accuri 
C6) based on a forward scatter/side scatter gate or by positive signal for PE-anti-CD42b. 
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Figure 2- 1 Click chemistry for cross linking a thrombin-sensitive N-terminal 
azidopeptide (ThS-P) to anti-CD41. 
Dibenzylcyclooctyne-NHS ester (DBCO) was used to label free amine groups on anti-
human CD41.  The ThS-P contains a 5-FAM labeled Lys2 and a CPQ2 (quencher) Lys13.  
The Lys2 and Lys13 are separated by a thrombin cleavage site at Arg8.  The azide group 
specifically attacks the triple bond in DBCO linking the ThS-P to the anti-human CD41.   
Thrombin-mediated cleavage of the peptide releases the CPQ2 quencher, resulting in a 
fluorogenic signal at 581 nm. 
 
2.2.3 Microfluidic device for clotting on collagen/tissue factor surfaces 
	  
Polydimethylsiloxane (PDMS) microfluidic channels (250-µm wide x 60 µm-high) were 
generated as previously described 66,73.  Tissue factor liposomes (PS/PC/bPE) were 
generated for linking to collagen via streptavidin-conjugated anti-collagen antibody 
66,73,74.  A PDMS device was used to pattern fibrillar collagen (Chronolog) in a 250 µm-
wide stripe followed by binding of the biotinylated lipidated TF.  A second PDMS device 
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created flow channels to run perpendicular across the collagen/TF surface.  Whole blood 
with ThS-Ab (5 µg/mL) and Cy5-anti-fibrin (0.5 µg/mL) was perfused at a shear rate of 
100 s-1 over the coated surface using a syringe pump (Harvard Apparatus PHD 2000, 
Holliston, MA).   Fluorescent microscopy (IX81, Olympus America Inc., Center Valley, 
PA) was used to image clot formation in real time.    
 
2.2.4 Microfluidic device for generation of transthrombus pressure gradient  
 
An additional PDMS microfluidic device was used for creating a transthrombus pressure 
gradient across a thrombus as it forms on a porous collagen/TF liposome surface 
(Figure S2-7). Pressure was measured upstream, downstream, and at the exit of the 
collagen scaffold using pressure transducers (Honeywell Sensing & Control, Golden 
Valley, MN). Initial wall shear rate (521 s-1) and constant pressure were maintained using 
an upstream syringe pump (Harvard Apparatus PHD Ultra, Holliston, MA) containing 
CTI-treated whole blood along with a downstream syringe pump containing a Ca2+ buffer 
(5 mM).  Each syringe pump was controlled by LabVIEW (National Instruments, Austin, 
TX) to achieve a specified blood flow rate and pressure at the site of the collagen plug.  
Thrombotic events were visualized on a side view of the collagen scaffold which 
contained 50 µm diameter posts and a 250 µm-long blood contact region 75,76. Prior to 
loading the collagen scaffold onto the posts, the PDMS device was placed on a 
Sigmacote (Sigma-Aldrich, St. Louis, MO) treated glass slide and coated with 10% BSA 
for 30 min. Human type I collagen (Advanced BioMatrix, San Diego, CA) was 
polymerized at 2.4 mg/mL in a ratio of 8:1:1 mixture of collagen, 0.09M NaOH, 10X PBS.  
Biotinylated goat polyclonal anticollagen (4 µg/mL) and streptavidin (10 µg/mL) were 
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added subsequently in 5 minute intervals at a 1:10 ratio with polymerized collagen. TF 
liposomes were then added in a 1:20 ratio with collagen for 10 min.  Collagen/TF 
solution was pulled through the upstream and downstream pressure ports into the 
collagen scaffold region on the device using a 1 mL syringe.  Immediately following 
collagen/TF localization, channels were rinsed with Ca2+ buffer (5 mM).  Imaging 
protocols were identical to the previously mentioned device and real time pressure data 
was collected through LabVIEW (Figure S1B). 
 
2.2.5 Mouse intravital microscopy 
 
Mouse studies were approved by the IACUC of the University of Pennsylvania.  Intravital 
microscopy was performed as previously described 76.  Mice were anesthetized with 
sodium pentobarbital (90 mg/kg), and maintained at 5 mg/kg through a jugular vein 
cannula.  The cremaster muscle was exposed and kept under constant drip of buffer 
(135 mM NaCl, 4.7 mM KCl, 2.7 mM CaCl2, 18 mM NaHCO3, pH 7.4)  The mThS-Ab 
(4.5 µg) and anti-mouse fibrin (5 µg) were infused into the mouse.  Injuries, in selected 
arterioles, were made with a pulsed nitrogen dye laser at 440 nm.  Confocal fluorescent 
and brightfield images were taken every 30 sec for 10 min after injury using an Olympus 
BX-61WI fluorescence microscope (Olympus) coupled to a CSU-X1 spinning disk 
confocal head (Yokogawa) and CoolSnap HQ CCD camera (Photometrics).    
 
2.3 Results 
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2.3.1 Characterization of thrombin cleavage of ThS-P and ThS-Ab 
	  
The Michaelis-Menten parameters for thrombin cleavage of ThS-P at 50 nM thrombin at 
37C were Km = 40.3 µM and kcat = 1.5 s-1 (Figure 2-2A). ThS-P signal in response to 
thrombin generated by whole blood activation was tested by addition of 0, 2.5, or 25 pM 
TF to citrated whole blood diluted 1:10 with HBS with 15 mM CaCl2 (Figure 2-2B).  
Without TF, the contact pathway was insufficient at this dilution of blood to generate 
ample thrombin during a 1600 sec incubation (Figure 2-2B, triangles). Upon the addition 
of increasing amounts of lipidated TF, the extrinsic tenase pathway was sufficient to 
trigger thrombin generation after a short initiation phase.  The dose response and rates 
of thrombin cleavage of ThS-Ab were quite similar to those observed with ThS-P, 
indicating that the synthesis reaction did not significantly alter the kinetics of ThS-P 
cleavage by thrombin (Figure 2-2C).  To determine the specificity of thrombin cleavage 
of ThS-P, hirudin (1.75 µM), a thrombin specific inhibitor, was added to whole blood 
(treated with CTI and diluted 1:5 with Hepes buffer pH 7.4) in the presence of TF (25 
pM) leading to complete ablation of ThS-P signal (Figure S2-8), demonstrating that the 
sensor was highly specific for detection of thrombin activity.  The maximal ThS-Ab signal 
was ~50-fold less than that of the maximal ThS-P signal due to the concentration of the 
ThS-Ab stock solution (50 µg/mL) deployed in order to avoid over-diluting the blood.   
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Figure 2- 2 Kinetics of ThS-P cleavage by thrombin was determined by titrating 
ThS-P concentration in the presence of 50 nM thrombin. 
Thrombin cleavage resulted in a 35-fold increase in ThS-P fluorescence (Km = 40.3 µM 
and kcat = 1.5 s-1) (A).  To determine if the synthesis of ThS-Ab affected the rate of 
cleavage by thrombin both ThS-Ab (0.05 mg/mL) (B) and ThS-P (5 µM)  (C) were added 
to citrated whole blood (re-calcified) with added tissue factor (TF 2.5 pM or 25 pM).  Both 
ThS-P and ThS-Ab had similar rates of cleavage as well as a dose response to 
increasing amounts of TF. 
 
2.3.2 Platelet surface localization of ThS-Ab and signal in response to thrombin 
 
To detect thrombin activity on the platelet surface, flow cytometry was performed on 
whole blood labeled with ThS-Ab in the presence or absence of added TF (25 pM) 
(Figure 3).  Citrated whole blood was incubated for 5 min with ThS-Ab (10 µg/mL) and 
then diluted 1:10 with the addition of 5 mM GPRP peptide to prevent fibrin 
polymerization and 15 mM CaCl2.   Without the addition of TF, very little change in ThS-
Ab signal was observed after 15 min (Figure 2-3A).  With 25 pM TF, thrombin was 
generated as indicated by a 20-fold increase in signal by 14 min.  To confirm the ThS-Ab 
signal was platelet specific, only cells positive for CD42b were positive for ThS-Ab signal 
in response to thrombin generation (Figure S2-8).    
 
24	  
	  
 
 
Figure 2- 3  Real time flow cytometry of whole blood labeled with ThS-Ab to 
detect platelet localized thrombin activity following TF addition. 
Whole blood was incubated with ThS-Ab (1:50 volume) either in the absence (A) or 
presence of 25 pM TF (B).  The mean fluorescence of the gated events demonstrated 
that TF caused a large increase in the platelet-specific thrombin signal (C). 
 
2.3.3 Thrombin sensing in a microfluidic model of thrombosis 
 
Thrombin localization within a growing thrombus under hemodynamic conditions was 
observed by perfusion of ThS-Ab labeled whole blood (CTI-treated) over a patterned 
collagen surface with antibody-linked lipidated TF at a shear rate of 100 s-1.  The 
collagen patterning of a stripe resulted in a discrete 250 µm wide x 250 µm long square 
of collagen when the fluidic channel was overlaid perpendicular to the stripe.  The 
upstream end of this discrete collagen region can be seen in Fig. 2-4 and Fig. S3.  At 0, 
0.1, or 1 molecule-TF/µm2 (as determined based on ref. 19), the simultaneous platelet 
deposition, fibrin deposition, and ThS-Ab signal were monitored in real time (Figure 2-
4A-C).  Whole blood with the thrombin inhibitor PPACK (100 µM) was perfused over the 
1 molecule-TF/µm2 surface.  In comparing Fig. 2-4C and 2-4D where blood was 
perfused over TF-labeled collagen with and without PPACK, PPACK caused a >50 % 
25	  
	  
decrease in platelet deposition and blocked detectable fibrin signal.  However, even 100 
µM PPACK was unable to fully block generation of the ThS-Ab signal  (Figure 2-4D).  
This indicated that thrombin produced as a result of the TF surface was able to cleave 
the platelet bound ThS-Ab before cleaving fibrinogen or encountering PPACK.  Thus, 
ThS-Ab was a more sensitive metric of local thrombin production than antibody-based 
detection of fibrin polymerization. 
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Figure 2- 4 Detection of thrombin in a blood clot forming under flow conditions. 
A microfluidic model of coagulation was generated by flowing whole blood (100 s-1) over 
collagen with linked lipidated TF.  ThS-Ab (green) and fibrin (red) were observed over 
time while flowing over collagen (A), collagen and TF (0.1 molec/µm2) (B), collagen and 
TF (1 molec/µm2) alone (C), and collagen and TF (1 molec/µm2) in the presence of 100 
µM PPACK (D). 
 
At 0.1 molecule-TF/µm2, the amount of thrombin generation decreased by ~65% (as 
indicated by fluorescence intensity) compared to 1 molecule-TF/µm2. Unique localized 
zones of thrombin generation were detectable at early times during thrombus formation 
(especially near the side walls of the device) that coexisted with other zones in the 
image field that lacked ThS-Ab fluorescence (Figure S2-9).  During early time points of 
blood perfusion over 0.1 molecule-TF/µm2, slightly more platelet deposition was seen at 
the front of the collagen/TF surface while the ThS-Ab and anti-fibrin signal was located 
down stream of the platelet mass (as previously observed 66).  This indicated that the 
observed signal was in fact due to increased levels of thrombin activity and not 
increased platelets with bound ThS-Ab.  The shear rates on the periphery side walls of 
the flow chamber were lower than in the center with consequent reduced rates of dilution 
of thrombin from the surface into the flow stream, thus allowing for increased 
accumulation of thrombin and fibrin along the periphery of the chamber 77.  Without 
added TF, no thrombin or fibrin was formed after 450 sec. After 10 to 13 minutes of flow 
over collagen (no TF), ThS-Ab fluorescence and fibrin formation were finally detected 
(not shown), most likely due to formation of XIIa despite the presence of CTI 16. 
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2.3.4 Microfluidic model of transthrombus pressure gradient-driven permeation 
during hemostasis   
	  
As a thrombus builds up at a site of vascular rupture or wounding, a pressure drop (ΔP) 
exists across the clot because the intraluminal pressure (up to arterial levels of 60 to 120 
mm-Hg) exceeds the interstitial pressure (~10-12 mm-Hg) 78,79. The pressure-driven 
permeation of plasma or serum across the porous clot structure and into the porous 
interstitial matrix at the point of injury represents a convective transport mechanism. To 
drive transthrombus permeation, a microfluidic device was developed that allowed a 
thrombus to form on a supported porous collagen plug at a controlled shear rate of blood 
perfusion (Figure 2-5A).  Since atmospheric pressure was maintained on the opposite 
(non-blood contacting) side of the collagen plug, a controlled pressure drop independent 
of the wall shear rate was maintained across the collagen and thrombus (Figure 2-5A 
and Figure S2-7), thus mimicking a bleed into the interstitial space.   The pressure drop 
was set to ΔP = 3200 Pa (32 mm-Hg) or ΔP = 0 Pa (by blocking the outlet) to control the 
permeating flow across the thrombus (Figure S2-7).  Blood labeled with ThS-Ab, 
fluorescent anti-CD61, and fluorescent anti-fibrin was perfused at 521 s-1 over the 
collagen/TF plug.   At ΔP = 3200 Pa, the increased permeation of thrombin across the 
thrombus resulted in ThS-Ab signal being only present in thin areas within the thrombus 
nearest the collagen/TF surface (Figure 2-5B).  At ΔP = 3200 Pa, ample fibrin was 
formed within the collagen due to permeation of thrombin and fibrinogen into the 
collagen (Fig. 2-5D).  Without a pressure drop (ΔP = 0), the thrombin transport within the 
thrombus was largely due to diffusion since no permeation across the collagen was 
possible.  This resulted in a 5-fold increase in ThS-Ab signal generated within the 
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thrombus, compared to the case of ΔP = 3200 Pa (Figure 2-5B-C). Fibrin signal was 
measured at the surface of the collagen/TF matrix as well as 10 µm into the thrombus to 
observe the rate of deposition (Figure S2-11).  At the surface of the collagen/TF matrix, 
the rate of fibrin deposition was unchanged by the change in ΔP and altered thrombin 
localization pattern (Figure S2-11A).  However, at 10 µm into the thrombus, the rate of 
fibrin deposition was decreased ~45% when ΔP = 3200 Pa and thrombin levels were 
decreased within the thrombus (Figure S2-11B).    
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Figure 2- 5  A microfluidic model of transthrombus pressure gradient 
modulation. 
A thrombogenic surface of collagen and TF was used in a microfluidic device to provide 
a side view of thrombus formed under flow conditions while a transthrombus pressure 
gradient drives permeation across the clot (A).  Blood was perfused at 521 s-1 and ThS-
AB (green), anti-fibrin (blue) and anti-CD61 (red) were observed over time during 
thrombus formation.  The pressure drop across the surface was altered to change the 
transport pattern of thrombin (ΔP = 3200 Pa or 0 Pa) (B).  The pressure drop caused a 
decrease in thrombin presence in the clot (C).  To quantify the rate of fibrin deposition 
the fluorescence signal of anti-fibrin was monitored at different distances from the 
coagulation surface (0 and 10 µm) for the different pressure drop states (D). 
 
2.3.5 In vivo monitoring of thrombin within a thrombus 
 
Laser induced injury created stable thrombi in mouse cremaster arterioles 76.  Mice were 
perfused with anti-fibrin and ThS-Ab anti-mouse CD41 (mThS-Ab) prior to injury.  
Images were taken of the bright field thrombus formation as well as fibrin deposition and 
mThS-Ab every 30 sec for 10 min.  Similar to microfluidic model thrombosis, the mouse 
thrombi showed a core of mThS-Ab signal that co-localized with fibrin deposition (Figure 
2-6 and Supplemental Movie M1).  Thrombus growth was stabilized where high mThS-
Ab signal was present, as low mThS-Ab regions appeared to be more prone to shearing 
forces of the blood flow and disassociated from the thrombus over time.  The stable 
thrombus core nearest the injury site had the highest mThS-Ab signal and was anchored 
by a layer of fibrin deposition at the vessel wall at the site of injury.  During early 
thrombosis the thrombus mass was large with a core of high mThS-Ab signal and a 
more diffuse signal occurred in the outer zones of the thrombus.  After 5 min, the 
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remaining clot was stable and had high mThS-Ab signal and high fibrin deposition 
(Figure 2-6).  To specifically inhibit thrombin function, 15 µg of hirudin was infused prior 
to injury and inhibited >90% of ThS-Ab signal 2 minutes post-injury (Figure S2-12).  
Similar to the in vitro findings with hirudin, ThS-Ab is a specific detector of thrombin 
activity, even in an in vivo thrombotic setting. 
 
 
Figure 2- 6  A mouse laser injury model was used to observe mThS-Ab signal in 
vivo. 
A mouse laser injury model was used to observe mThS-Ab signal in vivo.  The site of 
injury was observed using confocal fluorescent microscopy.  Blood flow is denoted by an 
arrow at t = 0.  ThS-Ab signal (green) is first observed at 40 seconds post-injury that co-
localizes with fibrin (blue).  As the clot grows ThS-Ab signal spreads away from the 
vessel wall as fibrin stays close to the vessel wall.  After 2 minutes post-injury the clot 
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begins shrinking and the core remains the area of high fibrin and high ThS-Ab signal and 
a shell of platelets that are thrombin-negative.   
 
2.4 Discussion 
 
The localization of thrombin is dictated by the site of generation and the movement of 
thrombin which is controlled by diffusion, binding, and convection.  Detection of thrombin 
activity via fluorogenic substrates is less suited under flow conditions due to convective 
removal of the soluble reporter.  We report, for the first time, detection of intrathrombus 
thrombin activity under flow conditions using ThS-Ab in microfluidic assays and in 
mouse.   
 
In order for ThS-Ab to serve as a stable marker for platelet surface-thrombin activity, it 
must localize to the surface of platelets and provide a robust signal upon thrombin 
generation.  By flow cytometry, platelets displayed a ~20-fold increase of ThS-Ab signal 
after 10 minutes of incubation with TF (Figure 2-3).  Platelets became positive for ThS-
Ab signal, as determined by co-staining with platelet-specific anti-CD42b and ThS-Ab 
signal (Figure S2-9).  ThS-P cleavage has a kcat/Km = 0.375 while fibrinogen has a kcat/Km  
= 11.3 78.  Despite the difference in kinetics, both in vitro and in vivo thrombosis models 
showed fibrin deposition and ThS-Ab signal as spatially and temporally co-localized 
(Figure S2-10 and Figure 2-6). 
 
To visualize the activity of thrombin within a hemostatic thrombus, a microfluidic device 
was used to trigger thrombosis on a pro-coagulant surface (collagen and TF) which 
provided a side view observation.  To further enhance the physiological relevance of this 
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microfluidic system, a pressure drop was established across the pro-coagulant surface 
to study the effect of transthrombus permeation (Figure 2-5A).  We have previously 
demonstrated that there is plasma loss using fluorescent plasma tracers as well as 
visible red blood cell escape into the endothelial space following laser injury.  The 
microfluidic device in Fig. 2-5 recreates certain aspects of in vivo vessel injury such as 
movement of blood or plasma across a porous clot or wall structure due to a pressure-
driven permeation or flow.   By combination of ThS-Ab with a novel microfluidic device 
that mimics hemostasis, this is the first study of thrombin levels in clots formed with a 
transthrombus pressure drop to drive permeation in a direction perpendicular to blood 
flow and in the direction of the interstitial space.  Transthrombus permeation into the 
interstitial space reduced platelet-associated thrombin activity and enhanced fibrin 
polymerization into the interstitial region (Figure 2-5B-D). Fibrin is shown occurring in the 
interstitial space especially when a pressure drop exists across the collagen-
TF/thrombus surface (Fig. 2-5D and Figure S2-11).  With zero pressure drop, the high 
level of thrombin formed at the collagen-TF/platelet interface (Fig. 2-5B) resulted in rapid 
fibrinogen conversion to immobile fibrin, which does not move into the collagen region.  
When the pressure drop is present, lower levels of thrombin accumulate (possibly 
because of dilution by permeation into the interstitial space).  Fibrinogen and lower 
levels of fibrin monomer can thus undergo permeation into the collagen region. This 
allows the fibrin to polymerize within the interstitial region as fibrin monomer is driven by 
the permeation of plasma through the interstitial space. While fibrin polymers are unable 
to penetrate into the interstitial space, thrombin is still highly diffusible and can enter into 
the interstitial space even without pressure drop induced flow.  ThS-Ab free in solution is 
also able to penetrate into the interstitial area by diffusion. Consistent with the in vitro 
observation of Fig. 2-5, interstitial fibrin has routinely been detected in the mouse laser 
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injury model 12.  While not well studied, the formation of fibrin in the interstitial region 
outside a blood vessel may be an attribute of in vivo hemostasis due to pressure driven-
permeation across a platelet mass.    
 
To verify the ThS-Ab sensor in an in vivo context, ThS-P was attached to anti-mouse 
CD41, infused into mice, and observed following laser injury of the cremaster muscle 
(Figure 2-6). Platelets quickly formed a plug at the site of injury without thrombin activity 
(t = 0 sec), and 20 sec after the injury both fibrin and thrombin signal appeared at the 
site of injury (Figure 2-6).  The fibrin signal was localized close to the vessel wall while 
the thrombin signal was highest close to the vessel wall but thrombin appeared to diffuse 
out into the thrombus as well.  After 80 sec post-injury, there was a large amount of fibrin 
deposition along the vessel wall that co-localized with the highest concentration of 
thrombin activity, however lower thrombin activity was also detected away from the 
vessel wall in the thrombus, but thrombin activity was not detected in the outer most 
shell of the thrombus.  After 80 sec post-injury, the thrombus decreased in size and the 
area positive for platelet also decreased, as the outer most shell of the thrombus 
remained thrombin-negative.  These results indicate that thrombin initially localizes at 
high concentrations at the site of injury and was capable of producing fibrin.   Decreased 
thrombin activity and increased convection may also contribute to the lack of fibrin 
formation further away from the vessel wall.  At 160 seconds post-injury, the fibrin plug 
and areas of high thrombin activity remain stably with an outer shell of thrombin-negative 
platelets.  These results show that thrombin was produced at the site of injury and was 
most active along the vessel wall leading to a stable fibrin plug.  Thrombin was also 
active further from the vessel wall but to a lesser extent and did not produce stable 
platelet deposits or fibrin polymers at large distances from the site of injury (Figure 2-6).  
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To our knowledge, this is the first direct imaging of thrombin activity in a forming 
thrombus in vivo. 
 
The use of a fluorogenic peptide sequence linked to an antibody by click chemistry 
represents a simple and general approach for visualizing proteases.   The approach may 
have also utility for the study of other proteases involved in thrombosis, inflammation, or 
metastasis. We demonstrated that thrombin activity can be detected on the time frame of 
a real clotting event.  The sensor allowed a very sensitive detection of thrombin in 
situations where fibrin was not necessarily generated.  Also local transport processes 
within the clots were shown to modulate the thrombin signal. 
 
2.5 Supplemental Materials 
 
 
 
Figure 2- 7 Design of microfluidic device to measure transthormbus pressure 
drop. 
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A microfluidic device for perfusion of blood at flow rate Q1 from an inlet across a 
collagen plug that covers an outlet maintained at P3 = atmospheric pressure.  Control of 
buffer flowrate (Q2) controls the pressure at P2 and P1 as well as the pressure drop 
maintained across the collagen plug.   A COMSOL simulation of the microfluidic device 
shows pressure control throughout the device (A).  Positions P1, P2, and P3 demonstrate 
the locations of 0-1 psig pressure transducers that were used to measure the pressure 
drop across the coagulation matrix.  Pressure was controlled and measured in real time 
through LabVIEW. The pressure drop was set at 3200 Pa (dashed line) to mimic 
physiological arterial pressure drops and reduced near 0 Pa (solid line) by obstructing 
flow exiting the collagen scaffold (B). 
 
 
 
Figure 2- 8 ThS-P is specific from thrombin cleavage. 
The cleavage of ThS-P was monitored using a fluorescent plate reader.  ThS-P (5 µM) 
was incubated with whole blood treated with CTI and diluted 1:5 with Hepes buffer.  The 
reactions were then incubated with TF (either 0 pM or 25 pM), and Hirudin (either 0 µM 
or 1.75 µM) and ThS-P cleavage was monitored over time.  Samples without TF failed to 
produce thrombin while TF (25 pM) was capable of inducing ThS-P cleavage that 
plateaued at 15 minutes.  When Hirudin, a thrombin specific inhibitor, was added even 
TF at 25 pM was unable to induce ThS-P cleavage. 
 
36	  
	  
 
 
Figure 2- 9 Kinetics of thrombin activity detected with ThS-Ab. 
Flow cytometry of clotting whole blood demonstrated that the ThS-Ab signal detected 
thrombin generation specifically on platelet surfaces.  Citrated whole blood was labeled 
with platelet marker anti-CD42b and ThS-Ab (1:50 volume).  The blood was exposed to 
TF (25 pM) and CaCl2 at t = 0.  Samples were taken at 0 min (A), 8 min (B), or 16 min 
(C).  In a replicate well with no TF added, a sample was taken at 16 min (D).   The mean 
fluorescence of the anti-CD42b positive cells were graphed of both TF exposed and 
unexposed (E). 
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Figure 2- 10 Co-localization of ThS-Ab and fibrin during thrombus formation 
under flow. 
During platelet deposition on collagen/TF surfaces, the platelet deposits displayed 
heterogeneity in thrombin activity and fibrin deposition. Whole blood was perfused (100s-
1) over a collagen and TF (0.1 mol/µm2) surface and fluorescent microscopy was used to 
observe ThS-Ab and anti-fibrin signal during coagulation.  Distinct areas of high thrombin 
generation were indicated by ThS-Ab (green) and these regions co-localized with areas 
of high fibrin deposition (red). 
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Figure 2- 11  The effect of a transthrombus pressure gradient on fibrin deposition 
kinetics. 
Fibrin deposition at the collagen/thrombus surface (0 µm) or 10 µm depth into the 
thrombus was measured using anti-fibrin fluorescence.  The rate of fibrin deposition at 
the collagen/thrombus surface was largely unaffected by presence or absence of a 
pressure drop across the fibrin (A). The rate of deposition fibrin deposition at 10 µm into 
the thrombus was significantly reduced by the presence of a pressure drop across the 
thrombus (3200 Pa) (B). 
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Figure 2- 12 The effect of a direct thrombin inhibitor on ThS-Ab signal in vivo. 
Intravital microscopy of mouse laser injury model was used to monitor ThS-Ab and fibrin 
signal during thrombosis.  The mice were injured and then infused with hirudin (15µg) 
and re-injured to observe the inhibition of hirudin on ThS-Ab signal (green) and fibrin 
(red).  Images show the thrombus formation, ThS-Ab signal, and fibrin signal 2 minutes 
after injury both with and without hirudin.  The graph quantifies the difference in ThS-Ab 
signal 2 minutes post-injury from several injuries. 
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CHAPTER 3: A systems approach to hemostasis: 1. The interdependence of 
thrombus architecture and agonist movements in the gaps between platelets  
	  
This research was originally published in Blood. Welsh JD, Stalker TJ, Voronov R, 
Muthard RW, Tomaiuolo M, Diamond SL, Brass LF. Blood. 2014;124(11):1808-15. © the 
American Society of Hematology. 
 
3.1 Introduction   
 
The hemostatic response balances the need to halt bleeding with the need to avoid 
inappropriate vascular occlusion.  Recent reports of hemostatic thrombi formed in vivo 
have demonstrated that the extent of platelet activation within a growing thrombus is 
heterogeneous 12,36,80-82 and can result in a characteristic core-and-shell architecture. We 
have shown that the core region develops adjacent to the injury site and consists of fully-
activated, closely-packed platelets that have undergone α-granule exocytosis, which 
allows them to be recognized by the appearance of the α-granule membrane protein, P-
selectin, on their surface 12. The shell is a less stable region that coats the core and 
consists of loosely-packed, less activated platelets 12. 
 
Regional differences in the extent of platelet activation can potentially be driven by 
multiple factors. Here we have adopted a systems biology perspective, looking beyond 
the events in any one platelet to test the idea that the emerging architecture of the 
hemostatic response serves as both a driver and a reflection of differences in 
intrathrombus molecular transport rates and consequent differences in agonist 
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distribution. Numerous platelet agonists are present during vascular injury, including 
collagen, thrombin, ADP and TxA2 83. Each of these varies in origin, potency and 
mobility. Collagen, for example, is immobile, while thrombin distribution is limited by 
interactions with other proteins, including inhibitors 84,85. By comparison, ADP and 
especially TxA2 are freely diffusible 86. 
 
Our goal in this study was to develop and apply methods to understand the relationship 
between molecular transport, platelet packing density and agonist distribution, examining 
how each affects platelet activation and thrombus growth in vivo. We asked whether 
regional differences in thrombus structure affect agonist movement and distribution, and, 
therefore, the extent of platelet activation. To test this hypothesis we developed a novel 
biosensor capable of measuring molecular transport in vivo in real time, and have used 
that biosensor in conjunction with a previously-developed thrombin biosensor 87 to 
compare transport rates and thrombin activity. The transport biosensor consists of 
albumin coupled to caged fluorescein molecules that uncage and fluoresce when flashed 
with 405 nm light. Subsequent loss of the fluorescence provides a direct measure of 
intrathrombus transport that we have combined with data generated by the thrombin 
biosensor and a thrombus porosity probe to produce a high resolution map of transport 
rates, thrombin activity and relative packing density within the thrombus. 
 
Here we show that molecular transport in the gaps between platelets is orders of 
magnitude slower within the thrombus than in the overlying blood stream, and even 
slower in the core than in the shell.  High-resolution mapping defines a low transport 
region coinciding with the region of greatest packing density and highest thrombin 
activity. Since greater packing density facilitates contact-dependent signaling between 
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adjacent platelets, we performed comparative studies in mice lacking Sema4D. These 
mice have a defect in contact-dependent amplification of collagen-induced platelet 
activation 88. Collectively, the results establish a timeline in which initial platelet 
accumulation and the narrowing gaps between platelets serve as obstacles to molecular 
movement in what will become the thrombus core. This creates a region of reduced 
transport that facilitates local thrombin accumulation and greater platelet activation, while 
faster transport rates and greater instability within the shell help to limit thrombin 
accumulation and thrombus size. Thus, even the early stages of platelet accumulation 
produce an altered microenvironment that influences subsequent thrombus growth and, 
potentially, the impact of antiplatelet agents. In this and the following two chapters we 
use complementary experimental and computational approaches to test this model. 
 
3.2 Materials and methods 
 
3.2.1 Materials 
	  
CMNB-Caged Carboxyfluorescein SE and Alexa-fluor 488/568/647 monoclonal antibody 
labeling kits (Life Technologies, Grand Island, NY, USA).  Bovine serum albumin (BSA, 
Jackson Immunological Research, West Grove, PA, USA). C57Bl/6J mice (Jackson 
Laboratories, Bar Harbor, ME, USA).  Anti-CD62P (IgG, clone RB40.34) and anti-CD41 
(F(ab)2 fragment, clone MWReg30) (BD Biosciences, San Diego, CA, USA).  
 
3.2.2 Synthesis of caged fluorescein (cAlb) conjugated to albumin (cAlb)  
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Bovine serum albumin was solubilized in 0.1 M sodium bicarbonate in PBS to a final 
concentration of 10 mg/mL.  The CMNB-caged Carboxyfluorescein SE was dissolved in 
100 µL of DMSO, and added to the solubilized BSA and mixed thoroughly.  The reaction 
was incubated for 1 hour at room temperature, and then excess caged fluorescein was 
removed using 7kD MWCO desalting columns (Thermo Scientific, Pittsburg, PA, USA).   
 
3.2.3 Hemostatic thrombus formation 
	  
Male mice 8-12 weeks of age were anesthetized with an intraperitoneal injection of 
sodium pentobarbital (90 mg/kg), and their jugular vein was cannulated for the 
introduction of cAlb (0.5 mg/mL), anti-CD41 AF-568, and anti-CD62P AF-647.  The 
mouse cremaster was exposed, cleaned of connective tissue, opened, and prepared for 
viewing by intravital microscopy.  The cremaster was maintained under a constant flow 
of bicarbonate buffer (37 °C) bubbled with 95%/5% N2/CO2.  Mouse arterioles of 30-50 
µm diameter were visualized with a BX61WI microscope (Olympus, St. Louis, MO, USA) 
with a 60X (0.9 NA) water immersion objective, and a CSU-X1 spinning disk confocal 
scanner (Yokogawa, Sugar Land, TX, USA).  Fluorescence imaging was done using 
diode pumped solid state lasers (405 nm, 488 nm, 561 nm, 647 nm) with AOTF control 
as an excitation source (LaserStack, Intelligent Imaging Innovations, Denver, CO, USA), 
and images were captured using an Evolve digital camera (Photometrics, Tucson, AZ, 
USA).  Endothelial cell ablation was performed with a pulsed nitrogen dye laser (SRS 
NL100, 440 nm) focused on the vessel wall through the microscope objective.  The laser 
was fired between 1-10 times until red blood cells either escaped into the extravascular 
space or became trapped within the layers of the vessel wall.  The University of 
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Pennsylvania Institutional Animal Care and Use Committee approved all procedures. In 
this and the two accompanying manuscripts, our focus is on the hemostatic response to 
injury and we have used the terms “hemostatic thrombus”, “hemostatic plug” and 
“thrombus” interchangeably. 
 
3.2.4 Injury visualization 
 
After injury the platelet deposition was monitored using anti-CD41 AF-568 fluorescence, 
and core development with anti-P-selectin (anti-CD62P). Background fluorescence was 
measured within the vessel for both anti-CD41 and anti-P-selectin, and subtracted from 
the images to determine the core and shell areas. In representative images of thrombi 
using anti-CD41, anti-P-selectin and thrombin sensor, the background fluorescence 
threshold is set and the results are displayed in binary mode unless otherwise noted in 
the figure legend. 
 
cAlb fluorescence was visualized by un-caging the caged carboxyfluorescein with a 500 
ms pulse of 405 nm light delivered through the microscope objective (Figure 1A and B).  
Immediately after the 405 nm light pulse cAlb fluorescence (ex: 488 nm), platelets (ex: 
568 nm), and P-selectin (ex: 647 nm) were tracked for 15 frames.  After 15 frames (~9 s) 
a new pulse was initiated.  This sequence was repeated for 3 minutes. Separate studies 
determined that the observed rapid decay is not due to photobleaching, as only very mild 
photobleaching was observed using the experimental capture settings (Figure S3-8). 
Microscope control, image capture, and analysis was performed by Slidebook 5.0 
(Intelligent Imaging Innovations, Denver, CO, USA). 
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3.2.5 Thrombin biosensor  
 
Mouse thrombin sensitive antibody (mThS-Ab) was synthesized using a protocol 
previously described 87. mThS-Ab was infused through the jugular cannula of the mouse 
prior to injury and was imaged every 10 seconds.  Platelets and P-selectin were labeled 
with fluorescent anti-GPIbb (Emfret Analytics, Eibelstadt, Germany, Clone: Xia.C3) and 
anti-CD62P respectively, and were imaged once per second.  Background fluorescence 
was measured within the vessel and subtracted from the mThS-Ab signal within the 
thrombus.  Determining the location of the stable core at 20 minutes post-injury identified 
the low transport region (LTR), and mThS-Ab was quantified within the LTR and shell 
over time. 
 
3.2.6 Analysis of cAlb data 
 
For core and shell cAlb decay rates, the core and shell were masked using P-selectin 
staining as the marker for core.  For each mask the cAlb decay curves were obtained 
once the region attained an area greater than 10 µm2.  The mean cAlb fluorescence 
intensity in the core and shell regions immediately prior to each 405 nm flash was 
defined as background fluorescence and subtracted from the cAlb images acquired 
subsequent to each flash.  The mean cAlb fluorescence for each of the images acquired 
following each flash were then normalized to the cAlb fluorescence in the first image 
post-flash (representing the peak cAlb signal for each flash), resulting in a decay curve 
for each 405 nm flash.  All the curves for a single injury were averaged to make a single 
decay curve, and curves for multiple injuries were averaged to generate the mean 
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curves with standard deviations reported.  The curves were averaged over several 
injuries from at least 3 mice.  
 
3.2.7 Sema4D-deficient mice  
 
Sema4D null mice were back crossed onto C57Bl/6 were described previously 89. All 
studies were performed using Sema4D+/+ (WT) and Sema4D-/- littermates produced by 
crossing heterozygotes.  
 
3.2.8 Porosity measurements  
 
BSA labeled with AlexaFluor 488 (Invitrogen, Carlsbad, CA, USA) was infused into the 
mouse through a jugular cannula prior to injury.  Fluorescence was measured 
continuously in the lumen, LTR, and shell during thrombus development.  The lumen 
was assumed to have a porosity of 0.6 due to 40% hematocrit in the flowing blood, and 
the measured lumen fluorescence was used to calculate the plasma fluorescence with a 
porosity of 1. By normalizing the fluorescence within the shell and LTR to the plasma, we 
were able to calculate the porosity of each region over time.  
 
3.3 Results 
 
3.3.1 Measuring regional heterogeneity of intrathrombus transport 
 
A necessary first step in this study was the development of a method to measure 
intrathrombus molecular transport rates in vivo in real time during hemostatic thrombus 
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formation. The injury model we have employed most frequently uses a laser or 
sharpened glass probe to produce a penetrating injury in the cremaster muscle 
microcirculation of a C57Bl/6 mouse 12.  Thus, in this and the two accompanying 
manuscripts, our focus is on the hemostatic response to injury and we have used the 
terms “hemostatic thrombus”, “hemostatic plug” and “thrombus” interchangeably.  
Confocal fluorescence microscopy with high speed video capture allows direct 
visualization of the response to injury and parameters such as platelet accumulation, 
platelet activation, packing density and thrombus porosity to be measured, the latter with 
stably-fluorescent albumin and dextran molecules 12. To create a transport rate sensor 
for the present studies, albumin was labeled with caged fluorescein molecules (cAlb) 
that become stably fluorescent only after being uncaged by exposure to 405 nm light 
(Figure 3-1A). In the example shown in Figure 3-1B, pulses of 405 nm light uncaged the 
fluorophore within the field of view resulting in fluorescence that could be visualized 
within the thrombus. The rise and subsequent washout of fluorescence within the 
thrombus caused by a series of repeated light pulses separated by 10 seconds is shown 
in Figure 3-1C. Albumin-associated fluorescence in the lumen moves too rapidly for 
capture and analysis. Each thrombus was monitored for 3 minutes after injury, during 
which time multiple pulses and decay curves were generated (Figure 3-1D). 
Photobleaching contributed minimally to the decline in cAlb fluorescence during the 
period of observation between activating pulses (Supplemental Figure S1). Platelet 
deposition and surface P-selectin expression (an index of α-granule exocytosis) were 
recorded at the same time (Figure 3-2A and B).  
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Figure 3- 1  Design of caged fluorescein-albumin biosensor (cAlb) for 
visualization of the molecular transport properties of thrombi generated in vivo. 
(A) Bovine serum albumin was labeled with caged fluorescein (cAlb) which is uncaged 
using 405 nm light to induce fluorescence.  (B) Intravital microscopy was used to 
observe cAlb in vivo.  Infusion of cAlb into the blood stream was followed by laser-
induced injury to the mouse cremaster muscle arterioles to induce thrombus formation.  
Periodic pulses of 405 nm light were used to uncage cAlb and the resulting fluorescence 
intensity and decay were monitored with fluorescent microscopy. The represented 
fluorescence intensity has had the background subtracted and then been scaled to 
demonstrate signal decay within the thrombus.  (C) Quantification of the intrathrombus 
cAlb signal was measured over multiple pulses of uncaging light for thrombus in B.  (D) 
An average intra-thrombus cAlb decay curve was generated by averaging the decay 
after each of 16 pulses taken over 3 minutes. 
 
As reported previously, platelets accumulate rapidly in this injury model, reaching a peak 
30-60 s after injury 12. Surface P-selectin appears more slowly, becoming detectable 
within the thrombus core at 20 s and continuing to increase throughout the experiment 
with growth slowing after approximately 150 s (Figure 3-2B).  To determine if molecular 
transport rates also show regional variation, cAlb decay was analyzed separately in the 
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P-selectin(+) core region and P-selectin(-) shell region of the thrombus.  Average cAlb 
decay curves were generated for 13 injuries during the first 3 min post-injury for both 
regions (Figure 3-2C).  We found that uncaged (i.e. fluorescent) cAlb was visible only 
within the thrombi. cAlb in the lumen of the vessel was traveling too fast to be flash-
activated and observed. The core region had an average cAlb half-life of 2.6 s, which is 
approximately two-fold greater than the shell region’s average half-life of 1.2 s. Detailed 
mapping showed that the slowest half-life recorded in the core was 8 s and the fastest in 
the shell was 0.5 s, yielding a maximum ratio of 16:1. Taken together these results 
demonstrate, first, that platelets retard the movement of soluble molecules in their 
vicinity and, second, the core and shell have differing transport properties, with the core 
retaining soluble proteins longer than the shell. 
 
  
Figure 3- 2  Regional heterogeneity of cAlb transport properties. 
(A) A representative image of a thrombus generated using a laser injury model in mouse 
cremaster arterioles (3 min post-injury).  Thrombi were monitored for platelet deposition 
(blue), P-selectin exposure (red), and cAlb (not shown) for 0-3 min post-injury.  (B) The 
growth of platelet (blue) and P-selectin(+) (red) areas were monitored over 3 minutes.  
The areas were measured by gating the images on either CD41(+) or P-selectin(+) 
pixels and then averaged across 20 injuries from 5 wild type mice. (C) Thrombus regions 
were defined as CD41(+)/P-selectin(+) and CD41(+)/P-selectin(-) for cAlb analysis.  
Pulses of 405 nm light were used to activate the cAlb infused prior to injury, and the 
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normalized decay curves for the P-selectin(+) (red) and P-selectin(-) (blue) regions were 
averaged over each pulse for 0-3 min post-injury (+/- SD).  
 
3.3.2 Determining the kinetics of reduced intrathrombus transport and platelet 
packing 
 
We hypothesized that slower molecular transport in the core leads to greater retention of 
soluble agonists, which in turn contributes to full platelet activation and α-granule 
secretion.  If so, then reduced transport rates in the core region would precede P-
selectin exposure on the platelet surface.  To compare the kinetics of the development of 
regions of reduced transport with the kinetics of platelet activation, we identified a 
transition zone, defined as the region that is P-selectin(-) at 3 min, but becomes P-
selectin(+) by 20 min (Figure 3-3A). Taking into account this definition of a transition 
zone, the shell region becomes the part of the thrombus that is neither core nor 
transition region. We found that the transition zone at 3 min post-injury, despite being P-
selectin(-), had significantly slower cAlb transport than the shell (Figure 3-3B).    
 
To generate a map of intrathrombus transport rates with the greatest possible resolution, 
we analyzed cAlb decay rates for single pixels within early thrombi (2-3 min post-injury), 
yielding high spatial-resolution cAlb T1/2 heat maps for each thrombus (Supplemental 
Methods and Figure 3-3C).  We observed a gradient of cAlb half lives extending from the 
region adjacent to the injury site showing the slowest transport. This region of low 
transport extended beyond the P-selectin(+) region into the transition zone (Figure 3-
3C). Taken together the transition zone and the core form a low transport region (LTR), 
which has significantly reduced transport compared to the shell region (Figure 3-3C and 
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D). The appearance of reduced transport rates within the LTR preceding full platelet 
activation suggests a model in which transport heterogeneity regulates agonist 
distribution and platelet activation, which in turn affect platelet packing density and, 
therefore, local transport rates. 
 
  
Figure 3- 3  Transport properties of the transition zone. 
(A) A representative image of a thrombus at 3 min and 20 min post-injury showing 
platelet deposition (blue) and P-selectin exposure (red) at 3 min and 20 minutes.  Also 
shown are the stable core (cyan outline) 20 min post-injury, and the transition zone 
(green outline) at 3 min post-injury.  (B) Eight of the injuries had transition zones (green) 
large enough (> 10 µm2) to be analyzed in addition to the core (red) and shell (blue) 
regions for their average cAlb decay curves (+/- SD).  (C) For those same images in A 
the resulting cAlb T1/2 time heat maps are shown with the low transport region (LTR) 
highlighted (cyan). The LTR is defined as the P-selectin(+) region plus the transition 
zone (i.e. the P-selectin(+) region at 20 minutes post-injury).  (D) Analysis of the low 
transport region (LTR, cyan) transport compared to the shell (blue) transport properties 
using cAlb.   
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3.3.3 Measuring platelet packing dynamics within the low transport region  
 
Within stable thrombi, the core maintains a higher platelet packing density, resulting in 
significantly decreased porosity 12. We hypothesized that this high-density structure 
produces lower transport rates in the core by increasing steric hindrance between 
platelets, reducing permeability, and by increasing the tortuosity of the path cAlb needs 
to traverse to escape the core.  To measure the dynamics of the increase in platelet 
packing density during early thrombus development, we infused albumin conjugated with 
stably-fluorescent (i.e. non-caged) AlexaFluor 488 and monitored changes in 
fluorescence within the low transport region and shell region. For reference, 
fluorescence was also measured outside of the thrombus in flowing blood, which 
consists of ≈40% hematocrit and a porosity of 0.6.  By normalizing the fluorescence 
within the thrombus regions to the known value of the flowing blood, we were able to 
determine the porosity of each region within the thrombus (Figure 3-4). We found that 
porosity decreases rapidly in both regions as platelets accumulate following injury, with 
the low transport region achieving a significantly higher packing density than the shell by 
60s after injury (p < 0.05).  As reductions in both porosity and transport are observed 
prior to full platelet activation, this also supports our model of transport having a 
regulatory role in local platelet activation. 
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Figure 3- 4  Dynamics of thrombus regional porosity. 
Albumin labeled with AlexaFluor 488 was infused into the mouse prior to injury and the 
fluorescence was monitored within the lumen, low transport region (LTR), and shell of 
the developing thrombi.  (A) A representative image of platelets (blue) and LTR (white 
outline) 120 s post-injury.  (B) For the same thrombus a pseudo colored image of the 
thrombus colored to represent the porosity based on the normalized fluorescence 
intensity.  (C) Average porosity of the shell (blue) and LTR (cyan) of eight individual 
injuries over 240 s post-injury. 
 
3.3.4 Regional heterogeneity of intrathrombus thrombin activity 
 
To determine whether the altered structure and transport of the low transport region 
serve to concentrate agonists leading to increased platelet activation and eventual P-
selectin exposure, we employed a recently developed thrombin activity sensor, 
designated mThS-Ab.  The thrombin sensor consists of a FRET-based fluorogenic 
peptide thrombin substrate linked to anti-mCD41 to target it to the platelet surface 87. 
Cleavage of the peptide by thrombin releases a quencher, allowing an increase in 
fluorescence. The resulting signal represents the spatial distribution of cumulative 
thrombin activity. Thrombin activity, platelet deposition, and P-selectin exposure were 
measured in developing (0-3 min after injury) and stable thrombi (20 min after injury) 
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(Figure 3-5A, Supplemental Movie M2). Consistent with our previous observation that 
fibrin deposition occurs only within the core region 12, we measured 6.5 times more 
thrombin activity within the low transport region than within the shell by 3 min after injury 
(Figure 3-5B). By 20 min even the minor signal in the shell was no longer detectable. 
 
 
 
Figure 3- 5 Thrombin activity within the low transport region (LTR). 
(A) A representative image of thrombin activity (mThS-Ab; green, binary mode) within a 
thrombus 20 min after injury also showing platelet deposition (blue) and core formation 
(red). Overlay of 3 channels is white. (B) The change in the mean mThS-Ab 
fluorescence was monitored within the low transport regions (cyan) and shell (blue) 
during the initial 3 minutes after injury and again at 20 min (+/- SEM).  
 
3.3.5 Determining pathways which initiate and support low transport region 
formation 
	  
Since the data described so far show that the drop in transport rates within hemostatic 
thrombi precedes full platelet activation, we examined the effect of impairing platelet 
activation on transport rates. To do this, we selected Sema4D-/- mice, whose signaling 
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defect we have characterized previously 88,89. Sema4D is a semaphorin family member 
on the surface of platelets that supports contact-dependent amplification of Syk 
activation downstream of the platelet collagen receptor, GPVI 88. When studied after 
penetrating injury, Sema4D-/- mice show a defect in platelet accumulation and delayed 
P-selectin exposure during the first 3 min of thrombus development 12. The studies in 
Figure 3-6 confirm this earlier observation. They also show that these mice have no 
significant defect in cAlb transport during this same period (Figure 3-6C and D). Thus, 
these results reinforce the idea that the drop in transport rates within the thrombus not 
only precedes full platelet activation (as defined in this case by α-granule exocytosis), 
but is at least partially independent of it. 
 
 
 
Figure 3- 6 The role of contact-dependent Sema4D signaling in LTR and core 
formation. 
(A) Representative images of a thrombus generated in Sema4D-/- and wild type mice 
cremaster muscle arterioles showing platelets (blue) and P-selectin (red) at 3 minutes 
post-injury.  (B) Quantification of the average P-selectin(+) area within Sema4D-/- and 
wild type thrombi at 3 and 20 min post-injury (n = 13 for both Sema4D-/- and WT; +/- SD) 
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showing a lag in P-selectin exposure in the knockout.  (C) For each representative 
thrombus the corresponding cAlb half-life heat map is shown with the LTR highlighted 
(cyan). (D) The cAlb decay curves of the LTR of wild type (black) and Sema4D-/- (grey) 
thrombi (wild type n= 10, Sema4D-/- n= 14; +/- SD).   
 
3.4 Discussion 
 
Rather than being a homogeneous mass of equally-activated platelets uniformly 
interspersed with fibrin, studies in mouse models reveal that the hemostatic response to 
penetrating injuries shows considerable regional variation in the extent of platelet 
activation as judged by metrics such as the extent of α-granule exocytosis. In this and 
the following two chapters we have adopted a systems approach to understanding these 
events, combining observational, experimental and computational approaches to ask 
whether regional differences extend to other aspects of the hemostatic response and, if 
so, how such differences arise, contribute to thrombus growth and affect the benefits 
and toxicities of antiplatelet agents. 
 
To do this, we developed a novel tool for measuring intrathrombus transport rates in vivo 
in real time and combined it with a recently-described thrombin activity sensor 87. The 
results presented here show that regional differences in the extent of platelet activation 
are accompanied by differences in platelet packing density, intrathrombus molecular 
transport rates, distribution of at least one platelet agonist (thrombin), and deposition of 
fibrin.  The results also show how these relationships evolve over time (Figure 3-7). 
High-resolution mapping based on confocal in vivo imaging studies transforms the 
transport data into a heat map and defines a hitherto unappreciated transition zone 
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between the thrombus core and shell. Within this zone are platelets that have not yet 
reached the point of α-granule exocytosis, but nonetheless retard the passage of solutes 
in the spaces between them. The transition zone plus the core of platelets that became 
P-selectin(+) early in the injury response form a low transport region that eventually 
becomes fully P-selectin(+).  
 
 
 
Figure 3- 7 Model of the role of transport on agonist distribution and thrombus 
architecture. 
As platelets within a developing thrombus become activated they change shape, retract, 
and pack tightly together driving the formation of the low transport region. This leads to 
the retention of larger agonists, such as thrombin, within the low transport region.  
Smaller agonists, such as ADP and TxA2, are able to diffuse more freely out of the low 
transport region.  The localization of these agonist gradients drives continued platelet 
activation in the low transport region leading to core formation consisting of high platelet 
packing density, decreased solute transport, α-granule exocytosis, and fibrin deposition.  
The restriction of thrombin to the core contributes to the shell consisting of loosely 
adherent platelets, high solute transport, reduced platelet activation and no fibrin. 
 
Changes in transport rates presumably reflect the increase in packing density as 
platelets grow closer to each other, increasingly hindering the movement of molecules in 
the gaps between platelets. Supporting this conclusion, we found that the distribution of 
thrombin activity within the thrombus mirrored the regions of slowest transport and 
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extended little, if at all, into the shell region of the thrombus where transport rates, 
although slower than in the remaining vascular lumen, were still faster than in the core. 
Data presented in Chapter 5 provide further support, showing that mice with a defect in 
αIIbβ3 outside-in signaling that impairs clot retraction form thrombi with increased 
transport in both the core and the shell, and decreased thrombin activity compared to 
wild type mice. Here we studied mice with a defect in contact-dependent signaling due to 
loss of the platelet surface ligand, Sema4D. These mice have a defect in core formation, 
but still developed a low transport region, supporting the idea that the reduced transport 
is not dependent on achieving full platelet activation. 
 
The close relationship between the low transport region and the region of greatest 
thrombin activity is particularly informative. Others have also presented models 
suggesting that solute transport may play a key role in regulating thrombus growth by 
impacting coagulation factor access to the injury site as well as agonist escape from the 
thrombus 54,56. These models have shown that limiting the gaps between platelets can 
greatly hinder transport and alter the movement of solutes through the thrombus 52,54,56. 
Within this study we were unable to tease apart the contribution of fibrin in filling these 
gaps, but other investigators 53 have suggested fibrin doesn’t have a large impact on 
protein transport. However, fibrin has been reported to decrease the permeability of 
platelet plugs 51, which may alter permeating flow and in turn protein transport.  
 
We have previously shown that thrombin inhibitors prevent the formation of the core 
region 12. Generation of thrombin in vivo begins with the exposure of tissue factor, but 
the local accumulation of thrombin is also governed by the availability of procoagulant 
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factors (including prothrombin), the exposure of negatively-charged phospholipids on the 
platelet and other membrane surfaces, the washout rates of thrombin from its original 
site of generation, and the ability of coagulation inhibitors such as TFPI and anti-
thrombin to reach the site where thrombin and other coagulation factors are produced. 
Some coagulation proteins and inhibitors are contained within platelet α-granules and 
are eventually secreted at the site of platelet activation.  Others are plasma-borne. To 
the extent that molecular transport becomes hindered in the region closest to the site of 
injury, secreted molecules will tend to accumulate and plasma-borne molecules will have 
difficulty gaining access. This means that as platelets begin to accumulate following 
vascular injury they participate not only by forming part of the hemostatic plug, but also 
by acting as obstacles to the free movement of molecules in the region closest to the 
injury. 
   
Thus we propose that regional differences in platelet activation and in thrombus 
structure are closely related to each other and are both the driver for and the 
consequence of regional variations in agonist distribution and packing density. The data 
presented here plus our earlier studies with the thrombin sensor highlight the overlap 
between the region of greatest packing density, slowest transport and greatest thrombin 
activity 12,87. We have previously shown that the size of the thrombus shell is dependent 
on signaling downstream of platelet P2Y12 receptors for ADP 12. At present, there is no 
way to detect ADP in vivo in real time.  However, the vulnerability of the shell to P2Y12 
antagonists and the increase of shell size observed with a gain of function mutation in 
Gi2α 12 suggest that ADP concentration gradients extend further than do thrombin 
gradients. Therefore, it is a reasonable hypothesis that platelet recruitment initially 
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establishes a shell-like thrombus that is converted to the transition zone and core by 
thrombin. In a sense, the emergence of greater packing density within the core helps to 
create a molecular prison for thrombin that, along with the presence of thrombin 
inhibitors, limits the size of the core and, therefore, the overall size of the thrombus. It is 
also reasonable to propose that differences in the distribution of ADP and thrombin, as 
well as differences in the properties of the core and shell presage differences in safety 
and efficacy of P2Y12 antagonists compared to PAR1 antagonists. 
 
3.5 Supplemental Material 
 
 
 
Figure 3- 8 Minimal photobleaching of cAlb. 
The rate of cAlb photobleaching was measured by monitoring the fluorescence of pre-
activated cAlb in a no-flow environment. The cAlb fluorescence was measured after 100 
successive 100 ms exposures, which are the same as used during in vivo imaging. The 
dashed line indicates the time of exposure in between activated pulses in vivo. 
 
3.5.1 Generation of cAlb heat maps 
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To generate the cAlb transport heat maps  the  raw  acquired  image captures typically 
consisted of 300 frames for each fluorescent channel, which were initially stored in a 
4D matrix of size: “Total Number of UV flashes” x “Number of Image Captures 
between each UV Flash” x “Image Width” x “Image Height”. For the late-stage 
thrombogenesis  images  (20  min  post injury), the whole duration of the image capture 
could be used for the analysis, since the thrombi were stable throughout the capture. 
Therefore, the albumin intensity channel matrix size was 20 x 15 x 456 x 508 for this 
case. That is, there were a total of 20 UV flashes with 15 image captures between 
each flash, and the resulting image sizes were 456 by 508 pixels. For the early-
stage thrombus development, on the other hand, the clot structure was still evolving 
during the beginning of the capture, so only the last 6 flash periods (thrombi were 
observed to be sufficiently stable during this time) were used, resulting in matrix size 
of 6 x 15 x 456 x 508. Next, in order to improve accuracy, each dataset was 
averaged over the first dimension of the matrix, resulting in a mean flash period 
representation of size 15 x 456 x 508, for each dataset. Once normalized, the data 
was smoothed in 3D using the custom medfilt3 Matlab function 
(http://www.biomecardio.com/matlab/medfilt3.html), where the first two dimensions were 
the X and Y directions in the plane of the image, and the third one was time. The 
default 3 x 3 x 3 neighborhood was used for the median filtering.   After that, the 
standard deviation of the pixel values over the 15 frame duration was calculated and 
the pixels that showed less than 20% deviation from their mean were excluded from 
the analysis. The reason for this was two fold: 1) pixels with negligible amount of 
albumin variation should not be taken into the consideration, because they could 
be representing a platelet, rather than albumin-filled voids between cells and 2) this 
resulted in significant computational savings, since the procedure effectively excluded 
the lumen and extra-vascular regions from the calculation. For similar reasons, the 
62	  
	  
CD41 mask was used to further exclude the non-thrombus pixels from the analysis. 
Finally, 1D piecewise cubic Hermite interpolation was used in order to estimate the 
half-life of the normalized albumin data for each pixel. A custom 2D median filter (ignores 
pixels previously excluded from analysis) with a tile size of 3 x 3 pixels was used to 
post-process the final results for noise reduction in the plane of the images. The 
resulting half-life “heatmap” (shown in color) was overlaid onto the mean thrombus 
representation shown in grayscale (CD41 channel image averaged over all frames). 
Peak half-life values were saturated at 4 seconds in order to highlight the differences 
between low and high albumin retention regions of the thrombi. 
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CHAPTER 4: A systems approach to hemostasis: 2. Computational analysis of 
molecular transport in the thrombus microenvironment 
 
This research was originally published in Blood. Tomaiuolo M, Stalker TJ, Welsh JD, 
Diamond SL, Sinno T, Brass LF. Blood. 2014;124(11):1816-23. © the American Society 
of Hematology. 
 
4.1 Introduction 
 
Platelets are central to hemostasis, helping to form a hemostatic plug or thrombus at an 
injury site without occluding the vessel. Recent work has shown that hemostatic thrombi 
formed following penetrating laser or probe injury in the cremaster muscle 
microcirculation are heterogeneous with respect to important properties such as the 
extent of platelet activation, platelet packing density, porosity and the distribution of 
thrombin activity 12,87. This heterogeneity is organized into a structure in which a core of 
highly activated platelets close to the injury site is covered by a shell of loosely adherent 
and less activated platelets 12. In Chapter 3, we showed that the transport of plasma 
proteins in the gaps between platelets is also heterogeneous, being slower in the core 
than in the shell. These findings raise new questions about the origins of the thrombus 
architecture that we and others have observed.  
 
Computational methods are useful for answering questions about complex systems, 
complementing experimental approaches and generating new hypotheses. 
Computational approaches have been used to model the hemostatic process (reviewed 
in reference 90), but few have explicitly examined the impact of platelet packing density 
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or molecular transport through the hemostatic plug 52,53,56,91. Here we propose that 
considering molecular transport leads to a more comprehensive understanding of how 
the internal organization of a hemostatic plug develops. Drawing on published studies 90 
and Chapter 3 we have examined plasma velocity in a hemostatic plug modeled in two 
dimensions. To simulate solute transport, we have modeled hemostatic thrombi as a 
porous media comprised of regions with distinct physical characteristics that represent 
the core and shell. Using this computational framework we have reproduced 
experimental data, and then explored the role of the core by comparing solute transport 
through a simulated hemostatic thrombus with or without a core. 
 
The results show that 1) once platelet accumulation begins, plasma velocity slows by 
orders of magnitude, and 2) relatively small number of platelets are sufficient to create a 
sheltered environment where diffusion, rather than convection, is dominant. Our results 
further emphasize that the core and shell are distinct physical microenvironments, and 
that the thrombus core acts as a selective molecular prison retaining some soluble 
agonists to increase their effective concentration. Predictions made based on this model 
are tested in Chapter 5.   
 
4.2 Materials and methods 
 
4.2.1 Model setup  
 
We used two models to study intrathrombus transport. The first model, which was only 
used to study the flow characteristics inside the thrombus, is a 2D representation of a 
thrombus with platelets represented explicitly by ellipses and will be referred to as the 
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“explicit-platelet” model in the text. For this model we used computational fluid dynamics 
based on the Stokes equation to resolve the flow in the narrow gaps between platelets 
as well as in the lumen surrounding the thrombus (Figures 1-3).  In the second model, 
the thrombus is represented as a two-compartment homogeneous porous medium; for 
this model, which includes species transport, we adopted a mathematical description 
similar to Kim et al. 53.  Here, we apply the Stokes equation for the lumen region and a 
Brinkman equation for the thrombus.  These equations are coupled with convection-
reaction diffusion equations to study solute transport in the thrombus (Figures 4-4 – 4-7). 
Both models were implemented and solved using COMSOL® version 4.3a. 
 
4.2.2 Thrombus design for the explicit-platelet model  
 
We designed a thrombus with size and geometry based upon in vivo images of stable 
thrombi (Figure S1). Each platelet was modeled as an ellipse with minor and major 
semiaxes of 0.6 µm and 1 µm. To investigate packing density we changed the 
dimensions of the ellipses without modifying their positions. We modeled the internal 
core-and-shell thrombus architecture by selectively changing the dimensions of a subset 
of platelets. Additional details may be found in the supplementary materials. 
 
4.2.3 Solute transport  
 
We used the “species transport in porous media package” in COMSOL® version 4.3a, 
solving the convection-reaction-diffusion equation: 𝜕𝑐 𝜕𝑡 = 𝐷∇!𝑐 − 𝑢∇𝑐 + 𝑅, where c is 
the concentration of chemical species of interest, D is the diffusion coefficient, u is the 
velocity vector field, and R describes sources of the various chemical species. We 
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imposed an initial uniform concentration of a tracer solute in the vessel, zero solute 
concentration at the influx boundary, and then ran the simulation until the concentration 
inside the thrombus regions decreased to zero. Additional details may be found in the 
supplementary materials. 
 
4.2.4 Single parameter sensitivity analysis  
	  
The value of each of the six parameters (porosity, permeability and effective diffusion 
coefficient for the core and shell regions of the thrombus) was varied by 50% above and 
below its base case regressed value. For each variation, the transport simulation was 
run and the error between the simulation and experimental data evaluated.   The 
sensitivity score with respect to each of the 6 parameters was calculated as the average 
of the root mean square error (RMSE) of the two simulations (+50% and -50%) relative 
to the RMSE of the base case fit.  
 
4.2.5 Global sensitivity analysis 
 
Each parameter was chosen randomly from a uniform distribution (Table 1). Each 
combination was chosen using a Latin hypercube sampling design. We simulated 
transport through the hemostatic thrombus and computed the RMSE between the 
simulation and the experimental data. We repeated this process 200 times with every 
simulation resulting from a different combination of parameters. 
 
Table 4-1 
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Parameter value ranges used in the species transport simulations (Figures 4-7) 
 
Parameter Minimum Reference Maximum Reference 
Porosity − ε >0 
Minimum physically 
possible 1 
Maximum 
physically possible 
Permeability (m2) − κ 10−18 14 10−14 14 
Effective diffusion coefficient (m2/s) − D 10−13 Current paper 5 × 10−11 11 
 
4.3 Results 
 
4.3.1 Model of in vivo thrombus formation  
 
We began by examining the impact of thrombus size and packing density on plasma 
velocity within a hemostatic thrombus, the former by varying the number of platelets and 
the latter by varying the size of the gaps between platelets. To replicate results from the 
mouse injury model we considered a vessel 30 µm in diameter and designed growing 
platelet masses in which the smallest gaps were located in either the middle or the front 
of the mass. These manipulations were meant to reproduce a hemostatic thrombus 
growing (an increase in platelet number), consolidating (a reduction in gap size), or 
developing the characteristic core-and-shell architecture (heterogeneous gap 
distribution). Unless otherwise stated, all of the simulations had an inlet centerline 
velocity of 2 mm/s, typical of what is measured in similar size vessels under 
physiological conditions.  
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The results show that once a threshold is reached, the average plasma velocity within a 
hemostatic thrombus is minimally affected by the number of platelets within the 
thrombus. With as little as sixteen platelets, the average intrathrombus plasma velocity 
was approximately three orders of magnitude less than the bulk velocity (Figure 1A). 
Further increases in platelet number had only a minimal effect (Figure 1B-D). Using the 
largest thrombus geometry shown in Figure 1C, we examined how gap size and 
distribution affect molecular movement in a thrombus. The range of gap sizes that we 
considered was selected from electron microscopy studies in the literature 8. We found 
that even when the minimum gap is as much as 400 nm, the average velocity within the 
thrombus is below 2 µm/s (Figure 2A). As gap size decreased, so did velocity, 
highlighting the ability of platelets to hinder flow.  
 
Figure 4- 1  Thrombus size does not determine intrathrombus plasma velocity. 
(A-C) Successive stages of thrombus growth with corresponding number of platelets and 
bulk plasma velocity field. (D) The horizontal axis represents the number of platelets in 
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the hemostatic thrombus. The vertical axis shows the average plasma velocity computed 
between the platelets. In all cases the inlet vessel velocity is modeled as a pressure-
driven parabolic profile with maximum velocity of 2 mm/s. 
 
4.3.2 Convection Vs. diffusion 
 
The relative impact of convection and diffusion is shown in Figure 2B, where minimum 
gap size is plotted against the Peclet number (see Methods), a value that estimates the 
relative contributions of convection and diffusion. A Peclet number of 1 indicates that 
convection and diffusion contribute equally, while a value <<1 indicates that diffusion 
dominates over convection. The results show that the small pore sizes within the 
thrombus produce a microenvironment in which molecular transport is dominated by 
diffusion. This effect was not substantially impacted by bulk plasma velocity. For 
instance even with a 4-fold increase in lumen velocity, from 2 to 8 mm/s, the 
intrathrombus velocity was still within the µm/s range (Figure 2C). 
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Figure 4- 2  Platelet gaps, plasma velocity and porosity in a hemostatic plug. 
.  
 
(A) The relationship of minimum gap size to mean intrathrombus plasma velocity. (B) 
The relationship between minimum gap size and the Peclet number shows that 
intrathrombus transport is dominated by diffusion. (C) The average velocity in a 
hemostatic thrombus increases linearly with the inlet velocity (slope = 0.28), but even 
when the velocity is quadrupled the velocity between platelets is still in the µ m/s range. 
 
4.3.3 The impact of heterogeneous thrombus architecture  
 
The presence of a tightly-packed thrombus core 12 was simulated by decreasing the 
minimum gap size between a subset of platelets from 200 to 10 nm (Figure 3, gray 
ellipses). The simulated core region was placed either in the front (Figure 3A and C) or 
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in the center (Figure 3B and D) of the platelet mass to determine whether the location of 
the core affected plasma velocity within the mass. Figure 3E illustrates how the plasma 
velocity is affected by the presence of platelets. The velocity of the plasma near the 
vessel wall immediately upstream of the thrombus is about 0.5 mm/s. Between platelets 
this falls to 1 µm/sec, decreasing even further where the narrowest gap between 
platelets is 10 nm. Notably, the location of the core had little effect (Figure 3F). 
 
 	  
Figure 4- 3  Heterogeneous gap size distribution. Based on experimental data. 
(A, B) Two different architectures were designed with a subset (the core) of more tightly 
packed platelets at the front (C) or in the center (D) of the hemostatic plug. The smallest 
72	  
	  
gaps are 200 nm and 10 nm between white and gra y platelets respectively. In all cases 
the inlet vessel velocity is modeled like a pressure driven parabolic profile with maximum 
velocity of 2 mm/s. E) Sample regions in a pre-thrombus area, behind core platelets 
(gray) and shell platelets (white) with their respective computed velocity magnitudes. F) 
Average intrathrombus plasma velocity computed for geometries with the core in the 
front (black) or in the middle (red). Platelet packing density, but not the core location, 
determines the average velocity between platelets. 
 
4.3.4 Solute transport within the hemostatic plug  
 
In the first manuscript in this series 22, we provide experimental evidence that solute 
transport rates are slower in the core than in the shell. Solute transport measures how 
molecules move in the complex geometry of a hemostatic plug. Particle movement in the 
absence of obstacles and convection is described by Brownian motion (i.e. the diffusion 
coefficient). The diffusion coefficient of albumin 92 is 6x10-11 m2/s, which given similarity 
in mass, resembles that of thrombin 93 (8x10-11 m2/s), but is much lower than non-protein 
agonists such as ADP 94 (50x10-11 m2/s). We next asked whether the observed 
differences in transport can be reproduced assuming that the core and shell are 
characterized by microenvironments with different transport properties, as opposed to 
being just two distinct geographical regions.  
 
To do this, we designed a thrombus with size, shape and architecture based on the in 
vivo observations. Because the model that we used to study flow characteristics places 
large computational demands when trying to resolve flow features in the narrow gaps 
between individual platelets, we modeled the thrombus as two homogeneous regions 
with physical characteristics described by three parameters: porosity, permeability and 
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the effective diffusion coefficient (Figure 4A). Porosity represents the fraction of empty 
space in the mass, with larger gaps corresponding to larger porosity values. Permeability 
is the ability of a porous material to allow fluid to pass through, thus describing pore 
connectivity. The effective diffusion coefficient represents how a molecule of a certain 
size diffuses through a porous material. The presence of solid boundaries within a 
porous media hinders molecular movement, and as a result the effective diffusion 
coefficient is smaller than the free diffusion coefficient. Note that these material 
characteristics are independent. Thus, it is possible for two materials, or two hemostatic 
plug regions, to have the same porosity but different permeability or diffusion 
coefficients, and vice versa. 
 
Porosity values for the core and shell were obtained in vivo 12. Permeability values were 
obtained in vitro 51 and do not distinguish between core and shell regions. These 
experimental estimates served as an initial guide for our simulations. We assumed the 
existence of a core and a shell, and in both regions assigned a value for each of the 
three parameters. Thus, each simulation is specified by six parameters, and the value of 
a parameter for the core cannot be larger than the value of the corresponding parameter 
for the shell. We simulated the transport through the hemostatic plug, computed the 
average concentration in each region over time, and compared it to the experimental 
data (see Methods). We found a set of parameters for which there is a good agreement 
between the simulation and experimental data (Figure 4A). Thus, by hypothesizing that 
the core is more densely packed than the shell, we found a combination of parameters 
(Table 2) that reproduces the experimental data. Assuming instead that the core is as 
densely packed as the shell, does not lead to a good agreement between experimental 
data and simulations (Figure 4B). 
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Table 4-2 
Parameter values used in Figure 4A 
 
Parameter Core Shell 
Porosity − ε 0.2 0.4 
Permeability (m2) − κ 10−17 10−16 
Effective diffusion coefficient (m2/s) − D 4 × 10−12 10−11 
 
 
Figure 4- 4  Solute transport can be computationally reproduced. 
The diagram of the geometry used to simulate the solute transport process is shown 
above each graph. The hemostatic plug is designed as a combination of two 
homogeneous regions, denoted as “core” and “shell”, in which physical characteristics 
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such as packing density and fibrin content are defined by porosity, permeability and 
effective diffusivity. The graphs show data (from Welsh at al., 2014) and simulations of 
caged fluorescent albumin transport. The vertical axis shows the normalized 
concentration of fluorescent albumin from experimental data (filled symbols –exp) and 
simulations (empty symbols – sim). Solute transport is faster in the shell (triangles)	  than 
in the core (circles) in vivo. These phenomena can be computationally reproduced only 
by assuming that the core and the shell have different packing densities (A) and not 
otherwise (B).  
 
Due to the multidimensional nature of the parameter space it is possible for multiple 
combinations of parameters to fit the data equally well. Since it is not feasible to 
investigate all possible combinations, we used sensitivity analysis to determine the 
impact of each parameter on solute transport. Two complementary approaches were 
used, single-parameter and global sensitivity analysis. Single parameter analysis reveals 
how sensitive the simulation output is to the change of a single parameter. The model is 
sensitive to the effective diffusion coefficient and, to a lesser degree, porosity (Table 3). 
Conversely, the model is insensitive to the choice of the permeability value. The large 
sensitivity to the effective diffusion coefficient fits well with the results obtained in the 
previous section where we observed that the intrathrombus microenvironment is 
diffusion dominated. The global sensitivity analysis was performed by running 
simulations using different parameter combinations. We found a nonlinear trend with a 
well-defined minimum for the effective diffusion coefficient (Figures 5A and B). This 
shows that choosing the correct value for the effective diffusion coefficient results in a 
good fit to the data regardless of other parameter values. This confirms the results of the 
single-parameter sensitivity analysis. Moreover the minimum in the scatter plots 
represents a theoretical estimate of the effective diffusion coefficient values in a 
hemostatic plug (compare the minima in Figure 5 with the values shown in the bottom 
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row of Table 2). In contrast, the same analysis applied to porosity and permeability 
shows no pattern (Figure S5), confirming our previous conclusion that molecular 
movement in the thrombus is dominated by diffusion. 
 
Table 4-3 
Single parameter sensitivity analysis 
 
Sensitivity score 
Parameter Shell Core 
D (diffusion) 3.02 0.43 
ε (porosity) 0.82 0.06 
κ (permeability) 0.0006 0.0004 
 
 
 
Figure 4- 5  Global Sensitivity analysis. 
We implemented global sensitivity anal ysis performing 200 simulations, each with a 
different combination of parameters, and evaluated the fit (RMSE value) to the 
experimental data describing the transport of caged fluorescent albumin. We plot the 
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values sampled for the effective diffusion coefficient in the shell (A) and in the core (B) 
with the corresponding RMSE value. The effective diffusion coefficient values show a 
robust signal with respect to the fit, independently of the choice of the other parameter 
values. From this we estimate the effective diffusion coefficient to be 1x10-11 and 4x10-
12 m2/s for core and shell respectively. 
 
4.3.5 Release of soluble agonists from the injury site 
 
Potent platelets agonists, such as thrombin, are primarily produced in close proximity of 
the injury site 12,87. We examined how a closely-packed core region affects the 
distribution of thrombin-like solutes that are produced in a small region under the core of 
the hemostatic plug. Parameter values estimated in the previous section (porosity, 
permeability and effective diffusion coefficient) were used to describe the physical 
characteristics of the core and the shell. We simulated the constant release of a 
substance with the same diffusion coefficient as albumin from a 1 µm patch on the 
vessel wall under the core. We ran the simulation until it reached steady state (usually at 
about 30 seconds) and computed the average concentrations of the solute in the 
simulated core and shell, comparing a model in which packing density is greater in the 
core than the shell (which is what we observe in vivo) with a model in which packing 
densities are equal in the core and shell.  
 
The results are summarized in Figure 6 with the computed concentrations normalized to 
the value calculated in the core when the packing densities are equal. Having a densely 
packed core increases the effective concentration of soluble agonists in the core 
approximately 4.5-fold (Figure 6 lower left). In contrast, the concentration attained in the 
shell was 10- to 20-fold lower than in the core, regardless of whether the core and shell 
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were consider as having equal or unequal packing density (Figure 6 lower right). The 
core is thus acting as a selective molecular prison, where molecules may get ‘trapped’ in 
a gap size dependent manner. Conceivably, as platelets transition to a state of full 
activation and fibrin polymerization fills the available spaces within the core 12, the core 
becomes a prison for an even broader set of molecules. 
 
 
 
Figure 4- 6  The core is retentive. 
Relative concentrations in a simulated core (C) and shell (S) were calculated when a 
substance with the same diffusion coefficient as albumin was released from a 1 µm 
patch under the core. Simulations were run until steady state was reached, comparing 
two scenarios in which the packing density in the core was either equal to or greater 
than the shell. Calculated concentrations were normalized to the value attained in the 
core when the packing densities are equal. The graph on the lower left shows steady 
state concentrations in the core, which are higher when density in the core is greater 
than the shell. The graph on the lower right shows steady state concentrations in the 
shell, which are lower than in the core and unaffected by having core density greater 
than the shell. 
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4.3.6 Testing model predictions 
 
The simulations described so far show that packing density dictates transport rates. We 
hypothesized that a decrease in packing density would modify the thrombus architecture 
by reducing the size of the core and total platelet accumulation. This would happen 
because: 1) larger average gaps between platelets decrease the effective concentration 
of agonists, especially in the core, which is where we have shown 12,87 that most of the 
thrombin is found; 2) the decrease in agonist concentration reduces platelet activation, 
leading to a smaller core; and 3) fewer fully activated platelets diminish the paracrine 
effects of agonists such as ADP and TxA2 released from activated platelets, causing a 
decrease in total platelet accumulation.  
 
We tested this hypothesis using data obtained with mice carrying a substitution of 
phenylalanine for two tyrosine residues in the cytoplasmic domain of the β subunit of the 
αIIbβ3 integrin. This diYF mutation impairs integrin outside-in signaling and slows clot 
retraction in vitro 95. In the following chapter 96, we show that this mutation also impairs 
retraction in vivo, suggesting that hemostatic thrombi in these mice will have larger gaps 
between platelets compared to wild type. Figure 7A shows the comparison of caged 
fluorescent albumin transport experiments in control and diYF mice (from Chapter 5, 
Figure 5-2). Consistent with our hypothesis, transport in both the core and the shell is 
faster in the diYF mice.  
 
We modeled conditions in the diYF mice using the parameter values listed in Table 2, 
changing only the value of the effective diffusion coefficient in both the core and the shell 
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to simulate the looser platelet packing. We used the RMSE to estimate the fit to the data. 
We found a good agreement with the experimental data (Figure 7B) when the value of 
the effective diffusion coefficient was doubled in both the core and shell (Dc = 8x10-12 
m2/s; Ds = 2x10-11 m2/s). These results illustrate that we can reproduce the experimental 
observations of solute transport in diYF mice by modeling a thrombus with decreased 
packing density compared to wild-type.  
 
Next we utilized the parameter set that provided the best fit to the diYF data to simulate 
the constant release of an agonist from the vessel wall and compared the results with 
the wild type simulation (Figure 7C). This simulation demonstrates that when the gaps 
between platelets become larger, as in the diYF mice, the concentration of thrombin-like 
agonists is decreased in the core and in the shell. This supports our hypothesis that a 
reduction in the size of the core in diYF mice is due not to the inability of platelets to be 
activated or to a decrease in agonist production, but to an increase in the size of the 
gaps between the platelets. 
81	  
	  
 
 
Figure 4- 7  Larger gaps predict faster solute transport and decreased platelet 
activation. 
A) Solute transport, as measured by caged fluorescent albumin, is faster, both in the 
core (circles) and in the shell (triangles), of diYF mice (empty symbols) compared to WT 
mice (filled symbols) (experimental data are from Chapter 5, Figure 5-2). B) Simulations 
(empty symbols) predict measured solute transport data, for both the core (circles) and 
the shell (triangles) of diYF (filled symbols) mice. C) Simulation of solute release from a 
wall region under the core predicts that the average concentration at steady state will be 
lower in both regions in the diYF mice. 
 
4.4 Discussion 
 
The hemostatic response requires platelets to adhere to the vessel wall and then to each 
other, forming part of a plug that prevents further bleeding and fostering the local 
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production of thrombin and fibrin. Here we have considered platelets from a different 
perspective, focusing on their ability to alter their local environment by obstructing the 
free flow of plasma-borne molecules into the region of injury and the free flow of platelet-
derived molecules out of the region. Our goal was to understand how the physical 
attributes of a platelet-enriched thrombus impact the hemostatic response, an idea 
previously examined by Kim, et al. using data obtained in vitro 53. To accomplish this 
goal, we utilized experimental solute transport data 22 to inform numerical simulations. 
 
The results show that by acting as obstacles platelets can retard plasma flow by orders 
of magnitude. Our estimates for intrathrombus velocity are in agreement with in vitro 
estimates 51 and 3D simulations 4. A further reduction in plasma velocity is achieved by 
decreasing the size of the gaps between platelets. The end result is the formation of a 
sheltered microenvironment where diffusion, rather than convection, becomes the 
dominant mechanism for molecular movement. Using simulations benchmarked on 
experimental evidence we estimate the effective diffusion coefficient for an albumin-like 
substance to be five times smaller in the shell than in the vessel lumen, and even 
smaller in the core. We expect the effective diffusion coefficient of thrombin to be even 
smaller given its binding kinetics. 
 
Solute transport within a hemostatic mass has recently received attention. Hindered 
protein transport through a fibrin cap has been considered 53, with results suggesting 
that the cap limits thrombus growth. Hindered transport was also considered as a 
mechanism capable of stopping thrombus growth 54,56. In a previous study from our 
group, transport through a reconstructed 3D thrombus was examined4. The results show 
that a protein-sized solute released from the bottom of the thrombus will escape from the 
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sides. Thus, a variety of experimental and theoretical approaches have reached similar 
conclusions. This speaks to the generality of hindered transport as a mechanism to limit 
thrombus growth following injury in order to achieve hemostasis while avoiding 
unnecessary vascular occlusion. Hemostasis begins with platelets being recruited at a 
site of injury, stably-attached platelets becoming progressively more activated by potent 
agonists, such as thrombin, which are produced primarily at the site of injury 12,87. As 
platelets become more activated, the gaps between them shrink and soluble agonists 
can either be trapped (i.e. thrombin), or prevented from penetrating in quantities 
sufficient to drive excessive platelet activation and fibrin deposition (i.e. prothrombin and 
other coagulation factors) 54,59.  
 
As in any model, certain simplifications and assumptions are necessary. In the explicit-
platelet model (Figures 1-3), where only fluid flow was examined, platelets were 
assumed to be ellipsoids with semi-axes of 1 and 0.6 µm. However, our results suggest 
that intrathrombus flow is governed primarily by gap size and not by the details of 
platelet shape.  Platelet shape change, variability in platelet size, or the presence of 
larger cells such as leukocytes would all alter the flow, but we assume that such effects 
are captured implicitly by varying the gap size distribution. The effect of gap size 
distribution on flow is illustrated in Figure 1. Intrathrombus velocity is progressively 
decreased as the gap size decreases. For all gap size distributions considered the flow 
is always in the regime of low Reynolds, Peclet and Womersley numbers (see 
supplementary materials). Under the physiological conditions we examined we can 
expect constant laminar flow in the lumen and diffusion to be dominant in the thrombus.  
The homogeneous species transport model, which is based on a porous medium 
representation of the thrombus, is parameterized using measurements obtained in vivo 
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(Chapter 3 and 5). The parameters in the homogeneous transport model (diffusivity, 
permeability and porosity) implicitly capture the macroscopic details such as platelet 
packing density or shape change and fibrin content, or any combination of the two. Our 
species transport simulations (Figures 4-7) depend, therefore, on an effective diffusivity 
derived from experimental data. 
 
The solute transport data (Figure 4) show the loss of fluorescence over time in a 2D thin 
slice (~0.5 µm) of the thrombus taken with a confocal microscope. The caged 
fluorescent albumin, however, elutes from the thrombus in a 3D volume, thus it can take 
paths that cannot be accounted for in a 2D model. Macroscopically, 2D simulations 
assume that transport in the 3rd dimension is not important, or that the thrombus is “long” 
in the neglected dimension. While this is obviously a simplification, the 2D results remain 
meaningful for analyzing the effects studied here. In the Supplementary Materials we 
show that in a 3D diffusion-only version of the thrombus where the depth-to-length 
aspect ratio approaches 0.5, the 2D simulation results become a good approximation to 
the 3D simulations (Figure S7B). 
 
An increasing amount of in vivo evidence is consistent with the model we propose. 
Porosity measurements indicate that the differences between core and shell are size 
selective 12. Thrombin activity can be detected only in the core 12,87. Full platelet 
activation, as measured by P-selectin expression, occurs only in the core, whose size is 
neither by eliminating ADP signaling nor enhanced by boosting it 12. Artificially increasing 
plasma prothrombin concentration does not increase total platelet accumulation in an 
arterial injury model 97, suggesting that increasing the concentration of thrombin 
precursor does not lead to increased thrombin production or increased platelet 
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recruitment. Finally, our model predicts that changing the dynamics of transport changes 
the effective concentration of agonists and thus thrombus architecture. We verified this 
prediction experimentally in an in vivo mouse model characterized by a defect in platelet 
retraction. We found that thrombi with larger gaps developed smaller cores and 
accumulated less fibrin 96. 
 
Taken together, this study and the accompanying chapters demonstrate the importance 
that gap size has in shaping molecular transport and platelet activation status. Although 
others have addressed the potential importance of gaps 98 or estimated gap sizes 
53,99,100, this is the first effort of which we are aware that combines observational and 
computational approaches to understand the effect of gap size on thrombus growth. In 
3D one can expect that some platelets, or portions of platelets, may be in direct 
membrane-membrane contact (0 nm), or in indirect contact mediated by protein-protein 
interactions (tens of nm), integrin-fibrinogen-integrin interactions (less than 100 nm) 101 
or GPIb/IX-VWF interactions (possibly ≥100 nm) 102. In this microstructure it is important 
to know the gap size distribution, because that is what ultimately determines transport 
rates. 
 
In conclusion, the results presented here demonstrate that the interactions between 
platelet biology and molecular transport are important in shaping thrombus architecture 
and determining platelet activation status. These interactions have already been partially 
unmasked by in vivo data 12 indicating that the outer, less closely-packed region of a 
hemostatic thrombus is driven primarily by platelet-derived highly-diffusible molecules 
such as ADP, and is therefore most susceptible to P2Y12 antagonists. In contrast, the 
tightly-packed core region is primarily driven by the less diffusible thrombin and is more 
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susceptible to thrombin inhibitors. The effects of intrathrombus transport should 
therefore be considered when designing new and improved antiplatelet agents. 
 
4.5 Supplemental materials 
 
4.5.1 Thrombus design.  
 
To investigate plasma velocity we designed a thrombus with size and geometry based 
upon in vivo images of stable thrombi formed following penetrating laser-induced injuries 
in mouse cremaster arterioles (Figure S1). Each platelet was modeled as an ellipse with 
minor and major semiaxis measuring respectively 0.6 µm and 1 µm. To investigate 
packing density we changed the dimensions of the ellipses without modifying their 
positions. The minimum gap size allowed corresponds to the minimum distance between 
two ellipses stacked vertically; this metric is correlated with, but does not always 
correspond to, the absolute minimum gap size in the entire thrombus. The gap size 
distribution shown in Figure S2A depends on the minimum gap size; increasing the 
minimum gap size also increases the average gap size (Figure S2B) and the porosity 
(Figure S2C). These results show that the minimum gap size is an appropriate variable 
for controlling changes in the internal gap size distribution. To ensure that the particular 
thrombus geometry we chose (Figure S1) does not introduce bias, we also generated 
randomly packed semicircular ‘thrombi’, using ellipses of the same dimensions, where 
the minimum allowed gap was the same minimum gap we used in our design (Figure 
S3A and B). A similar gap size distribution was found (Figure S3C). Finally we modeled 
the internal core-and-shell heterogeneous thrombus architecture by selectively changing 
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the dimensions of a subset of platelets to reproduce images of thrombi formed in vivo 
following penetrating injuries in the microcirculation 12. 
 
4.5.2 Computational Fluid Dynamics.  
 
We used COMSOL® version 4.3a (a commercial finite element fluid dynamics solver) to 
simulate the flow of fluid in a blood vessel. In the cremaster vasculature, under 
physiological conditions, the blood flow is slow (i.e. Reynolds number ~ 0.01) and thus 
one can use the Stokes equations to simulate the fluid flow. For our explicit platelet 
model (Figure 1) we solved the Stokes equations: 𝛻!𝑢   − 𝛻𝑝 = 0;	  𝜌𝛻 ∙ 𝑢 = 0, where η is 
the dynamic viscosity, u is the velocity, ρ is the fluid’s density, and p is the pressure. In 
this model the hemostatic plug is represented explicitly by a collection of ellipses 
(platelets) variable in size and number, with gaps between them, placed at the bottom of 
a 30 µm vessel. 
 
For the homogenous porous media model, in which the platelets are replaced by an 
effective homogeneous medium, we computed the intrathrombus fluid velocity using the 
Brinkman equation:   𝜂 𝜀 𝛻!𝑢   − 𝛻𝑝   − 𝜂 𝑘 𝑢 = 0; where k denotes the permeability of the 
porous medium, and ε is the porosity. The Brinkman equation is a semiempirical 
adaptation of Darcy’s law and, given the slow flow velocity, can be applied inside the 
thrombus. The effective viscosity term present in the Brinkman equation, is defined as 
viscosity/porosity (η/ε) and incorporates the effects of thrombus porosity and tortuosity 
on fluid viscosity. In this model the hemostatic plug consists of two homogeneous porous 
media regions each characterized by three parameters: porosity (ε), permeability (κ) and 
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effective diffusion coefficient (D). The initial parameter values were chosen from the 
literature: the initial value for porosity was chosen to be 0.6 for the shell and 0.4 for the 
core, based on earlier in vivo measurements 12 while the initial value for permeability 51 
was taken to be 10-18 m2. We simulated a fluid having properties similar to water, with 
constant density of 1000 kg/m3 and viscosity of 0.0008 Pa s. To estimate the relative 
contribution of diffusion and convection in our designed thrombus we defined a Peclet 
number as follows: Pe = (average diameter of an intrathrombus pore) x (average 
intrathrombus velocity) / (value of the bulk diffusion coefficient). In both models (explicit 
platelet and homogeneous porous media) we chose a pressure drop of 3 Pa that 
corresponds to a centerline velocity of a typical cremaster blood vessel as measured 
from velocimetry (i.e. 2 mm/s). No-slip boundary conditions were applied at the vessel 
walls and platelet walls. From the numerical solvers embedded in COMSOL we used 
PARDISO 103 with a relative tolerance of 10-4. Other solvers (i.e. MUMPS and 
SPOOLES) were tested with similar tolerance levels, minor differences were observed in 
the solution time, but not in the solution result. The simulation time was 2 minutes using 
an Intel i7 with 8 cores and 12 GB of RAM.  
 
4.5.3 Solute transport  
 
Solute transport was simulated using the species transport in porous media in 
COMSOL® version 4.3a using the convection-reaction-diffusion equation: 𝜕𝑐 𝜕𝑡 =𝐷∇!𝑐 − 𝑢∇𝑐 + 𝑅, where c is the concentration of chemical species of interest, D is the 
diffusion coefficient, u is the velocity vector field, R describes sources of the chemical 
species (e.g. ADP from platelet dense granules). The albumin diffusion coefficient in the 
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bulk is 6x10-11 m2/s 104, the corresponding effective diffusion coefficient values for 
albumin in the core and shell regions were estimated in this study from the caged 
fluorescent albumin transport data reported in chapter 3. To simulate the transport of 
caged fluorescent albumin we set an initial uniform concentration of a tracer solute in the 
vessel, imposed a zero concentration at the influx boundary and ran the simulation until 
the concentration inside the thrombus regions was zero. We imposed zero diffusive flux 
(𝑛 ∙ ∇𝑐 = 0) boundary conditions at the outlet boundary and no flux boundary conditions 
at the vessel walls. From the numerical solvers embedded in COMSOL we used 
MUMPS 105 with a relative tolerance of 10-3 and an absolute tolerance of 10-6. The 
simulation time was approximately 1 hour using a maximum step size of 10-3 seconds. 
To assess the fit to the experimental data we computed the average concentration in 
each region over time and the root mean square error (RMSE), which we computed as 
follows: for each experimental data point available we calculated the square deviation 
from the simulated point and then computed the average of all such points. 
 
4.5.4 3-dimensional species transport simulations.  
 
Here we asked if the parameters estimated in the 2D model are a good approximation 
for a 3D representation of the model. The experimental data (Figure 4) shows the loss of 
fluorescence over time in a 2D image of a thin (~0.5 µm) longitudinal slice of the 
thrombus taken with a confocal microscope. In reality however, the caged fluorescent 
albumin elutes from the thrombus in a 3D volume, and thus can take paths to escape 
that cannot be represented explicitly in a 2D model. In other words, in a 2D model it is 
implicitly assumed that the 3rd dimension is long enough that edge effects do not 
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influence the dynamics in the middle. Here we examined the influence of the 3rd 
dimension by comparing transport in simplified 2D and 3D models. 
 
We started by comparing the 2D homogeneous porous media model used in the main 
text (which included fluid flow in the lumen) with a simplified model using the same 2D 
geometry but without explicit consideration of the flow in the lumen. In this new model, 
we only need to specify 2 parameters for each homogeneous porous media region (core 
and shell), namely the porosity and the diffusion coefficient (both as in Table 2). No-flux 
boundary conditions were applied at the base of the thrombus and zero concentration at 
the outer boundary of the thrombus. The latter boundary conditions simulate the rapid 
disappearance of a solute leaving the thrombus via flow in the lumen. We set an initial 
uniform concentration of a tracer solute in the thrombus and ran the simulation until the 
concentration inside the thrombus regions was zero. We computed the average 
concentration over the entire thrombus at each time point and compared it to a 
simulation where fluid flow in the lumen was explicitly considered. The results show that 
the simplified 2D model is a good approximation of the full system, at least when only 
considering the overall average concentration (Figure S6).  
 
Next we compared the simplified 2D model results with a 3D representation. We 
considered the aspect ratio between the length and the depth of a thrombus (Figure S7, 
upper insert). For each aspect ratio examined we used the same parameter values, 
initial conditions and boundary conditions as in the 2D diffusion model. We ran the 
simulations and determined the ratio between the diffusion coefficient in the 3D model 
and the diffusion coefficient in the 2D model (D3D   /  D2D)  needed for the 3D simulation 
results to match the 2D simulations (Figure 7B). We found that when the aspect ratio is 
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greater than about 0.5, the 2D model is a meaningful comparison to the 3D model. This 
suggests that the estimates we obtained from our homogeneous porous media 2D 
model are a good approximation for the 3D case if the geometry of the thrombus is such 
that the depth of the thrombus is at least about half its length.  
  
4.5.5 Non-dimensional parameters.  
 
To compute the Reynolds and Womersley numbers we used a diameter of 30 µm, 
matching that of the arterioles we use in our experiments, and a heart rate of 600 beats 
per minute to compute the angular frequency of the oscillations (i.e. 10 Hz). The value 
for the blood dynamic viscosity at 37 degrees C, and at a shear rate of 100 s-1, was 
taken from Rosenson et al. 106. 
 
Reynolds number: 
𝑅! =   𝑢𝐿𝜈 =    2 ∗ 10!!  𝑚  𝑠!! 30 ∗ 10!!  𝑚  10!!𝑚!  𝑠!! = 0.06; 
where u is the velocity, L is the characteristic length and ν is the kinematic viscosity.  
Womersley number (mouse arteriole): 
𝛼 = 𝑅 𝜔𝜈 !/! = 15 ∗ 10!!𝑚 ∗ 10  𝑠!!10!!𝑚!𝑠!! !! = 0.0474; 
 
where R is the radius, ω is the angular frequency of the oscillations and ν is the 
kinematic viscosity. 
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Figure 4- 8  Geometry used in the simulations. 
(A) Geometry used in the simulations is based on thrombus in vivo image (B).  
 
 
 
 
Figure 4- 9 Relation between minimum gap size and mean gap size. 
A) Relation between minimum gap size and mean gap size. B) Distributions of gap size 
between platelets using different minimum gap sizes (10 nm bins). C) Relation between 
minimum gap size and porosity, computed as the fraction of empty space in the 2D 
geometry. 
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Figure 4- 10  Thrombus simulation architecture. 
A) Thrombus used for simulations in main text with minimum gap size of 100 nm. B) 
Sample thrombus generated by a random packing algorithm with minimum gap size of 
100 nm. C) Comparison between the distributions of gap sizes of A and B (50 nm bins). 
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Figure 4- 11  Schematic illustration of the relationship between the explicit 
platelet and homogenous porous media models. 
The velocity fields are computed using the Stokes equation in the model with explicit 
platelets, and using the Brinkman equation in the model with homogenous porous 
media.  
 
 
 
Figure 4- 12  Global sensitivity analysis. 
A) Global sensitivity analysis simulations evaluated as the fit (RMSE value) to the 
experimental data describing the transport of caged fluorescent albumin. We plot the 
values sampled for the porosity in the shell (A) and in the core (B), and for the 
permeability in the shell (C) and in the core (D), with the corresponding RMSE value. No 
correlation is found for any of the parameters, or for any of the regions, illustrating that 
the choice of these parameters does not influence the fit to the experimental transport 
data. 
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Figure 4- 13 Comparison between 2D advection-diffusion and 2D diffusion model 
inside of the thrombus. 
 
Average concentration computed over the entire thrombus using advection-diffusion in a 
homogeneous porous media (black line) is compared to a model with only diffusion (red 
line). For both models we used the parameter values listed in Table 2 for porosity and 
diffusion coefficient. 
 
 
 
Figure 4- 14  3D core and shell homogeneous porous media diffusion model. 
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The x-axis shows the aspect ratio between the depth and the length (see upper insert). 
The y-axis shows, on a log scale, the ratio between the 3D and the 2D diffusion 
coefficient value for which the 3D results closely match the 2D results. When the depth-
to-length aspect ratio is greater than about 0.5, the 2D simulation becomes a good 
approximation to the 3D model. 
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CHAPTER 5: A systems approach to hemostasis: 3. Thrombus consolidation 
regulates intrathrombus solute transport and local thrombin activity 
	  
This research was originally published in Blood. Stalker TJ, Welsh JD, Tomaiuolo M, Wu 
J, Colace TV, Diamond SL, Brass LF. Blood. 2014;124(11):1824-31. © the American 
Society of Hematology. 
 
5.1 Introduction 
 
In previous studies, we and others have shown that the extent of platelet activation 
during the hemostatic response to penetrating injuries is heterogeneous, resulting in a 
distinctive thrombus architecture that consists of a core of fully-activated platelets 
immediately adjacent to the site of injury overlaid by a shell of minimally activated 
platelets12,80,81,107-109. We have also shown that different signaling pathways within the 
platelet signaling network predominate in different regions of the thrombus, with 
ADP/P2Y12 signaling being critical for platelet recruitment and retention in the shell, while 
thrombin signaling drives full platelet activation and firm adhesion in the core12. These 
findings show how partially overlapping gradients of soluble agonists emanating from the 
site of injury can support platelet accumulation, promote platelet activation and produce 
the characteristic thrombus architecture.   
 
Regional differences within hemostatic thrombi are not limited to the extent of platelet 
activation. There are physical differences as well. Most notably, our previous studies 
showed that the core region has reduced porosity and decreased plasma molecule 
penetration compared to the shell, indicative of increased platelet packing density in the 
98	  
	  
core12. Solute transport in the gaps between platelets is also slower in the core than in 
the shell, both of which are orders of magnitude slower than in the remaining vessel 
lumen110. The drop in transport rates occurs soon after platelet accumulation begins, 
preceding full platelet activation as detected by the appearance of P-selectin on the 
platelet surface. A computational analysis based on these observations indicates that 
diffusion, rather than convection, governs the movement of plasma and platelet-derived 
molecules in the small gaps between platelets found in the core, and suggests that the 
observed difference in transport rates is sufficient to confine the accumulation of 
thrombin to the core111. 
 
Based on these findings, we now propose an extended model for hemostasis in which 1) 
greater platelet packing density in the thrombus core helps to determine local thrombin 
activity by providing a microenvironment in which thrombin can accumulate, and 2) 
active regulation of platelet packing density contributes to thrombus growth and stability 
by helping to determine where thrombin is generated and fibrin accumulates. Here we 
have tested this model by perturbing platelet packing density and measuring its effects 
on intrathrombus solute transport, localization of thrombin activity and platelet activation. 
Doing so required the development of a novel method to measure thrombus 
consolidation in real time in vivo in mice with a defect in clot retraction. Prior studies 
have demonstrated that following initial platelet accumulation at a site of vascular injury, 
the platelet mass rapidly consolidates via platelet-mediated retractile processes112,113. 
Law et al.114 showed that substituting Phe for Tyr747 and Tyr759 (diYF) in the 
cytoplasmic domain of the β subunit of αIIbβ3 inhibits outside-in signaling through the 
integrin and impairs clot retraction without affecting integrin activation and fibrinogen 
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binding. Here, we have tested the same diYF mice following vascular injury using a 
newly-established method for assessing molecular transport in the gaps between 
platelets110. The results show that the diYF mice have a defect in thrombus mass 
consolidation and that this defect is accompanied by the increase in transport rates and 
a decrease in fibrin accumulation in the thrombus core predicted by the computational 
modeling. Taken together, these studies reveal a novel role for outside-in signaling in the 
regulation of platelet mass consolidation and intrathrombus solute transport in the gaps 
between platelets. They also show that physical properties such as platelet packing and 
molecular transport are integral components of the hemostatic response, helping to 
determine agonist distribution and platelet activation within an evolving platelet mass. 
 
5.2 Materials and methods 
 
5.2.1 Mice 
 
DiYF mice were described previously114,115. They were originally generated in the 
laboratory of Dr. David Phillips at Portola Pharmaceuticals (San Francisco, CA) and 
were obtained by us from Dr. Tatiana Byzova at the Cleveland Clinic Foundation 
(Cleveland, OH).  They are backcrossed on to the C57Bl/6 background at least 7 
times115, and were therefore compared with C57Bl/6 mice from Jackson Laboratories 
(Bar Harbor, ME) as controls.  Male mice 8-12 weeks of age were used for intravital 
microscopy experiments. The University of Pennsylvania Institutional Animal Care and 
Use Committee approved all animal procedures. 
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5.2.2 Laser-induced injury in mouse cremaster arterioles 
 
The laser-induced thrombosis model as performed here was described in detail 
previously12.  Additional information is provided in the Supplementary Materials.  
 
5.2.3 Platelet mass consolidation  
 
Platelet mass consolidation was measured using an approach modified from Ono et 
al112.  Blood was drawn from a donor mouse via cardiac puncture using heparin as the 
anticoagulant and diluted 1:1 with modified Tyrode’s buffer (4 mM HEPES, pH 7.4, 135 
mM NaCl, 2.7 mM KCl, 3.3 mM NaH2PO4, 2.4 mM MgCl2, 0.1% glucose and 0.1% BSA).  
Platelet rich plasma (PRP) was obtained by centrifugation at 150 g for 7 minutes.  Alexa-
fluor 568 labeled anti-CD41 F(ab)2 was added for 15 minutes, followed by gel filtration of 
the platelets to remove plasma proteins and unbound labeling antibody.  Approximately 
50 million gel filtered platelets in 200 µl sterile Tyrode’s buffer were infused into a 
recipient mouse prepared for intravital microscopy using standard procedures via a 
jugular vein cannula.  The donor platelets were easily distinguished from the recipient’s 
endogenous platelets via their fluorescent label, and they were incorporated into laser-
induced thrombi normally.  To assess platelet mass consolidation, time-lapse image 
captures of thrombus formation were analyzed offline.  Stably adherent donor platelets 
were identified based on their Alexa-fluor 568 label, and the center of each donor 
platelet was marked manually frame-by-frame using the Manual Tracking procedure in 
Slidebook image analysis software (Intelligent Imaging Innovations, Denver, CO).  Once 
marked, the straight line distance from where a platelet first firmly adhered to its final 
position at the conclusion of the timelapse (3 minutes post-injury) was calculated using 
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Slidebook and is reported as the end displacement.  Multiple platelets were tracked in 
each thrombus and multiple thrombi from several mice were studied. 
 
5.2.4 Intrathrombus solute transport  
 
Intrathrombus solute transport was measured using caged fluoroscein coupled to 
albumin (cAlb) as described in detail in Welsh et al 110.  A detailed description is provided 
in the Supplementary Materials.   
 
5.2.5 Computational simulation of solute transport  
 
A detailed description of computational methods including model design and parameter 
description is included in an accompanying manuscript111.  Additional information is 
provided in the Supplementary Materials. 
 
5.2.6 Flow cytometry 
 
Mouse blood was obtained via the inferior vena cava using heparin as the anti-
coagulant, diluted 1:1 in modified Tyrode’s buffer and centrifuged at 150 g for 7 minutes 
to obtain PRP.  Alexa-647 fibrinogen, anti-P-selectin and Annexin V were added to 
separate samples, and the platelets were stimulated with either PAR-4 agonist peptide 
(AYPGKF, Bachem, Torrance, CA) for fibrinogen binding and P-selectin expression 
studies or the combination of AYPGKF and convulxin for Annexin V binding studies.  
Platelets were incubated for 15 minutes at 37˚C, diluted 5-fold with PBS and 
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fluorescence immediately measured using a BD FACS Calibur flow cytometer with 
subsequent analysis using FlowJo flow cytometry software. 
 
5.2.7 Statistics 
 
For data obtained from intravital microscopy experiments, statistics were calculated 
using the Mann-Whitney test for non-parametric data using GraphPad Prism 6.0 
software. 
 
5.3 Results 
 
5.3.1 Role of β3 integrin tyrosine phosphorylation in platelet mass consolidation  
 
Mice in which the two tyrosines in the β3 cytoplasmic domain have been mutated to Phe 
(diYF) were described previously, and showed a defect in integrin function, but the exact 
mechanism of this inhibition is unclear 114.  Platelets from diYF mice have normal αIIbβ3 
integrin inside-out activation and ligand binding, but ligand binding induced β3 tyrosine 
phosphorylation is absent 114.  Outside-in signaling pathways that require β3 
phosphorylation are thus impaired, resulting in unstable platelet aggregate formation and 
impaired fibrin clot retraction 114.   
 
Previous reports have used intravital microscopy to observe consolidation of the platelet 
mass during the early stages of thrombus formation in vivo112,113.  Although distinct from 
fibrin clot retraction in vitro, some of the same signaling mechanisms have been shown 
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to play a role in both processes, including myosin dependent platelet retraction112,113.  
Since diYF platelets were previously shown to have a defect in fibrin clot retraction, we 
sought to determine whether platelet mass consolidation was impaired following 
vascular injury in diYF mice.  To accomplish this goal, we employed a single platelet 
tracking approach in which the movement of individually labeled platelets is tracked as 
the entire platelet mass consolidates towards the site of injury. In this case, platelets are 
removed from donor mice, labeled with Alexa-568 anti-CD41 F(ab)2 fragments, and then 
infused into a syngeneic recipient mouse in numbers that result in labeling of a small 
percentage of the circulating platelet pool (described in the Methods section).  
Penetrating injuries were inflicted in cremaster muscle arterioles using a laser fired 
through the optics of the microscope116. We have previously shown that the response to 
laser injury is similar to the response observed when injuries are inflicted with a 
sharpened glass pipette12. 
 
Using this combination of injury and tracking techniques in wild-type mice, individual 
platelets within the platelet mass may be observed to move toward the site of injury as 
the mass consolidates with a mean end displacement of 4.2±0.27 µm (mean±SEM, 
Figure 1A-B, supplemental video 1).  The bulk of the consolidation occurred during the 
first 60-90 seconds post-injury.  Inward movement was reduced by approximately 50% in 
thrombi formed in diYF mice, which had a mean end displacement of 2.1±0.27 µm 
(p<0.0001 vs. WT, Figure 1B, supplemental video 2).  These findings demonstrate that 
platelet mass consolidation is decreased in diYF mouse thrombi. 
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Figure 5- 1  Loss of β3 integrin tyrosine phosphorylation attenuates platelet 
mass consolidation following vascular injury in vivo. 
Platelet mass consolidation was monitored by tracking the movement of individual 
platelets following adhesion to a developing thrombus, as described in Methods.  A) 
Photomicrographs show representative thrombus from a wild-type mouse.  The panel on 
the left shows 4 fluorescently labeled platelets within the platelet mass (outlined by the 
dotted line).  The panel on the right shows the region in the left panel outlined by the 
gray box.  The movement of the four platelets was tracked over time using image 
analysis software, and the tracks of each platelet in the image can be seen.  B) The 
movement of individual wild-type and diYF platelets during laser-induced thrombus 
formation is reported as the end displacement (total distance along a straight line from 
platelet starting point to endpoint).  Horizontal line and error bars indicate the 
mean±SEM.  For wild-type, n=78 platelets from 14 thrombi and for diYF n=43 platelets 
from 12 thrombi.  Statistics were calculated using the Mann-Whitney test. 
 
5.3.2 Intrathrombus solute transport 
 
One possible consequence of impaired platelet mass consolidation in diYF thrombi is 
altered plasma and solute transport in the narrow spaces between platelets.  
Intrathrombus solute transport is a critical regulator of platelet activation and thrombus 
evolution as it determines how far soluble molecular species generated at the injury site 
(e.g. thrombin) may distribute from their source before they are washed out111.  Solute 
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transport was measured during hemostatic thrombus formation in vivo using caged 
fluorescein molecules conjugated to albumin (cAlb) as described in the Methods section.  
Following a flash of 405 nm laser light, the washout of the cAlb may be quantified over 
time to generate decay curves as a measure of solute transport within a platelet mass as 
a whole or in specific subregions (i.e. core and shell regions; Figure 2A-B).  Consistent 
with the findings reported in Welsh et al110, we found that in wild-type mice cAlb washout 
(i.e. solute transport) was substantially slower in the core region of thrombi as compared 
to the shell region (Figure 2B).  This result is consistent with our previously reported 
finding of decreased porosity (i.e. increased platelet density) in the thrombus core vs. 
shell regions12.  Interestingly, solute transport was increased relative to controls in both 
regions of the diYF thrombi, with transport in the core region of diYF thrombi similar to 
transport in the shell region of wild-type thrombi (Figure 2B).  This finding suggests 
reduced platelet packing throughout thrombi in diYF mice, consistent with the impaired 
ability of diYF platelets to retract and consolidate the platelet mass as described above.  
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Figure 5- 2  Molecular transport is increased in diYF thrombi. 
Caged fluorescent albumin (cAlb) was used to calculate molecular transport in thrombi 
formed following laser-induced injury in cremaster arterioles of wild-type and diYF mice.  
A) Photomicrographs show caged-FITC albumin fluorescence within a representative 
wild-type and diYF thrombus.  The fluorescence is shown in pseudocolor to indicate 
relative concentration (blue is low, red is high).  From left to right, panels show the same 
wild-type (top row) or diYF (bottom row) thrombus immediately following a flash of 405 
nm laser light to uncage the cAlb in the thrombus (0s), followed by images captured 1 
sec and 2 sec after the flash.  The decrease in albumin fluorescence from 0-2 seconds is 
due to washout of the albumin from the platelet mass.  Note the albumin is retained 
longer in the core region of the thrombi.  B) Graph shows cAlb washout in the core (P-
selectin positive, triangles) and shell (P-selectin negative, squares) regions of wild-type 
(blue) and diYF thrombi (red).  Quantification and normalization procedure is described 
in Methods.  Values are mean ±SEM for n=11 wild-type and n=12 diYF thrombi. 
 
5.3.3 Computational simulation of agonist distribution in diYF thrombi 
 
To investigate the impact of altered intrathrombus solute transport on platelet agonist 
distribution within a thrombus, we used computational modeling to simulate the physical 
conditions present within wild-type vs. diYF thrombi.  Specifically, we examined the 
impact of the physical microenvironment on the distribution of a protein-sized solute 
released from the vessel wall at the base of a simulated platelet mass to mimic thrombin 
generation at a site of injury in vivo. The Navier-Stokes equations (COMSOL v4.3a) 
were used to resolve the flow field in a simulated 30 µm diameter blood vessel with a 
centerline velocity of 2 mm/s (i.e. mimicking a mouse cremaster arteriole). The Brinkman 
equations117 were used to solve the velocity field in the thrombus modeled as a porous 
media and the advection-reaction-diffusion equation was used to simulate the transport 
of solutes in a porous media describing the hemostatic mass. To simulate the core and 
107	  
	  
shell architecture of wild-type and diYF thrombi, two regions were created in which the 
porosity, permeability and effective diffusion coefficient were varied by region to 
reproduce the solute transport conditions observed in vivo111 (Figure 3A).  Next, the 
constant release of a protein-sized solute from a 3 µm patch below the core region was 
simulated until a steady state was reached.  The concentration of the solute in the core 
region of diYF thrombi was significantly reduced compared to its concentration in the 
core of wild-type thrombi (Figure 3B).  The solute concentration was also significantly 
reduced in the shell of diYF thrombi compared to wild-type, although it should be noted 
that very little solute was retained in the shell region in both cases (note the difference in 
y-axis scale between Figure 3B and C).  Thus, these computational simulations suggest 
that structural differences between the core and shell region can account for the 
heterogeneity of platelet activation observed in wild-type mice in vivo, and further predict 
that altered molecular transport within diYF thrombi will result in reduced local thrombin 
activity.   
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Figure 5- 3  Computational modeling studies demonstrating the impact of 
impaired platelet mass consolidation on solute distribution within a thrombus. 
 A) A snapshot of the simulation at steady state showing the core and shell regions, as 
well as the relative concentration of a solute released at a constant rate from a 3 µm 
patch on the vessel wall beneath the core region (shown in pseudocolor – red is high, 
blue low concentration).  B and C) Graphs depict relative concentration in the core (B) 
and shell (C) regions of a solute released at a constant rate from the vessel wall beneath 
the core region.  The core and shell regions were defined by values for porosity, 
permeability and effective diffusion coefficient that were chosen based on their ability to 
fit the transport data for wild-type and diYF mice shown in Figure 2. 
 
5.3.4 Laser injury-induced platelet accumulation, activation and fibrin formation in 
diYF mice 
 
The above results indicate that αIIbβ3 outside-in signaling mediated by β3 integrin 
tyrosine phosphorylation helps to regulate thrombus architecture and solute transport.  
Thus, diYF mice serve as a good model to test our hypothesis that thrombus structure 
and intrathrombus solute transport are key regulators of agonist distribution and 
subsequent platelet activation at sites of vascular injury in vivo.  We quantified total 
platelet accumulation, P-selectin expression and fibrin deposition in diYF mice compared 
to wild-type controls following laser-induced injury in mouse cremaster arterioles.  Total 
platelet accumulation was moderately reduced in diYF mice as compared to wild-type 
controls (Figure 4A-C), although peak platelet accumulation was not significantly 
different between the two strains (Figure 4C).  In both cases the kinetics of platelet 
accumulation were comparable to prior reports using this thrombosis model 12,39,116.  In 
contrast, the number of P-selectin positive platelets was significantly reduced in thrombi 
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formed in diYF mice (Figure 4D-F), indicating decreased full platelet activation following 
vascular injury in vivo in the absence of β3 integrin tyrosine phosphorylation.   
 
Figure 5- 4  Loss of β3 integrin tyrosine phosphorylation attenuates platelet 
activation following vascular injury in vivo. 
Total platelet accumulation and α-granule secretion were monitored following laser-
induced injury in mouse cremaster arterioles using fluorescently tagged antibodies 
against mouse CD41 and P-selectin, respectively.  The graphs in A/B and D/E show 
total platelet accumulation (CD41 positive area; A mean±SEM, B median) and α-granule 
secretion (P-selectin positive area; D mean±SEM, E median) over time in wild-type 
(black circles) and diYF mice (gray squares).  Graphs in C and F show peak thrombus 
(C) and P-selectin positive (F) areas for wild-type and diYF mice.  The horizontal line 
and error bars indicate median and interquartile range.  For wild-type, n=38 thrombi from 
7 mice and for diYF n=41 thrombi from 6 mice.  Statistics were calculated using the 
Mann-Whitney test for non-parametric data. 
 
In agreement with prior findings114, fibrinogen binding by individual diYF platelets in 
response to the PAR-4 agonist AYPGKF was normal (Figure 5A), demonstrating that the 
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attenuated platelet accumulation and activation in vivo is not related to a direct effect of 
the diYF mutation on inside-out αIIbβ3 activation.  Further, the ability of diYF platelets to 
secrete their α-granules and express P-selectin in vitro as assessed by flow cytometry 
was normal (Figure 5B), as was their ability to mobilize P-selectin to the surface of 
platelets spread on immobilized fibrinogen (Figure 5C-D).  These findings indicate that 
the defect in P-selectin expression observed in vivo was not due to reduced P-selectin 
levels in diYF platelets or a direct effect of β3 tyrosine phosphorylation-dependent 
signaling on α-granule secretion. 
 
 
 
Figure 5- 5  Fibrinogen binding and P-selectin expression are normal in diYF 
platelets. 
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A-B) Flow cytometry analysis of fibrinogen binding (A) and P-selectin expression (B) in 
wild-type and diYF platelets.  Platelets were stimulated with the indicated concentrations 
of the PAR-4 agonist AYPGKF.  Data are expressed as the percentage of positive cells 
(mean±SEM, n=3).  C) Representative photomicrographs from wild-type and diYF 
platelets showing GPIb (red) and P-selectin (green) expression by immunofluorescence.  
Platelets were stimulated with 100 µm AYPGKF and allowed to spread on immobilized 
fibrinogen for 45 minutes at 37˚C.  The cells were fixed and stained with anti-GPIb and 
anti-P-selectin without permeabilization to assess surface protein expression. 
 
5.3.5 Fibrin deposition 
 
Prior studies have demonstrated that full platelet activation and α-granule secretion in 
the laser-induced injury model as used here are primarily due to thrombin-dependent 
platelet activation12,39,108,118.  To determine whether there was reduced thrombin activity 
in diYF mice, we measured fibrin deposition during thrombus formation.  We found that 
the total area of fibrin deposition was significantly attenuated in diYF mice as compared 
to wild-type (Figure 6A-C).   Further, the fibrin specifically colocalized with platelets was 
significantly reduced (Figure 6D-F), suggesting attenuated local thrombin activity within 
the platelet mass.  Importantly, the decrease in fibrin area corresponded to decreased 
total fibrin accumulation, as quantification of fibrin fluorescence intensity mirrored the 
results obtained by analyzing fibrin area (Supplemental Figure 1A-C).  This reduced 
thrombin activity was not a result of impaired ability of diYF platelets to expose 
phosphatidylserine on the outer leaflet of the plasma membrane, as annexin V binding to 
diYF platelets was normal (Supplemental Figure 1D).  Thus, it is likely that the reduced 
thrombin activity observed in diYF mice is attributable to decreased thrombin retention 
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within the platelet mass as a result of impaired platelet packing and increased 
intrathrombus solute transport. 
 
 
Figure 5- 6  Loss of β3 integrin tyrosine phosphorylation attenuates fibrin 
formation following vascular injury in vivo. 
(A-C) Total fibrin accumulation was monitored following laser-induced injury in mouse 
cremaster arterioles using a fluorescently tagged antibody that specifically recognizes 
mouse fibrin.  The graphs in A and B show total fibrin area (A, mean±SEM; B, median) 
over time.  Panel C shows peak fibrin area for wild-type and diYF mice.  The horizontal 
line and error bars indicate median and interquartile range.  D-F) Platelet-associated 
fibrin was defined as the area that was positive for both fibrin and CD41 fluorescence.  
The graphs in D and E show platelet associated fibrin area (D, mean±SEM; E, median) 
over time.  Panel F shows peak platelet-associated fibrin area for wild-type and diYF 
mice.  For wild-type, n=30 thrombi from 6 mice and for diYF n=19 thrombi from 4 mice.   
Statistics were calculated using the Mann-Whitney test for non-parametric data.  E) Flow 
cytometry analysis of Annexin V binding to wild-type and diYF platelets.  Platelets were 
stimulated with 100 µM PAR-4 agonist AYPGKF and the indicated concentrations of 
convulxin.  Data are expressed as the percentage of positive cells (mean ±SEM, n=3). 
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5.4 Discussion 
 
Platelet accumulation at a site of vascular injury is a dynamic process that requires 
assimilation of chemical and physical cues regarding the extracellular environment to 
promote a cellular response that is coordinated in both time and space to achieve 
optimal hemostasis.  Extensive studies of platelet intracellular signaling pathways over 
the past several decades have greatly enhanced our understanding of platelet function.  
Still, it is only by examining platelet function in the complex milieu of an intact 
vasculature that we can begin to understand how these multiple signaling components 
are integrated along with contributions from other cells, the vessel wall and local 
hemodynamic conditions in order to generate a hemostatic plug.  In this regard, the 
current study sought to investigate how a platelet signaling pathway (αIIbβ3 outside-in 
signaling), physical characteristics of the platelet mass (platelet mass consolidation), and 
local molecular transport within the microenvironment of a platelet mass, interact with 
each other during hemostatic plug formation in vivo.  The data demonstrate that each of 
these components contributes to platelet accumulation and particularly platelet activation 
following vascular injury. They show that as platelets begin to accumulate at a site of 
injury they act as physical obstacles, limiting the movement of molecules through the 
spaces between them. As more platelets accumulate and become activated, outside-in 
signaling resulting in β3 phosphorylation contributes to the regulated consolidation of the 
platelet mass and increased platelet packing density.  The increase in packing density 
results in reduced solute transport within the platelet mass, particularly in the core 
region.  This region of reduced molecular transport provides a protected 
microenvironment where soluble species such as thrombin generated at the site of injury 
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are retained, leading to robust, irreversible platelet activation (Figure 7).  Thus, the 
platelet response is dictated by the interaction of local conditions impacting agonist 
distribution and concentration with the platelet signaling network. 
 
 
 
Figure 5- 7  A model for the role of intrathrombus molecular transport in the 
regulation of agonist distribution and platelet activation. 
A) Diagrams show relative gradients of intrathrombus molecular transport rates (left), 
platelet agonist distribution (middle), and platelet activation (right) following vascular 
injury in vivo.  B) The impact of impaired beta 3 integrin phosphorylation is shown. 
 
Prior studies have demonstrated that platelet mass consolidation is critical for ensuring 
the stable accumulation of platelets at a site of injury in vivo112,113.  Consolidation is 
mediated by platelet retraction, as demonstrated by the attenuation of this process by a 
myosin IIa inhibitor. However, Ono et al112 found that this process is independent of fibrin 
formation and therefore distinct from platelet-mediated fibrin clot retraction. In the 
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present study, we found that mice in which the two β3 cytoplasmic tail NxxY tyrosines 
are mutated to phenylalanine (diYF) have impaired platelet retraction during platelet 
accumulation in vivo, resulting in a more loosely packed platelet mass.  Thus, β3 integrin 
tyrosine phosphorylation is a critical upstream signaling component necessary for 
efficient platelet mass consolidation in vivo.  As primary platelet activation events 
(including inside-out αIIbβ3 activation, fibrinogen binding and granule secretion) are 
normal when diYF platelets are studied ex vivo, diYF mice provide a unique model in 
which the role of platelet packing density and platelet mass architecture may be studied 
independently of direct effects on primary platelet activation pathways. 
 
In conjunction with the impaired platelet mass consolidation seen in diYF mice, we found 
that intrathrombus transport was increased, allowing molecules to elute out of the 
platelet mass faster in diYF mice.  The importance of solute transport through a 
thrombus or blood clot has been proposed in several prior studies using combinations of 
in vitro and theoretical approaches56,59,63,119,120.  In general, these studies predicted that 
the presence of a platelet/fibrin plug will substantially impact solute transport, including 
movement of coagulation and fibrinolytic enzymes, at a site of vascular injury.  In one 
recent example, Kim et al53 demonstrated that the density of a fibrin network overlaying 
a platelet plug has a significant impact on the permeability of solutes moving through the 
network. They found that denser networks reduced permeability such that a larger layer 
of solute may develop at the boundary between the shell and core regions.  This study 
and others52,91 relied on computational models based on thrombus architectures 
observed using confocal imaging to simulate solute transport. In the first manuscript of 
this series110, we provide for the first time a description of molecular transport measured 
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directly within a platelet mass in vivo, and relate dynamic changes in intrathrombus 
molecular transport to changes in platelet mass architecture, thrombin distribution and 
platelet activation.  The results of that study indicated that irreversible platelet activation 
is preceded by a decrease in solute transport in the same region of the platelet mass 
that will become P-selectin positive (i.e. the core region).  These results are consistent 
with the finding that porosity of the core region is significantly reduced compared to the 
shell region with similar kinetics to the platelet mass consolidation observed here.  
Taken together with the results of studies from the diYF mice, a model emerges in which 
regulated changes in platelet mass consolidation, dictated at least in part by β3 tyrosine 
phosphorylation dependent platelet retraction, contribute to an altered hemodynamic 
microenvironment within the core region of the platelet mass in which molecular 
transport is slowed and solutes are retained to promote platelet activation (Figure 7). 
 
Several factors determine the movement of molecular species within and/or around a 
pile of platelets, including the size of the pores (plasma volume) between platelets, how 
well connected are the pores as well as their spatial distribution, the tortuosity of the 
pore space, the plasma velocity and the size of the solute.  In the second manuscript in 
this series111, computational modeling studies were performed to examine the 
importance of each of these variables in determining molecular transport within a platelet 
mass, as well as the likely impact of interplatelet molecular transport on the distribution 
of soluble species generated at a site of injury, such as thrombin.  Those studies 
demonstrate that as platelets accumulate and become tightly packed, molecular 
movement is primarily determined by the effective diffusion of the molecular species.  In 
other words, the small gaps between platelets within a hemostatic plug or thrombus, 
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particularly in the core region where they are most tightly packed, provide a 
microenvironment where soluble species are protected from washout.  Further, 
differences in physical factors between the core and shell regions suggest that retention 
of soluble species within the core region not only has the potential to promote platelet 
activation in that region, but may also provide a mechanism to limit the extension of 
hemostatic plug.  The data in the present study indicate that platelet mass consolidation 
is a critical component regulating molecular transport within a platelet plug, as reduced 
consolidation in diYF mice resulted in increased solute transport during platelet plug 
formation. They further provide evidence supporting a model in which the consequences 
of increased solute transport include reduced concentration/distribution of bioactive 
molecules, as demonstrated by the finding of decreased thrombin activity and decreased 
platelet activation in diYF thrombi.  It should be noted, however, that while we have ruled 
out several possibilities for direct effects of the diYF mutation on platelet activation, we 
cannot at present rule out the possibility that other, currently unappreciated effects of the 
diYF mutation could also contribute. 
 
While we have not explicitly considered the contribution of fibrin(ogen) to solute transport 
in this study, it likely plays an important role. Indeed, the contribution of fibrin to solute 
transport is captured in our in vivo measurements, as fibrin is present within the 
developing platelet mass.  Similarly, the physical properties used to define our 
computational model included the contribution of fibrin as these were based on our in 
vivo measurements where fibrin was present. With regard to solute transport, the 
expected impact of fibrin formation would be similar to platelet retraction shrinking the 
spaces between platelets, e.g. decreased pore volume and increased tortuosity.  In 
addition, several pro- and anti-coagulant proteins (including thrombin itself) bind to fibrin, 
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further impacting their distribution within a platelet mass. Additional approaches are 
required to tease out the precise contribution fibrin, but are beyond the scope of the 
current study. 
 
In conclusion, we have demonstrated a novel role for αIIbβ3 outside-in signaling in the 
regulation of platelet mass consolidation in vivo.  Further, we provided evidence that the 
extent of platelet packing in a hemostatic plug regulates interplatelet molecular transport, 
agonist distribution and subsequent platelet activation.  Taken together, these 
observations demonstrate that optimal hemostatic plug formation results from the 
interaction of physics, biochemistry and cell biology. 
 
5.5 Supplemental Materials and Methods 
	  
Laser-induced injury in mouse cremaster arterioles was performed essentially as 
described previously12. Alexa-fluor 568 anti-CD41 F(ab)2 (clone MWReg30, BD 
Bioscience, San Jose, CA) was used to label platelets, Alexa-fluor 488 anti-P-selectin 
(clone RB40.34, BD Bioscience) used to label activated platelets that had secreted their 
α-granules, and Alexa-647 anti-fibrin antibody (clone 59D8, a generous gift from Dr. 
Hartmut Weiler and Dr. Rodney Camire) was used to label fibrin, which serves as a 
surrogate for thrombin activity.  There was no significant difference in the diameter of 
arterioles selected for laser injury studies between wild-type and diYF (33.84±0.78 µm vs 
31.92±0.76 µm, respectively).  Similarly, centerline red blood cell velocities were not 
significantly different in cremaster arterioles of wild-type and diYF mice (3.6±0.5 mm/s 
vs. 3.4±0.8 mm/s, respectively). 
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Intrathrombus solute transport was measured using caged fluoroscein coupled to 
albumin (cAlb) as described in detail in Welsh et al110.  The cAlb was infused 
intravenously via the jugular vein cannula following preparation of mice for intravital 
microscopy.  The cAlb was flash activated using a 500 ms pulse of 405 nm laser light to 
uncage the fluorophore during image acquisition following laser-induced injury.  Each 
flash was followed by FITC fluorescence image acquisition for 15 frames (approximately 
10 seconds) at which time a new flash was initiated.  This sequence was repeated 
continuously for 3 minutes post-injury.  The FITC fluorescence is observed as a peak of 
fluorescence immediately following the 405 nm flash, followed by a rapid decay as the 
cAlb is washed out of the thrombus and field of view.  Pilot studies determined that the 
observed rapid decay is not related to photobleaching, but rather reflects cAlb transport. 
cAlb decay curves were generated for each thrombus by averaging each of the 
normalized decay curves for that thrombus.  The cAlb decay curves of multiple thrombi 
were then averaged to generate a mean decay curve for each genotype (wild-type and 
diYF) as a measure of intrathrombus molecular transport. 
 
Computational simulation of solute transport: A detailed description of computational 
methods including model design and parameter description is included in chapter 4.  
Briefly, the thrombus is represented as a two-compartment homogeneous porous 
medium.  We apply the Stokes equation to solve the flow field in the lumen region and a 
Brinkman equation for the flow field in the thrombus.  We used the “species transport in 
porous media package” in COMSOL® version 4.3a, solving the convection-reaction-
diffusion equation: 𝜕𝑐 𝜕𝑡 = 𝐷∇!𝑐 − 𝑢∇𝑐 + 𝑅, where c is the concentration of chemical 
species of interest, D is the diffusion coefficient, u is the velocity vector field, and R 
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describes sources of the various chemical species. We imposed an initial uniform 
concentration of a tracer solute in the vessel, zero solute concentration at the influx 
boundary, and then ran the simulation until the concentration inside the thrombus 
regions decreased to zero. 
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Chapter 6: More than just stopping red cells: how hemostatic thrombi limit 
extravasation of plasma- and platelet-borne molecules 
 
6.1 Introduction 
 
Recent reports show that hemostatic thrombi formed after vessel damage in vivo in 
mice, and ex vivo using human blood, develop a heterogeneous structure13,36,80,81,121 in 
which a core of fully-activated platelets and fibrin is overlaid by a shell of less-activated 
platelets 12. A prominent characteristic of the core is that it consists of densely-packed 
platelets, with increased packing density driven by contraction of cross-linked platelets 
through αIIbβ3 integrin-dependent outside-in signaling 12,95,96. We have shown that tight 
platelet packing restricts molecular transport within the core, producing a region with a 
corresponding increase in local thrombin activity and platelet activation. Based on 
studies in cremaster muscle arterioles, we have previously proposed that this 
heterogeneous architecture is important for regulating the distribution of soluble agonists 
within the thrombus and, therefore, thrombus growth and core formation. Here we 
extend those observations into venules and test the hypothesis that thrombus 
architecture is also a key to understanding how hemostatic thrombi prevent the loss of 
plasma as well as the escape of red cells. 
 
After a penetrating injury red cells and plasma permeate through the injury site and into 
the extravascular space, driven by the pressure differential between the vessel lumen 
and the surrounding tissue. Thrombus formation at the injury site resists the movement 
of plasma and red cells out of the vessel, and restricts the transport of molecules within 
and across the thrombus microenvironment 51,55,120. Previously we have shown that 
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thrombi formed from human blood flowing over a collagen/tissue factor surface have a 
Darcy permeability (κ = 2x10-14 cm2), approaching that of an intact endothelium 13. Put 
differently, hemostatic thrombus formation in theory serves not only to halt the escape of 
red cells, but also to alter the transport of plasma-borne and platelet-derived molecules 
from the lumen and thrombus microenvironment into the extravascular space 22,52,56. 
Since plasma and platelets are the source of numerous coagulation factors 63,122,123, 
growth factors 124-127 and mediators of inflammation 128,129, transport properties at the site 
of vascular injury are potentially an important regulator of wound healing and recovery in 
the surrounding tissues. Thus we propose that the complex architecture of fully 
hemostatic thrombi is needed in part to limit the loss of soluble molecules and further 
propose that achieving “plasma stasis” may require attributes that are not precisely the 
same as those required to stop red cell loss.  
 
Here we have tested these ideas, first developing a novel method for quantifying plasma 
protein extravasation at the site of penetrating injuries in the mouse microvasculature in 
real time and then using it to examine the relationships between thrombus architecture 
and plasma protein loss following penetrating injuries in mouse cremaster muscle 
venules. By infusing albumin labeled with a caged fluorophore (cAlb) into mice we used 
intravital microscopy to measure the kinetics of plasma protein escape concurrently with 
markers of thrombus formation. A combination of pharmacologic and genetic 
approaches resolved the relative contributions of platelets, fibrin, clot retraction and 
thrombus architecture in vessel sealing. 
 
The results show that the core-and-shell architecture observed in arterioles is largely 
recapitulated in venules. The studies with cAlb show that while red cell escape after 
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small penetrating injuries can be stopped by only a few platelets, a larger, more stringent 
structure is required to limit plasma protein extravasation. We found that the rate of 
plasma protein extravasation is highly sensitive to small changes within the platelet 
mass, including changes in platelet packing density, but not the accumulation of fibrin. 
Plasma stasis is especially sensitive to inhibition of ADP-dependent signaling. Defects in 
clot retraction, especially when combined with defects in platelet accumulation, cause a 
large increase in plasma protein extravasation. Together with previous studies, this 
helps to explain how a fully competent hemostatic thrombus structure matures over time 
to eventually halt not only the loss of red cells, but also the outflow of soluble plasma-
borne molecules into the extravascular space. It also shows how members of two 
widely-used classes of antiplatelet agents (P2Y12 and αIIbβb antagonists) can prolong the 
escape of plasma-borne molecules by delaying formation of an effective vascular seal in 
the microvasculature. 
 
6.2 Methods and Materials   
 
6.2.1 Mice.  
 
Male mice 8-12 weeks of age were used for all intravital experiments. C57Bl/6 mice 
(Jackson Laboratories, Bar Harbor, ME) were used for experiments utilizing anti-platelet 
agents, and were compared to diYF mutant mice that had been backcrossed on to the 
C57Bl/6 background at least 7 times. DiYF mice were originally generated in the 
laboratory of Dr. David Phillips at Portola Pharmaceuticals (San Francisco, CA 95) and 
were obtained by us with his approval from Dr. Tatiana Byzova at the Cleveland Clinic 
Foundation (Cleveland, OH). Gi2α(G184S) mutant mice were provided by Dr. Richard 
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Neubig (Michigan State University). The mice used in this study were heterozygous for 
the mutant allele (Gnai2G184S), which we have previously showed confers a gain of 
function in their platelets in vitro and in vivo 130. Their wild-type littermates were used as 
controls. 
 
6.2.2 Caged albumin synthesis.  
 
As described previously 22, bovine serum albumin (BSA, Jackson Immunological 
Research West Grove, PA, USA) was labeled with CMNB-Caged Carboxyfluorescein, 
SE (5-Carboxyfluorescein-Bis-(5-Carboxymethoxy-2-Nitrobenzyl) Ether, β-Alanine-
Carboxamide, Succinimidyl Ester) (Life Technologies, Frederick, MD, USA). Briefly, the 
BSA was solubilized in 0.1 M sodium bicarbonate in phosphate buffered saline to a final 
concentration of 10 mg / mL. Concurrently, 1 mg of CMNB-caged carboxyfluorescein 
was solubilized in 100 μL of dimethyl sulfoxide and was thoroughly mixed with the BSA 
solution. The reaction was incubated for 1 hour at room temperature before purified over 
a 7 kDa molecular weight cutoff desalting column from Thermo Scientific (Waltham, MA, 
USA). 
 
6.2.3 Intravital microscopy and injury generation.  
 
Mice were anesthetized with sodium pentobarbital (90 mg/kg) through an intraperitoneal 
injection. The mouse jugular vein was cannulated to allow for the infusion of fluorescent 
markers and pharmaceutical agents. The cremaster muscle was then exposed and 
prepared for viewing by confocal microscopy. The cremaster muscle was under 
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continuous flow of bicarbonate buffer maintained at 37°C and bubbled with 95%/5% 
N2/CO2. Venules with a diameter of 30-50 μm were utilized, and injury was induced with 
a pulsed nitrogen dye laser (SRS NL100, 440nm). The laser was fired until red blood 
cells escaped the vessel indicating sufficient vessel wall damage. The area was then 
visualized with a BX61WI microscope (Olympus, Center Valley, PA, USA) with a 60X 
(0.9 NA) water immersion objective, and a CSU-X1 spinning disk confocal scanner 
(Yokogawa, Sugar Land, TX, USA). Fluorescence imaging was performed using a diode 
optic tunable filter control as an excitation source (LaserStack; Intelligent Imaging 
Innovations, Denver, CO, USA). Images were captured with an Evolve digital camera 
(Photometrics Tucson, AZ, USA). 
 
Platelets were visualized by anti-GPIbβ (clone Xia.C3; Emfret Analytics, Eibelstadt, 
Germany) labeled with Alexa-568, or anti-CD41 (F(ab)2 fragment, clone MWReg30, and 
anti-CD62P (P-selectin; IgG, clone RB40.34) labeled with Alexa-647 obtained from BD 
Biosciences (San Jose, CA, USA), and Alexa-647 anti-fibrin antibody (clone 59D8, a 
generous gift from Dr. Hartmut Weiler and Dr. Rodney Camire) was used to label fibrin.  
 
Plasma protein extravasation (L(t)) was measured by the extravasation of caged albumin 
(cAlb), which was uncaged every 15 fames by exposure of 405 nm light and then 
quantified by the resulting increase in fluorescence excitation at 488 nm (Supplemental 
Figure S1B). Thrombus formation was modified by the addition of Cangrelor (a generous 
gift from The Medicines Company, Parsippany, NJ, USA), Hirudin (a gift from Dr. Sriram 
Krishnaswamay, Children’s Hospital of Philadelphia) or eptifibatide (Integrilin; purchased 
from Schering Plough). 
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In pilot studies plasma protein extravasation was measured in both arterioles and 
venules. Although similar extravasation dynamics were observed in both, only venule 
data were used for the studies reported here because the thicker walls of the arterioles 
resulted in some of the leaked plasma being retained within the wall in a pseudo-
aneurysm that interfered with extravasation measurements. 
 
6.2.4 In vitro thrombus permeability measurements.  
 
A sidearm microfluidic chamber was used to generate thrombi ex vivo as previously 
described 13. Briefly, re-calcified (10 mM) citrated whole blood, from wild type and diYF 
mice, was perfused over a collagen/tissue factor surface to induce thrombus formation. 
Blood flow was maintained at a shear rate of 200 s-1, and a transthrombus pressure drop 
of 15 mmHg. Platelet and fibrin deposition were monitored for 10 min, and then Texas 
Red fluorophore (Life Technologies) was infused and dynamically imaged to measure 
the thrombus permeability as described 13,51.  
 
 
6.3 Results 
 
6.3.1 Thrombus formation and maturation limits plasma protein loss from the 
site of injury. 
 
As we have previously shown in mouse arterioles 12, laser injury of healthy mouse 
venules results in the formation of a non-occlusive hemostatic thrombus, which 
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differentiates into a P-selectin(+) core region and a P-selectin(-) shell region over the first 
few minutes after injury (Figure 1A-C). To measure plasma protein loss from the injury 
site in real time, we infused albumin conjugated with caged carboxyfluorescein (denoted 
“cAlb”) prior to injury. After injury we used pulses of 405 nm light to flash-activate any 
cAlb that escaped into extravascular tissue planes (Figure 1A and Supplemental Figure 
S1A). By measuring the gain in extravascular cAlb fluorescence at 15 s time intervals, 
we quantified relative cAlb extravasation (L(t)) over time for as long as 20 minutes (1200 
seconds) after injury (Supplemental Figure S1B and S1C).  
 
The results show a rapid initial loss of plasma protein after injury, followed by a gradual 
decrease in cAlb extravasation over 3 minutes (Figure 1A and D). We monitored cAlb 
extravasation concurrently with red cell loss, platelet accumulation, fibrin deposition and 
P-selectin exposure, allowing us to compare the kinetics of each of these events. As in 
arterioles, we found that red cell loss ended within the first few seconds of injury. Fibrin 
and platelet accumulation continued after that point, peaking at approximately 60 s. cAlb 
extravasation continued well after the peak in platelet accumulation, but continued to 
gradually decline to a level above background (pre-injury) escape. The continued decline 
in cAlb escape is informative, suggesting that ongoing structural changes within the 
thrombus contribute to plasma protein retention (Figure 1B-D). At 200 s after injury, 
relative cAlb extravasation rates were ~60% less than at 15 s, but not a total cessation 
of plasma protein extravasation (Figure 1E and Supplemental Figure S1C). These data 
demonstrate that in response to vascular damage in the microvasculature few platelets 
are required to achieve hemostasis, however plasma protein extravasation continues 
beyond stable thrombus formation and beyond 20 minutes post-injury (Supplemental 
Figure S1). 
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Figure 6- 1  Measuring plasma protein extravasation in vivo. 
(A) Representative images of a thrombus formed in a mouse cremaster venule showing 
platelets (blue) and flash-activated cAlb (green). Each image is taken directly after an 
activating-pulse of 405 nm light. (B) Time course of average platelet (black) and fibrin 
(white) area (n=24; +/- SEM). (C) For a separate data set we tracked average platelet 
area (black) and P-selectin positive area (white) (n=23; +/- SEM). (D) Time course of the 
average relative cAlb extravasation (L(t)). (E) A dot plot of the relative cAlb extravasation 
for each injury at 200 s post-injury (n=47; +/- SEM). 
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6.3.2 The relative contributions of platelets and fibrin to vessel sealing. 
 
The initial rapid decrease in plasma protein extravasation (~60 s post-injury) coincided 
with initial platelet deposition and fibrin accumulation. To determine how each of these 
events contributes to vessel sealing, we infused the integrin αIIbβ3 antagonist, eptifibatide 
(20 mg/kg) 131, to inhibit platelet cohesion and decrease platelet accumulation (Figure 
2A-C). Eptifibatide treatment led to a ~70% decrease in peak platelet area (p< 0.001), 
but had no impact on peak fibrin formation (p = 0.79) (Figure 2A-C). Eptifibatide-treated 
thrombi were still hemostatic with no increase in red cell escape observed, but had a 
large increase in plasma protein extravasation post-injury (Figure 2DE&F). When we 
examined the dynamics of cAlb extravasation over 200 s post-injury, we observed a 
significant portion (36%) of the eptifibatide-treated thrombi showed cAlb extravasation 
had increased from 15-200 s post-injury, in contrast to vehicle treated thrombi which all 
had decreased cAlb extravasation, suggesting that the eptifibatide-treated thrombi were 
not stable and weakened over time (Figure 2F).  
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Figure 6- 2 Inhibition of αIIbβ3 integrin reduces platelet accumulation and 
vessel sealing. 
(A) Representative images of thrombi formed in the presence of either vehicle or 
eptifibatide (20 mg/kg), showing both platelets (blue) and fibrin (red) 3 minutes post-
injury. (B) Average platelet area and (C) fibrin area for both the vehicle-treated (black) 
and eptifibatide-treated (white) thrombi (+/- SEM). (D) Representative images of cAlb 
extravasation (green) at both 30 and 180 s post-injury for vehicle and eptifibatide treated 
thrombi (blue). (E) Time course and (F) dot plot of relative cAlb extravasation for vehicle 
(black) and eptifibatide (white) treated thrombi (vehicle n=12, eptifibatide n=11; +/- 
SEM). 
 
Given the eptifibatide results, which highlight the contribution of platelets to achieving 
plasma stasis, we tested whether increased thrombus size would further reduce plasma 
protein extravasation, or if thrombus driven vessel sealing is largely maximized. To test 
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this hypothesis we used Gi2α(+/G184S) mice whose platelets show an increase in 
responsiveness to ADP because of resistance to signal termination by RGS proteins 
downstream of Gi2-coupled P2Y12 receptors. As we have previously reported 12, laser 
injury induced 72% larger thrombi in the Gi2α(+/G184S) mice than in paired wild type 
control mice (Supplemental Figure S2A-B). However, this increase in platelet 
accumulation had no effect on the dynamics of vessel sealing, implying that normal 
sized thrombi reflect the limit to how much platelets can restrict plasma protein transport 
(Supplemental Figure S2C). 
 
6.3.3 Platelet retraction contributes to vessel sealing. 
 
In previous studies we demonstrated the importance of platelet packing density in 
limiting intrathrombus solute transport. To test the hypothesis that platelet retraction 
helps to limit plasma protein extravasation, we compared cAlb extravasation in wild type 
mice with cAlb extravasation in mice in which two critical tyrosines in the cytoplasmic 
domain of the β subunit of integrin αIIbβ3 were replaced with phenylalanine residues 
(denoted diYF). The platelets from these mice show normal integrin activation, but have 
a defect in outside-in signaling that leads to delayed clot retraction in vitro and reduced 
thrombus consolidation in vivo 95,96. 
 
Consistent with the studies in arterioles, we observed no defect in either the kinetics of 
platelet accumulation or the total area of the platelet mass in the diYF mice (Figure 3A). 
For the first 60 seconds (the period of greatest platelet accumulation), there was also no 
difference between diYF and matched control mice in their ability to slow the 
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extravasation of cAlb (Figure 3B and C). After 60 seconds, however, extravasation in the 
diYF mice remained elevated compared to the controls. This suggests that after initial 
platelet recruitment, platelet retraction drives intrathrombus remodeling to further seal 
the injury site (Figure 3B). The lack of retraction in the diYF mice led to a 54% increase 
in relative cAlb extravasation at 200 s post-injury (Figure 3C). We saw a similar 
difference in Darcy permeability measurements performed ex vivo using wild type and 
diYF mouse blood in a microfluidics device (Supplemental Figure S3). Taken together, 
these results suggest that initial vessel sealing is driven by the rapid accumulation of 
platelets, while continued sealing is driven in part by the same integrin αIIbβ3-mediated 
retraction that increases platelet packing density and decreases thrombus permeability. 
Thus cAlb extravasation is highly sensitive to small changes in the intrathrombus 
structure, although the differential impact of retraction on plasma protein permeation and 
diffusion remains unresolved. 
 
 
 
Figure 6- 3  Outside-in signaling drives platelet retraction and vessel sealing. 
(A) The average platelet area for wild type (black) and diYF thrombi (white) (+/- SEM). 
(B) Time course and (C) dot plot of cAlb extravasation for wild type (black) and diYF 
(white) thrombi (wild type n=24, diYF n=19; +/- SEM). 
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6.3.4 The role of fibrin accumulation, ADP and thrombus architecture in 
restricting plasma protein loss. 
 
In our prior studies on arterioles, we found that fibrin accumulation after penetrating 
injuries is restricted to the thrombus core, as is detectable thrombin activity 12,87. Addition 
of a direct thrombin antagonist, such as hirudin or bivalirudin, abolished fibrin 
accumulation and caused a decrease in the size of the thrombus core as well as a 
reduction in overall thrombus size. In the present studies, we found that hirudin also 
causes a reduction in overall thrombus size in venules, but did not alter platelet 
activation measured by P-selectin exposure (Figure 4). Fibrin accumulation was 
essentially abolished (Figure 4C). Despite these changes, hirudin had no significant 
effect on plasma protein extravasation (Figure 4E and F). This suggests that fibrin 
accumulation plays no role in preventing the extravasation of plasma proteins in this 
injury model. 
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Figure 6- 4  Thrombin inhibition decreases fibrin accumulation and thrombus 
size, but not vessel sealing. 
(A) Representative images of thrombi formed either in the presence of vehicle or 
thrombin inhibitor Hirudin (2 µm) showing platelets (blue) and P-selectin (red) 3 minutes 
post-injury. (B) Quantification of average platelet area, (C) fibrin area, and (D) peak P-
selectin area for both vehicle-treated (closed) and hirudin-treated (open) thrombi (+/- 
SEM). (D) Time course of average cAlb extravasation and (E) dot plot of cAlb 
extravasation at 200 s for both vehicle-treated (closed circle) and hirudin treated (open 
circle) thrombi (vehicle n=17, Hirudin n=18; +/- SEM). 
 
The results with hirudin contrast with those obtained with the direct-acting P2Y12 
antagonist, cangrelor. Like hirudin, cangrelor caused a decrease in overall thrombus 
size, and had no effect on platelet activation measured by P-selectin exposure (Figure 
5A-B). However, cangrelor-treated thrombi showed a significant increase in plasma 
protein extravasation (Figure 5C-D). Combining hirudin and cangrelor had an effect on 
extravasation that was similar to adding cangrelor alone, despite having an even greater 
effect on platelet deposition and P-selectin exposure (Figure 5E-H). Taken together 
these results suggest that ADP is crucial for driving decreased thrombus permeability. 
This is consistent with previous observations that in human thrombi, ADP and 
thromboxane A2 are the major drivers of retraction in the absence of thrombin 51. The 
results also suggest that P-selectin exposure, while informative about α-granule 
exocytosis, is not directly tied to formation of a tight vascular seal limiting plasma protein 
extravasation.  
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Figure 6- 5  ADP drives fully competent core formation and shell recruitment. 
(A) Quantification of average platelet area and (B) peak P-selectin positive area of 
vehicle (black) and cangrelor-treated (white) thrombi. (C) Average cAlb extravasation 
time course and (D) dot plot of relative cAlb extravasation at 200 s post-injury (vehicle 
n=15, Cangrelor n=20; +/- SEM). (E) The average platelet area and (F) peak P-selectin 
positive area for vehicle (black) and cangrelor / hirudin (white) treated thrombi (+/- SEM). 
(G) Time course of relative cAlb extravasation, and (H) dot plot of cAlb extravasation at 
200 s post-injury (Vehicle, black n = 13; Cangrelor / hirudin, white n = 15).  
 
6.3.5 Plasma protein accumulation in the extravascular space. 
 
Lumenal proteins will accumulate in the extravascular space when the rate of delivery 
out of the vessel exceeds the rate at which proteins disperse into the surrounding tissue. 
To measure the dispersion rate of cAlb we observed the rate of cAlb fluorescence decay 
(ΔF(decay)) between fluorescence-activating pulses of 405 nm light. The decay of 
fluorescent cAlb correlates to the rate at which extravascular fluorescent cAlb molecules 
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disperse within the surrounding tissue (Supplemental figure S4A and B). We found that 
the cAlb dispersion rate was greatest initially, peaking 60 s after injury, which is 
approximately the same time that peak platelet accumulation is achieved (compare 
Supplemental Figure S4C with earlier figures). Despite the higher initial rate of 
dispersion the extravasation of cAlb into the extravascular tissue greatly exceeded the 
dispersion during the first 60-75 s post-injury, causing substantial cAlb accumulation 
(Figure 6A). However, after sufficient thrombus growth to limit cAlb extravasation below 
the rate of dispersion, leading to a gradual but consistent decline in fluorescent 
extravascular cAlb (Figure 6A). 
 
 
Figure 6- 6 cAlb accumulation in the extravascular space. 
(A) cAlb accumulation (A(t)) was measured by the relative fluorescence remaining 15 s 
after each activating light pulse for 200 s. (B) cAlb accumulation was measured for 
Eptifibatide-treated thrombi (open) and vehicle-treated thrombi (closed). (C) A pseudo-
colored image of cAlb intensity 3 min post-injury with the vessel shown in white and 
platelets outlined in black. (D) cAlb accumulation for diYF and wild type thrombi, (E) 
cangrelor-treated, (F) hirudin-treated, and (G) cangrelor/hirudin treated, vs vehicle 
treated thrombi. 
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Perturbations in thrombus structure that impacted cAlb extravasation similarly affected 
cAlb accumulation. Eptifibatide-treated injuries showed no change in average cAlb 
fluorescence decay rates compared to vehicle, suggesting that the dispersion rate is 
independent of the extravasation rate (Supplemental Figure S4D). However, since the 
extravasation rate remained elevated (Figure 2), there was greater extravascular cAlb 
accumulation (Figure 6B). This led to a continuously increasing gradient of cAlb in the 
tissue surrounding the injury site, while vehicle treated thrombi had shrinking cAlb 
gradients by 200 s post-injury (Figure 6C).  Thrombi formed in diYF mice also allowed 
for moderate accumulation of cAlb (Figure 6D), as did thrombi formed in the presence of 
cangrelor (Figure 6E). Consistent with the hypothesis that cAlb accumulation is primarily 
driven by to extravasation rates, we observed no effect of hirudin alone on cAlb 
accumulation (Figure 6F).  
 
Taken together these results demonstrate that hemostatic thrombi are able to achieve a 
level of vessel sealing that limits plasma protein extravasation to rates less than the rate 
at which plasma protein dissipates into the surrounding tissue, preventing the continued 
concentration of plasma proteins in the surrounding tissue. Thus, small changes in the 
structure of the thrombus that impair vessel sealing can produce a larger than normal 
gradient of potentially bioactive molecules at the site of injury.  
 
6.4 Discussion 
 
It has been well established that soluble plasma-borne and platelet-derived molecules 
play a role in post-injury inflammation and wound healing 124-129,132.  It is less clear how 
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the delivery of these molecules is constrained following injury. It has also been well 
established through computational 53,55,56 and experimental 22,51,59,96,120 examination that 
thrombi are capable of acting as a molecular sieve altering the transport of proteins and 
small molecules through dense platelet packing and fibrin formation. Here we tested the 
idea that thrombus structure plays a regulatory role in protein extravasation, just as we 
have previously shown it contributes to the local accumulation of thrombin and ADP, the 
deposition of fibrin, and the cessation of red cell loss. To investigate this hypothesis we 
designed a novel sensor able to measure plasma protein extravasation in real time, 
allowing us to correlate changes in plasma protein transport and intrathrombus structure. 
We found that following small penetrating injuries in the microcirculation in healthy mice, 
hemostatic thrombus formation significantly reduces the rate of plasma protein 
extravasation, just as it brings an end to red cell escape. However, we found that plasma 
protein loss continues beyond the time when red cell escape ends, persisting for at least 
20 minutes after injury, an observation that suggests that maintaining molecular 
exchange between the circulating blood and surrounding tissue may be beneficial, or at 
least not harmful, for achieving an optimal for post-hemostatic responses.  
 
In addition to providing information about the kinetics of vascular sealing, our results 
demonstrate that platelets, not fibrin, are primarily responsible for limiting the loss of 
soluble proteins. Data obtained with inhibitors of platelet activation and cohesion, and 
with the retraction-deficient diYF mice show that both total platelet accumulation and 
platelet retraction are involved. However, there appears to be a limit to how much 
platelet accumulation alone can reduce plasma protein movements. Thus, although 
considerably larger thrombi formed in mice expressing the Gi2α(G184S) gain of function 
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allele, we found no difference in extravasation rates. The inability of fibrin to significantly 
block plasma protein extravasation is consistent with observations in human blood 
demonstrating the limited effect of fibrin on clot permeability 13,51. Together these 
observations demonstrate that platelet accumulation and organization are the driving 
events for resisting molecular permeation into the extravascular space. 
 
The ability of a thrombus to restrict plasma protein extravasation is defined by the size 
and structure of the thrombus microenvironment. Therefore, the differential effects of the 
inhibitors that we employed are informative in examining how specific pathways shape 
the physical structure of the thrombus microenvironment. We found that both hirudin and 
cangrelor decrease thrombus size to a similar extent without effecting P-selectin 
exposure. However, hirudin treatment had no effect on plasma protein extravasation, 
while cangrelor treatment induced a significant increase in plasma protein extravasation. 
This suggests that ADP inhibition, but not thrombin, alters the structure of the resulting 
thrombus microenvironment allowing for increased protein extravasation. These results 
also confirm that fibrin accumulation, which is ablated in the presence of hirudin, 
contributes little to preventing plasma protein extravasation, at least in the acute setting.  
 
Notably, while having a greater impact on overall platelet accumulation, the combination 
of cangrelor and hirudin had no greater impact than cangrelor alone on plasma protein 
extravasation. Therefore, we suggest that the impact of ADP receptor inhibition on the 
intrathrombus microenvironment is likely limited to the region immediately adjacent to 
the injury site. Thus, further decreasing platelet deposition in the case of combined 
cangrelor-hirudin treatment does not increase plasma protein extravasation. 
Interestingly, the combined cangrelor-hirudin treatment also significantly decreased P-
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selectin exposure. However, the extent of P-selectin exposure, which we have 
previously used as a marker to define the thrombus core region did not correlate with 
plasma protein extravasation. Even though antagonizing platelet P2Y12 receptors alone 
has no effect on P-selectin expression in either arterioles (our previous studies 12) or 
venules (the present data), it clearly affects transport properties. Thus, the two 
processes (α-granule exocytosis and vessel sealing) are not irrevocably linked. 
 
Finally, our results also show that thrombus formation is capable of limiting plasma 
protein extravasation sufficiently to prevent the continuous accumulation of plasma 
borne protein within the local tissue. Since extravasated cAlb dispersed into surrounding 
tissues at a relatively steady rate, accumulation was primarily dependent upon the 
delivery rate of cAlb through the thrombus. Directly after vessel injury rapid plasma 
protein extravasation leads to local cAlb accumulation until progressive vessel sealing 
slows the rate of plasma protein extravasation below the rate of dispersion causing a net 
decrease in the concentration of cAlb in the local area (Figure 7). Within the sequence of 
events, platelet retraction drives the transition from plasma protein accumulation to 
dispersion.  
 
 
 
141	  
	  
Figure 6- 7  Model of plasma-stasis in mouse cremaster venules. 
A model depicting the evolution of plasma-stasis during thrombus formation. From 0-1 
minute post-injury plasma protein extravasation (L(t)) is greater than the rate of plasma 
protein dispersion (ΔF(decay)) into the tissue resulting in increasing accumulation (A(t)). 
From 1-2 minutes thrombus formation limits L(t) to be equal to ΔF(decay) bringing A(t) 
into a steady state. Finally, after 2 minutes post-injury L(t) becomes slightly less than 
ΔF(decay), causing a slight but steady decrease in A(t). 
 
In conclusion our study demonstrates a novel method for both measuring the transport 
of luminal proteins into the extravascular space and evaluating the integrity of thrombi 
forming in vivo. The results show that the hemostatic response produces a core-and-
shell structure in venules that resembles the response in arterioles, but is less 
dependent thrombin. We have previously suggested that the core-and-shell architecture 
is needed in part to allow local differential accumulation of platelet agonists 22,55,96. The 
results obtained here refine our understanding of the implications of thrombus structure, 
showing that the pace of achieving plasma stasis is much slower than for halting red cell 
loss and the structural requirements are greater. While red cell loss in this model ceases 
after very few platelets have accumulated, halting plasma protein escape requires 
greater platelet accumulation, ADP-dependent signaling and increased platelet packing 
density, thus providing another reason for the complex architecture observed in fully 
hemostatic thrombi. Formation of a vascular seal appears not to require fibrin 
accumulation. We assume, but have not shown here, that the delivery of soluble platelet-
derived molecules, including growth factors and cytokines, is subject to the same 
constraints as the delivery of plasma-borne molecules. Finally, the results obtained in 
the presence of members of two widely-used classes of antiplatelet agents (P2Y12 and 
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αIIbβ3 antagonists), show how these drugs can prolong the escape of plasma-borne 
molecules by delaying formation of an effective vascular seal. 
 
6.5 Supplemental materials 
 
 
 
Figure 6- 8  Using cAlb to measure plasma protein extravasation in real time. 
(A) A representative image of cAlb localization before and after laser-induced vascular 
injury (white arrow). Both images were captured immediately following an activating 
pulse of 405 nm light. (B) The mean cAlb fluorescence measured in the extravascular 
space, and how the gain and loss are measured following a light pulse every 15 s. (C) 
Time course of cAlb extravasation from wild type venules from 15-1200 s post-injury. 
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Figure 6- 9  Increased shell formation does not increase vessel sealing. 
(A) Representative images of thrombi formed in wild type and RGS-resistant 
Gi2α(+/G188S) mice showing platelet deposition (blue) and P-selectin exposure (red) at 
200 s post-injury. (B) The area of platelet deposition and (C) cAlb extravasation was 
quantified over time for both the wild type (closed circle) and Gi2α(+/G188S) (open circle) 
thrombi (wild type n=13, Gi2 n=23; +/- SEM). 
 
 
 
Figure 6- 10  Permeability of wild type and diYF thrombi. 
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(A) Representative images of thrombi formed in a side-arm microfluidic chamber 
showing platelets (red) and fibrin (green) formed using re-citrated blood drawn from wild 
type and diYF mice (n=3). (B) Average thrombus width after 10 minutes of blood flow. 
(C) Quantification of the average thrombus permeability at 10 minutes.    
 
 
 
Figure 6- 11  Extravascular cAlb transport and accumulation. 
(A) The accumulation (A(t)) of  extravascular cAlb was measured by calculating the 
differences between the delivery (ΔF(t)) and the dispersion (ΔF(decay)) of cAlb 
normalized by ΔF(ref). (B) A schematic representation of extravascular cAlb transport. 
(C) The rate of extravascular cAlb dispersion was measured by quantifying the relative 
decay rate of fluorescent cAlb between activating light pulses. Shown are the average 
cAlb decay curves a 0s (closed circle), 30 s (open circle), 60 s (closed square), and 180 
s (open square). (B) The total average extravascular cAlb decay for both vehicle and 
eptifibatide-treated thrombi. 
 
 
145	  
	  
Chapter 7: Real time intravital imaging of thrombus formation in the mouse 
femoral artery reveals critical differences from events in the microvasculature 
 
7.1 Introduction 
 
Following vascular injury hemostatic thrombi must prevent blood loss without obstructing 
vessel flow and causing ischemic injury. Hemostatic thrombi formed in the mouse 
microvasculature and in microfluidic devices using human blood, form a characteristic 
architecture with a core of densely packed and highly activated (P-selectin (+)) platelets 
forming at the site of injury 12,13. The core is covered with a shell of loosely packed and 
less activated (P-selectin (-)) platelets. The core is also differentiated from the shell by 
the presence of fibrin deposition which is limited to the extravascular space and the core. 
In the mouse microvasculature platelets rapidly accumulate at the site of injury, and 
thrombin activity drives stable platelet accumulation and eventual α-granule exocytosis 
and fibrin deposition within the core region 12. Concurrently, ADP and TxA2 released 
during thrombus formation extend beyond the core and recruit platelets which make up 
the shell region 12. We have also presented a model in which dense platelet packing 
within the core region regulates thrombin localization shaping local platelet activation, 
fibrin deposition, and thrombus development 22,55,96. Here we aim to extend these 
observations to the mouse macrocirculation, namely the femoral artery and vein, and 
determine the relative contribution of various agonists to thrombus growth and 
development.  
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Clinically relevant thrombosis often occurs within the macrocirculation, and the large 
blood volume within these vessels makes occlusion especially damaging. The 
macrocirculation differs from the microcirculation significantly in vessel wall biology and 
architecture 46,49,50,133-136, and local hemodynamics 47,137. These differences affect the 
underlying molecular mechanisms driving platelet activation and thrombus formation. 
While platelet adhesive proteins, such as αIIbβ3 and GPIb-α, are universally important the 
mechanisms of platelet activation and thrombus development vary between vascular 
beds and injury type 33-35,40. To further understand how variations in vessel biology and 
physics impact thrombus formation we developed a method to image thrombus 
formation in response to laser injury in the mouse femoral artery and vein. We then 
compared thrombus architecture development and agonist contributions in the femoral 
artery and vein to previous observations in the cremaster arteriole and venules. 
 
Our results demonstrated that hemostatic thrombi formed in the femoral artery develop 
an architecture of a highly activated P-selectin(+) core covered by a less activated P-
selectin(-) shell, similar to what is observed in the microvasculature. However, the 
relative rate of core formation is significantly slower in the femoral artery. Also similar to 
observations in the microvasculature, P2Y12 inhibition resulted in embolization of the 
shell region, and thrombin activity drove core formation. However, inhibition of thrombin, 
which leads to 80-90% reduction of thrombus size in the microvasculature, had no 
impact on total platelet deposition in the femoral artery, suggesting a separate 
mechanism behind stable platelet accumulation. Histological analysis of tissue factor 
distribution showed that, consistent with previous observations 57, in both the cremaster 
arterioles and the femoral artery tissue factor is predominately localized to the vessel 
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adventitia. However, this results in tissue factor being 10-fold further from the vessel 
lumen in the femoral artery, which may delay thrombin generation. 
 
Taken together our results present a model in which there are several key similarities 
and differences between thrombus formation in the macro- and microcirculation. 
Platelets rapidly deposit at the injury site to stem bleeding, and accumulate into the 
lumen and downstream driven by ADP recruitment. After an initial lag phase, thrombin 
activity drives further platelet activation and P-selectin exposure creating a core-shell 
architecture. These results demonstrate a new technique to get high-resolution imaging 
of thrombi formed in the mouse macrocirculation, provide evidence of how vessel 
architecture impacts agonist production, and demonstrate the conservation of the 
previously described core-shell architecture. 
 
7.2 Material and Methods 
 
7.2.1 Materials 
 
C57Bl/6J mice 8-12 weeks old were used for all experiments (Jackson Laboratories, Bar 
Harbor,ME, USA). Thrombus formation was visualized using anti-CD62P (IgG, clone 
RB40.34) and anti-CD41 (F(ab)2 fragment, clone MWReg30) (BD Biosciences, San 
Diego, CA, USA). Fluorescent fibrinogen conjugated to AlexaFluor 488 provided 
information about fibrin(ogen) deposition (Life Technologies, Grand Island, NY, USA). 
Thrombus formation was modified by the infusion of cangrelor (a generous gift from The 
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Medicines Company) or hirudin (a gift from Dr. Sriram Krishnaswamay, Children’s 
Hospital of Philadelphia). 
 
7.2.2 Femoral artery and vein visualization 
 
Mice were anesthetized with an intraperitoneal injection of either sodium pentobarbital 
(90 mg/kg) or ketamine/xylazine/acepromazine (100 mg/kg b.w. ketamine, 10 mg/kg b.w. 
xylazine 3 mg/kg b.w. acepromazine). The mouse jugular vein was then cannulated for 
the infusion of anti-CD41 (3 μg), anti-CD62P (5 μg), and fluorescent fibrinogen (50 μg) to 
visualize thrombus formation. For inhibitor studies cangrelor (10 μM final concentration) 
and hirudin (2 μM final concentration) were also infused directly before each treatment 
injury. 
 
The femoral artery and vein were then exteriorized and connective tissue was surgically 
removed from on top of the vessels. A plastic ring was then adhered to the surrounding 
tissue to allow for the retention of constantly perfused bicarbonate buffer (37 °C, bubbled 
with 95%/5% N2CO2) to facilitate imaging with a 40X water immersion objective 
(Olympus, St. Louis, MO, USA) (Supplemental Figure S1A). Vessel injury was induced 
with a pulsed nitrogen dye laser (SRS NL100, 440nm). Two levels of injury were made 
with the laser: a severe injury (laser fired until blood escaped from the vessel), or a mild 
injury (10-12 laser pulses focused on the intimal face of the vessel) (Supplemental 
Figure S1B). The resulting thrombi were imaged using a BX61WI microscope (Olympus, 
St. Louis, MO, USA) and a CSU-X1 spinning disk confocal scanner (Yokogawa). 
Fluorescence imaging was performed using a diode optic tunable filter control as an 
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excitation source (LaserStack; Intelligent Imaging Innovations). Images were captured 
with an Evolve digital camera (Photometrics) (Supplemental Figure S1C). 
 
7.2.3 Image analysis 
 
The maximum background fluorescence signal for each channel was measured within 
the thrombus-free portion of the lumen within the same field of view as the thrombus. 
The image was then converted to a binary mask of all pixels above that maximum and 
either the area (μm2) or sum fluorescence (FI 106 RFU) from that mask were measured 
for each mask.  
 
Real time tracking of mask area and fluorescence intensity allowed for us to quantify 3 
distinct metrics: initial growth rate (over 60 s for thrombus area, and 20 s for fibrinogen 
deposition as they were typical ranges of the linear phase of growth), peak thrombus/P-
selectin area and fibrinogen FI, and final thrombus/P-selectin area and fibrinogen FI. We 
then performed statistical analysis on these metrics.  
 
7.2.4 Histology 
 
Mouse femoral artery and vein were isolated without perfusion, briefly washed with 1x 
PBS and fixed with 4% formalin for 4 hours. Tissue was dehydrated and processed for 
paraffin embedding and sectioned (5 µm). After paraffin removal and rehydration, 
antigen retrieval was done with citrate buffer (10 mM, pH 6) for 20 minutes, blocking of 
peroxidase activity with 3% H2O2 in 1x PBS for 20 minutes, followed by 3 washes with 
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deionized water of 10 minutes each. Sections were blocked with 2% normal rabbit serum 
(Vector Laboratories: S-5000) for 15 minutes and with Avidin/Biotin Blocking Kit (Vector 
Laboratories: SP-2001) as suggested by manufacturer. Primary antibody incubation was 
done overnight at 4oC at a dilution of 1:200 for tissue factor (R&D: AF3178) and 1:150 
for PECAM-1 (Santa Cruz: sc-1506). Sections were incubated with Biotinylated Rabbit 
Anti-Goat (Vector Laboratories: BA-5000) at a 1:1000 dilution for 45 minutes and with 
Vector Elite ABC kit (Vector Laboratories: PK-6200) as specified by manufacturer. 
Staining was developed with DAB substrate (Dako: K3467), counterstaining with 
hematoxylin and mounting with Cytoseal-60 (Richard-Allan Scientific: 8310-4). 
 
7.3 Results 
 
7.3.1 Thrombus architecture in the femoral artery 
 
To observe thrombus formation in the mouse femoral artery we exteriorized the femoral 
artery and vein, removed overlaying connective tissue, and immersed the area in 37 °C 
physiological buffer. By rapidly firing the injury laser focused on the vessel wall blood 
loss could be induced from the femoral artery and vein. Blood loss was visible under the 
microscope but only lasted for 1-2 s post-injury, and was therefore not captured during 
subsequent imaging. The resulting rupture was 10-15 µm in diameter (Supplemental 
Figure S1D), a much smaller injury than was made in recent reports of laser injury in the 
mouse saphenous vein (50-100 µm diameter) 40 where blood loss was prolonged and 
quantifiable.  
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To determine if thrombi formed in the femoral artery form a core and shell architecture 
we monitored platelet deposition, P-selectin exposure, and fluorescent fibrinogen signal. 
We observed rapid platelet accumulation around the injury site forming a large 
amorphous mass by 60 s post-injury (Figure 1A). P-selectin exposure slowly 
accumulated over several minutes forming a substantial core region by 5 minutes post-
injury, and a very well defined core and shell region was observable by 20 minutes post-
injury (Figure 1A). During that time the platelet mass also became more aligned with the 
flow (Figure 1A). Concurrently, fibrin(ogen) was deposited at the injury site and spread 
perpendicular to flow within the vessel wall (Figure 1B and Supplemental Figure S2). 
The P-selectin(+) core formed largely within the vessel wall, and the P-selectin(-) shell 
formed in the lumen on top of the core and downstream (Figure 1B and Supplemental 
Figure S2). This architecture was also reproduced using a mild injury model, where the 
vessel endothelium is damaged, but the vessel isn’t ruptured and no blood loss occurs 
(Supplemental Figure S3A). 
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Figure 7- 1  Thrombus architecture in the femoral artery. 
(A) A time course of a representative thrombus after femoral artery rupture injury, 
showing platelets (blue) and P-selectin (red). (B) A 3D reconstruction of a thrombus 
showing fibrin(ogen) (green), P-selectin (red), and platelets (blue). (C) A quantification of 
platelet deposition, P-selectin area, and (D) firbin(ogen) deposition from femoral artery 
rupture injuries (n = 20, +/- SEM).  
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Real time thrombus growth, core formation, and fibrin(ogen) deposition were monitored 
in response to both the rupture injury, and the mild injury (Figure 1C and D, 
Supplemental Figure S3B and C). In both types of injury platelet accumulation peaked at 
30-40 s post-injury, however, the rupture injury thrombi were 50-60% larger than the mild 
injury thrombi. Also after reaching peak size the rupture thrombi were largely stable 
while the mild injury thrombi were reduced by 60-70% by 5 minutes post-injury (Figure 
1C and Supplemental Figure S3B). The mild injury model formed a core region 10-fold 
smaller than the rupture injury, despite only a 50-60% reduction in peak thrombus size 
(Figure 1C and Supplemental Figure S3B). However, fibrin(ogen) deposition was greater 
in the mild injury compared to the rupture, suggesting that fibrin(ogen) deposition in the 
wall is independent of platelet accumulation and activation (Figure 1D and Supplemental 
Figure S3C). 
 
7.3.2 Thrombus dynamics in the femoral artery and cremaster arterioles 
 
In the cremaster arterioles, we injured the vessels sufficiently to induce red cell escape 
out of the vessel. The average peak thrombus size in the cremaster was 5.5-fold smaller 
than in the femoral artery, however, the thrombi appear to be quite stable with minimal 
reduction in thrombus area between the peak size and 5 minutes post-injury 
(Supplemental Figure S4). The cremaster thrombi also rapidly formed a substantial core 
region (Supplemental Figure S4A and B). Both of these results suggest that the femoral 
artery rupture injury, and not the mild injury, is a comparable injury to the cremaster 
injury model. 
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The cremaster and femoral artery thrombi peaked in area between 30-60 s post-injury, 
with the initial growth rate (0-20 s) of the femoral artery thrombi being 6.6-fold faster than 
the cremaster thrombi (Figure 1C and Supplemental Figure S4B, D and E). However, 
thrombus growth rates normalized by peak thrombus size showed no difference in 
thrombus growth dynamics (Figure 2A and B). However, normalized core formation of 
the femoral artery thrombi showed a significant delay in initiation (time to 10% formation) 
compared to the cremaster thrombi (Figure 2C and D). Taken together these results 
demonstrate that vessel rupture, not just damage, in both the macro- and 
microcirculation leads to stable thrombus formation. Also there is a consistent growth 
phase (0-60 s) regardless of the extent of injury, vasculature, and final thrombus size. 
Finally, despite forming significantly larger thrombi, there is a significant delay in platelet 
activation and core formation in both mild and rupture injuries in the femoral artery 
compared to the cremaster thrombi. 
 
Figure 7- 2  Thrombus growth and core formation dynamics. 
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(A) Thrombus growth in the femoral artery (black circles) and the cremaster arterioles 
(open circles) were normalized to peak thrombus for each individual injury and graphed 
over 300 s post-injury. (B) The normalized growth rate (0-20 s post-injury) was 
determined for both data sets. (C) Similarly, the rate of relative core formation was 
calculated, and (D) the time to 10% core formation measured for each injury (femoral 
artery n = 20; cremaster arterioles n = 17, +/- SEM). 
 
7.3.3 The role of ADP in femoral artery thrombus formation 
 
ADP driven activation of platelets through P2Y12 receptors on the platelet surface has 
been shown to be important for stable αIIbβ3 integrin activation and stable thrombus 
formation in the cremaster and saphenous vein 12,40,138. In the cremaster thrombi the 
thrombus instability leads to a loss in stable shell accumulation, but does not impact the 
size or activation level of the core region 12. Infusion of cangrelor, a direct P2Y12 
antagonist, showed a very similar effect in the femoral artery rupture injury model (Figure 
3). Cangrelor-treated thrombi showed decreased thrombus size compared to vehicle-
treated, but peak thrombus size was not significantly different between the two 
conditions (Figure 3A and B). The difference in final thrombus size was due to extensive 
embolization of the downstream region of the thrombus (Figure 3C and Supplemental 
movie M1). This resulted in the cangrelor-treated thrombi forming a stable structure 
lacking any platelets downstream from the injury site (Figure 3D). Similarly to the 
cremaster, the cangrelor treatment had no effect on platelet activation or core formation 
(Figure 3E). This phenotype was also maintained in the mild injury of the femoral artery 
(Supplemental Figure S5). Taken together these results show a highly-conserved role of 
ADP in shaping hemostatic thrombus architecture across vascular beds and injury types. 
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Figure 7- 3  The role of ADP signaling in thrombus architecture formation in the 
femoral artery. 
(A) Platelet deposition for vehicle-treated (black) and cangrelor-treated (white) thrombi 
over 300 s post-injury. (B) The final platelet area, and (C) percent embolization for each 
data set. (D) Representative 3D reconstructions of thrombi formed in the presence of 
vehicle or cangrelor showing platelets (blue) and fibrin(ogen) (green). (E) Peak P-
selectin area for vehicle (black) and cangrelor-treated (white) thrombi. (vehicle n = 8; 
cangrelor n = 9, +/- SEM). 
 
7.3.4 Thrombin drives core formation but not platelet deposition in the femoral 
artery 
 
Unlike ADP the role of thrombin in thrombus formation appears to be more dependent 
upon the nature of the vascular injury. In the cremaster arterioles inhibition of thrombin 
activity reduces thrombus size by 80-90% and abolishes P-selectin(+) core formation 12. 
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However, it has also been reported that in the mesentery arterioles thrombin activity is 
dependent upon injury severity 36,38,39, with more mild penetrating injuries being 
dependent upon thrombin and collagen induced signaling, and severe injuries shifting to 
more thrombin signaling dependency 36.  In the venous macrocirculation, Getz et al., 
showed that low tissue factor mice had no hemostatic defect in response to laser 
induced vessel rupture 40, suggesting a limited role for thrombin.  
 
To investigate the role of thrombin in the arterial macrocirculation we used hirudin, a 
direct thrombin inhibitor in the femoral artery injury model. We observed no significant 
impact of thrombin inhibition on platelet deposition after a rupture injury, despite the loss 
of fibrin(ogen) signal (Figure 4A-C). However, thrombin inhibition did significantly deplete 
P-selectin exposure leading to a 60% reduction in core size by 5 minutes post-injury 
(Figure 4D). In response to a mild injury in the femoral artery there was also no impact 
on total platelet deposition (Supplemental Figure S6A and C). However, the mild injury 
creates much smaller and variable core regions and thrombin inhibition lead to a mild but 
non-significant reduction in P-selectin(+) core formation (Supplemental Figure S6B). 
These result demonstrate that while platelet adhesion and accumulation are not 
thrombin dependent in the femoral artery, fibrin formation, platelet activation, and core 
formation are still driven by thrombin activity, and that the role of thrombin appears to be 
somewhat sensitive to the extent of vascular injury. 
 
Tissue factor has been identified as the initiator of coagulation in the cremaster laser 
injury model 11,133,139, so we used histology to observe the tissue factor distribution in 
both the cremaster microvasculature and the femoral artery (Supplemental Figure S7). 
Similar to previous reports 57 we found that tissue factor was localized to the vessel 
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adventitia in both the macro- and microcirculation. However, in the femoral artery this 
lead to a much greater distance between the vessel lumen and the tissue factor 
expressing area of the vessel wall compared to the cremaster. This distance may 
contribute to the delay in core formation by either delaying thrombin formation or 
distribution within the thrombus. 
 
 
Figure 7- 4  Thrombin drives core formation but not platelet deposition in the 
femoral artery. 
(A) A representative image of a vehicle-treated or hirudin-treated thrombus formed in the 
femoral artery showing platelets (blue) and fibrin(ogen) (green) 5 minutes post-injury. (B) 
Platelet area and (C) fibrin(ogen) deposition were monitored for  300 s post-injury. (D) P-
selectin area was also monitored (vehicle n = 11; hirudin n = 14, +/- SEM). 
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7.3.5 Platelet GPVI signaling in response to penetrating injury of the mouse 
femoral artery 
 
Similar to thrombin, the importance of GPVI signaling during thrombus formation is 
dependent upon the mechanism and extent of injury. Mechanisms of injury in which 
there is extensive endothelial cell denudation, exposing subendothelial collagen, GPVI 
signaling is crucial in driving thrombus formation 39,41-43. However, in penetrating injuries 
increasing severity of the injury increases the importance of thrombin signaling, and 
lessens the impact of GPVI defects 36-39. Consistent with these reports in the femoral 
artery rupture injury model there is no significant difference in platelet accumulation or 
activation in thrombi formed in mice treated with Jaq-1 antibody to deplete GPVI function 
(Supplemental Figure S8), or control mice (Figure 5). These results demonstrate that 
collagen exposure in this injury model is limited, and platelet deposition is driven by a 
collagen and thrombin independent mechanism, but core formation is still largely driven 
by thrombin activity. 
 
 
 
Figure 7- 5  GPVI signaling does not impact platelet accumulation or activation 
in the femoral artery injury model. 
160	  
	  
(A) Platelet area was monitored for wild type (black) and Jaq-1 treated mice (white). (B) 
Peak platelet deposition for each treatment was compared. (C) P-selectin area was also 
monitored over time for both wild type and Jaq-1 mice (wild type n = 9; Jaq-1 n = 12, +/- 
SEM). 
 
7.3.6 Similarities and differences in thrombus formation in the femoral artery and 
vein 
 
Vessel wall and hemodynamic differences between arterial and venous vessels drive 
differences in the hemostatic response even within the same vascular beds 33,34,140. To 
investigate how thrombus architecture and signaling compares between the femoral 
artery and vein we monitored thrombus formation, and the effects of cangrelor and 
hirudin on thrombus architecture in the femoral vein (Figure 6). Thrombi in the femoral 
vein form a core and shell architecture similar to that seen in the femoral artery and the 
cremaster microvasculature (Figure 6A). Femoral vein thrombi also form with similar 
dynamics to femoral artery thrombi, but are ~2.5-fold smaller (Figure 6B and 
Supplemental Figure 98A and B). Femoral vein thrombi are also more stable than the 
femoral artery thrombi with less embolization after reaching peak size, which may be 
due to decreased shear stress in the vein (Supplemental Figure S9C). Similarly, to the 
femoral artery P-selectin exposure dynamics are significantly delayed compared to the 
cremaster (Figure 6B and Supplemental Figure S9D).  
 
The role of ADP signaling in thrombus architecture formation was also conserved in the 
femoral vein, with cangrelor-treated thrombi becoming highly-unstable reducing final 
thrombus size, but not impacting core formation (Figure 6D-H). Thrombin inhibition also 
did not impact total thrombus size in the femoral vein, and did slow down core formation, 
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but did not significantly reduce peak core size formation by 5 minutes post-injury (Figure 
6I-M). These results demonstrate that thrombus architecture and dynamics are highly 
conserved between the femoral artery and vein, despite vessel biology and 
hemodynamic differences, but the contribution of thrombin activity to core formation 
appears to be different within the vein. 
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Figure 7- 6  Thrombus architecture and agonist contributions in the femoral 
vein. 
(A) A representative image of the architecture of a thrombus formed in the femoral vein 
showing fibrin(ogen) (green), P-selectin (red), and platelets (blue). (B) Platelets, P-
selectin, and (D) fibrin(ogen) deposition were monitored for 300 s post-injury (n = 22, +/- 
SEM). (D) Platelet area dynamcis, (E) final platelet area, and (F) percent embolization 
were quantified for femoral vein thrombi either in the presence of vehicle (black) or 
cangrelor (white). (G and H) The rate of P-selectin (+) area accumulation and peak P-
selectin area for vehicle and cangrelor-treated thrombi (vehicle n = 10; cangrelor n = 12, 
+/- SEM). (I and J) The dynamics of platelet accumulation and P-selectin exposure in 
vehicle- (black) or hirudin-treated thrombi (white). (K) Quantification of peak platelet 
area, (L) peak P-selectin area, and (M) time to 50% core formation for vehicle- and 
hirudin-treated thrombi (vehicle n = 10; hirudin n = 13, +/- SEM). 
 
7.4 Discussion 
 
Techniques to monitor thrombus formation in vivo have been expanding, leading to 
numerous injury models in different vascular beds 33-35,40,133. The contribution of various 
agonists varies with injury mechanism and the vascular location of injury 33,36,38,39,41,42. 
Laser injury of the mouse cremaster microcirculation is perhaps the best characterized 
injury model. Numerous studies have shown that initial stable platelet accumulation is 
thrombin dependent, driven by tissue factor exposed at the injury site and propagated 
through factors XIII and IX 11,12,139,141,142. Secondary thrombus growth is driven by ADP 
and TxA2 12. Continued thrombin activity restricted within the densely packed platelets 
proximal to the injury site drive further platelet activation resulting in α-granule release 
and surface P-selectin exposure 12,22,55,96. This leads to a stable hemostatic thrombus 
consisting of a core and shell architecture. To determine how agonist generation and 
activity is altered in the macrovasculature we developed a new technique to induce a 
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penetrating laser injury to the mouse femoral artery and vein, and compared it to results 
obtained in the cremaster muscle microvasculature. 
 
We found several key similarities between thrombus formation in the macro- and 
microcirculation. Namely, the core and shell architecture observed in the cremaster was 
conserved in the femoral artery, in response to mild and rupture injuries, and in the 
femoral vein. We also observed similarities in the relative rate of thrombus growth, with 
stable platelet recruitment being limited to 0-60 s post-injury in the femoral artery, vein, 
and cremaster microcirculation. Interestingly, the initial rate of thrombus growth was not 
affected by the extent of vessel injury, as a mild injury to the femoral artery showed 
similar kinetics in platelet recruitment. However, thrombus stability and final thrombus 
size was greatly impacted by the extent of vessel damage. We also observed similarities 
in the role of ADP and thrombin in impacting thrombus architecture formation. Inhibition 
of ADP activity with cangrelor decreased shell stability, leading to a significant decrease 
in lumenal and downstream thrombus growth in the femoral artery and vein, but did not 
affect formation of the highly activated core region in the injury site. This effect was 
similar to that observed in the cremaster arterioles and venules, and demonstrates why 
P2Y12 antagonists have been so successful in preventing occlusive thrombus formation 
with limited hemostatic defects. We also found a consistent role of thrombin in driving full 
platelet activation resulting in α-granule release and surface P-selectin exposure in the 
core region.  
 
Interestingly, thrombin inhibition in the femoral artery and vein did not affect platelet 
accumulation, despite decreasing platelet activation and fibrin deposition. This result 
was in stark contrast to previous experiments in the cremaster arterioles where stable 
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thrombus formation was driven by thrombin activity and inhibition resulted in an 80-90% 
reduction in thrombus size. One key difference between the macro- and microcirculation 
that may contribute to this difference is the amount of the thrombus that within the vessel 
wall. Thrombus formation in the cremaster results in thrombi that are almost entirely in 
the vessel lumen, however, in the macrocirculation a significant portion of the thrombus, 
largely the core region, is within the vessel wall (Supplemental Figure S2). This suggests 
that numerous vessel wall proteins may be driving initial platelet accumulation and 
activation within the region that will form the core, and ADP drives shell recruitment. We 
were able to rule out collagen as a significant mediator of platelet recruitment or 
activation, and Getz et al. recently demonstrated the importance of vWF/GPIb 
interactions in platelet recruitment at the injury site in the saphenous vein injury model. 
This suggests that vWF released from injury site proximal endothelium, or polymerized 
during the flow of blood out of the vessel drives initial platelet recruitment at the injury 
site.  
 
Also different between the thrombi formed in the femoral artery and vein and the 
cremaster microvasculature is the relative dynamics of core formation. Numerous 
studies have shown that core formation typically consists of a short lag phase, followed 
by a linear growth phase, and then a plateau 12,22,96. However, in the femoral artery core 
formation appeared to be more exponential in growth with a prolonged lag phase (Figure 
1C). However, fibrin(ogen) rapidly accumulates at the injury site with dynamics similar in 
the femoral artery and cremaster injury models, suggesting that thrombin generation is 
not delayed significantly. We hypothesize that architectural differences in the macro- and 
microcvasculature may delay thrombin accumulation within the thrombus. In cremaster 
thrombi core formation is preceded by the formation of a transition zone, defined by the 
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tight platelet packing and restricted solute transport that facilitates platelet activation and 
core formation. Therefore, we hypothesize that in the macrovasculature the expanded 
distance between the lumen and the adventitial tissue factor is plugged with a large 
transition zone that reduces protein transport within the platelet mass. Thus, thrombin 
has reduced access to the thrombus region on a larger scale in the macrovasculature, 
and is diverted within the vessel wall where much of the fibrin(ogen) is detected. This 
delay in thrombin activity within the thrombus would contribute to the delay in core 
formation, and reduce the role of thrombin in initial platelet recruitment. 
 
Here we present a novel method for producing laser injuries in the mouse femoral artery. 
These injuries are comparable to the injuries produced in the cremaster microcirculation, 
and thus provide a method to measure the impact of changing vessel biology and 
hemodynamics on the hemostatic process. Thrombus architecture, however, is highly 
conserved throughout both the macro- and microcirculation in both the arterial and 
venous vasculatures, suggesting that this architecture may play an important role in 
establishing a hemostatic thrombus. The role of ADP was also highly conserved 
between both the macro- and microcirculation and the arterial and venous vasculatures. 
Thrombin, however, shifted from driving stable thrombus formation in the 
microcirculation to having no role in platelet recruitment in either the femoral artery or 
vein. However, thrombin was still responsible for the majority of core formation in the 
femoral artery, but slightly less so in the vein. Together our results demonstrate how 
vessel architecture can impact the hemostatic response and we propose that this 
technique will prove informative in understanding events in clinically-relevant vascular 
diseases, including atherothrombosis. 
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7.5 Supplemental Material 
 
 
Figure 7- 7  Femoral artery laser injury model. 
(A) A schematic of the mouse femoral artery and vein, the microscope immersion 
strategy, and orientation of thrombus formation. (B) Schematic of the mild and 
severe injuries created by altering the duration of laser injury to the femoral 
artery. (C) A representative image of thrombus formation in response to a severe 
injury. (D) The platelet (blue) signal right at the surface of the femoral artery wall 
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showing the injury site, and the compressed image of the 3D thrombus formed at 
the injury site showing the injury site.  
 
 
 
Figure 7- 8  Femoral artery thrombus architecture and orientation. 
A 3D reconstruction of a thrombus formed in the femoral artery after a severe injury 
showing platelets (blue), P-selectin (red), and firbin(ogen) (green). The estimated vessel 
wall is shown with a dotted white line and the direction of flow is indicated with a white 
arrow. 
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Figure 7- 9  Thrombus architecture in response to mild laser injury of the 
femoral artery. 
(A) A representative image of a thrombus growing over time showing platelets (blue) and 
P-selectin (red). (B) Quantification of platelet area (blue), P-selectin area (red), and (C) 
fibrin(ogen) deposition at the injury site over 300 s post-injury (n = 27, +/- SEM). 
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Figure 7- 10  Thrombus architecture formation in the cremaster arterioles 
compared to the femoral artery. 
(A) A representative image of a thrombus formed after laser injury of a mouse cremaster 
arteriole showing platelets (blue), P-selectin (red), and fibrin(ogen) (green). (B) 
Quantification of platelet deposition, P-selectin area, and (C) fibrin(ogen) deposition for 
300 s post-injury. (D) A comparison of average thrombus size in the femoral artery 
(black) and the cremaster arterioles (white), and (E) the average initial growth rate (0-20 
s post-injury) for each injury model (femoral artery n = 20; cremaster n = 17, +/- SEM). 
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Figure 7- 11 The effect of cangrelor on thrombus formation after a mild injury in 
the femoral artery. 
(A) Quantification of platelet area over time of either vehicle- (black) or cangrelor-treated 
thrombi. (B) Peak platelet area and (C) peak P-selectin area for vehicle- and cangrelor-
treated thrombi (vehicle n = 14; cangrelor n = 16, +/- SEM). 
 
 
 
 
Figure 7- 12  The role of thrombin in shaping thrombus architecture after mild 
injury in the femoral artery. 
(A) Platelet area over time of either vehicle- (black) or hirudin-treated (white) thrombi 
over 300 s post-injury. (B) Peak P-selectin area and (C) fibrin(ogen) deposition in 
vehicle- and hirudin-treated thrombi (vehicle n = 13; hirudin n = 14, +/- SEM). 
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Figure 7- 13  Tissue factor distribution in the femoral artery and vein. 
(A) Histological slides showing the femoral artery and vein with endothelium stained 
(brown). (B) The same slide as in A with tissue factor (TF) stained (brown). N = femoral 
nerve, A = femoral artery, V = femoral vein, and L = vessel lumen. 
 
 
 
Figure 7- 14  Jaq-1 treatment depletes GPVI signaling in mouse platelets. 
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Platelets from mice treated injected with either saline (wt) or Jaq-1 antibody (Jaq-1) were 
collected and either kept resting, treated with AYP (200 mM), or treated with (0.6 μg/mL) 
convulxin. Platelet activation was measured with fluorescent fibrinogen binding, and wt 
platelets became activated with both AYP and convulxin treatment, but Jaq-1 platelets 
only responded to AYP stimulation. 
 
 
Figure 7- 15  Thrombus architecture comparison between the femoral artery and 
vein. 
(A) Thrombus growth rate (0-20 s post-injury) for femoral artery (black) and vein (gray) 
thrombi, and (B) the normalized growth rate. (C) The percent embolization of the femoral 
artery and vein thrombi. (D) Time to 10% core formation for the femoral artery (black) 
and femoral vein (gray) thrombi (artery n = 20; vein n = 22, +/-SEM). 
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Chapter 8: Discussion 
 
The aim of this work was to investigate the interplay between thrombus structure and the 
spatiotemporal distribution and transport of platelet agonists, and how this impacts 
thrombus formation in vivo. In vivo and ex vivo studies have shown that hemostatic 
thrombi form a characteristic architecture consisting of a core of highly-activated and 
fibrin associated platelets covered by a less-activated shell of platelets 12,22,51,55,96. This 
architecture emerges during thrombus formation where platelet accumulation and 
consolidation 12,22,96 is happening simultaneously with various agonist species being 
released/formed. Platelet aggregation, shape change, and granule release are all 
dependent upon agonist exposure. Thus, there is a constant feedback between the 
spatiotemporal distribution of agonists within the thrombus, and the biochemical and 
biophysical nature of the intrathrombus environment.  
 
During thrombus formation the platelet mass consolidates, particularly in the core region, 
which leads to dense platelet packing and contact dependent signaling between the 
platelets 76,88,143-147. Apart from direct effects on signaling, this dense packing has been 
shown to inhibit the transport properties of soluble molecules, including coagulation 
factors and agonists in vitro and in situ 54,59,63,148. To study, in vivo, how this consolidation 
impacts agonist distributions we developed a novel biosensor to detect the localization of 
thrombin activity within the platelet mass after cremaster arteriole laser injury 87. 
Consistent with the observation that fibrin is restricted to the core region, we also 
observed that thrombin activity was isolated to the core region. The binary distribution of 
thrombin activity mirrored that of P-selectin exposure, which was consistent with 
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previous observations showing that inhibition of thrombin prevented core formation 
12,22,87.  
 
As the core had also been shown to have the highest density of platelet packing we 
wanted to test the hypothesis that the intrathrombus structure could restrict thrombin 
movements. In order to do this we designed a protein transport sensor, consisting of 
bovine serum albumin labeled with a photoactivatable fluorescent tag (cAlb) 22. This 
allowed us, during intravital imaging in the mouse cremaster, to activate a bolus of 
plasma borne cAlb within the thrombus, and track its elution in real time. What we found 
is that protein transport was significantly restricted in the core region, and that this 
restrictive environment developed prior to core formation, in a region dubbed the 
transition zone 22.  
 
These results were confirmed using a computational model of protein transport within a 
computer generated thrombus architecture, which showed that dense platelet packing 
inhibited the convection of proteins by the surrounding flow, and restricted the diffusion 
of proteins 55. Further, we were able to perturb the formation of the densely packed 
transition zone, by inhibiting outside-in signaling, which lead to a significant decrease in 
thrombin activity within the platelet mass and thus decreased platelet activation 96. 
Taken together this work creates a model of hemostatic thrombus formation in which 
platelets accumulate rapidly, outside-in signaling mediates retraction of the platelets 
proximal to the injury site driving transition zone formation, thrombin generated at the 
injury site is then restricted to within the transition zone driving full platelet activation, 
fibrin deposition, and core formation. Concurrently, ADP and TxA2 are released from the 
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granules of activated platelets, and being more diffusible, escape the core region and 
drive shell recruitment and stabilization.  
 
This model also has implications for the regulation of plasma-borne molecular activity 
within different regions of the thrombus. The dense platelet packing that occurs in the 
transition zone likely limits the delivery of coagulation factors to tissue factor surfaces in 
the extravascular space 11,12,59, as well as anti-thrombotic proteins like tissue factor 
pathway inhibitor (TFPI) or antithrombin III, and infused pharmaceutical agents. 
Therefore, the thrombus forms a gradient of access based on molecular size, allowing 
for small molecules to move freely through the core, while larger molecules are either 
have restricted transport within the core or are excluded altogether 22. Future studies will 
address how different coagulation factor size may impact the spatiotemporal activity of 
the factors. Also future studies can determine if plasma protein packing into platelet 
granules circumvents the thrombus structural barrier, allowing for selective delivery of 
bioactive molecules within the thrombus.  
 
Future work examining this model in pathological settings will be important to determine 
the role of molecular transport in occlusive thrombus formation. In hemostatic thrombi 
we observed that platelet retraction serves to retain and promote thrombin activity in the 
core. However, in pathological settings where there is potent or systemic coagulation, 
thrombin generation may be too robust to be successfully limited by platelet packing, 
and dense platelet packing may instead increases thrombus stability and limit access of 
antithrombotic agents. Determining how these processes are shifted during pathological 
thrombi may inform the identification of future drug targets aimed at limiting occlusive 
thrombus formation without limiting hemostatic function. 
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To extend this model we also examined the ability of the thrombus structure to limit the 
extravasation of plasma proteins at the site of injury. Numerous proteins that are 
biologically significant to post-hemostatic processes, such as wound healing and 
inflammation, are present in circulating plasma and inside platelets. Upon vessel 
damage these plasma- and platelet-borne proteins are extravasated into the surrounding 
tissue. Thrombus formation forms a physical barrier to resist this transport. Therefore we 
hypothesized that tight platelet packing may also play a role in regulating the delivery of 
these bioactive proteins.  
 
We found that, in the cremaster venules, which recapitulate the core/shell architecture, 
red cell loss was prevented by just a few platelets accumulating at the injury site while 
plasma protein extravasation continued even beyond stable thrombus formation. Also 
the rate of extravasation was dependent upon total platelet accumulation, up to a point, 
and beyond that platelet retraction, but not fibrin deposition, drove continued vessel 
sealing. Interestingly, ADP signaling appeared to be particularly important in forming a 
tightly-packed structure, independent of overall platelet activation state. Thrombin 
inhibition did not have the same effect, but this may be restricted to the venules where 
thrombus formation is less dependent on thrombin than in the arterioles. Thus, we can 
extend the model outlined above to include that the transition zone and core formation 
alter the delivery, and thus the concentration gradient, of both plasma- and platelet-
borne proteins in the tissue surrounding the site of injury. Further investigation is still 
needed to determine how this impacts post-hemostatic processes such as wound 
healing and inflammation. 
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Formation of a tight vascular plug may also serve to shift the distribution of proteins 
being delivered into the tissue plane. Initial injury induces a large amount of plasma and 
red cell delivery into the tissue. However, thrombus-driven vessel sealing coincides with 
core formation and α-granule release (Figure 6-1). Proteins released from the α-granules 
are in close proximity to the injury site, and will easily diffuse into the extravascular 
tissue. This presents the possibility of two distinct phases of protein extravasation: 
initially plasma-derived protein phase, and then a platelet-derived protein phase begins 
which may each have a specific biological role. 
 
Future studies of protein transport during pathological thrombus formation may also 
provide insight into the role of protein extravasation as a possible sink for thrombin. In 
chapter 2 we demonstrated that the pressure drop across the injury site is capable of 
altering thrombin localization. In vivo, vessel rupture induces a strong pressure drop 
across the injury site driving blood out of the vessel and into the extravascular space. 
This pressure drop is the difference between the pressure in the vessel lumen and the 
surrounding tissue. However, in common pathological thrombotic diseases - 
atherosclerotic plaque rupture, DVT, or aneurisms - the pressure drop is minimal 
potentially facilitating increased thrombin activity in the lumen of the vessel driving 
occlusive thrombus formation. In a high thrombin environment the ability of platelets to 
restrict thrombin movement may be even more important in shaping thrombus growth. 
 
Finally, we wanted to observe how these observations made in the microcirculation 
extend to larger vessels that have very different biology and physics. We developed a 
novel technique for monitoring thrombus formation in the mouse femoral artery and vein 
in response to laser injury. We found that the core and shell architecture observed in the 
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microvasculature was conserved in the femoral artery and vein, despite the thrombi 
being 5-10 fold larger in the femoral artery. We also found that ADP plays a very similar 
role in driving shell formation in the femoral artery. Thrombin, however, appeared to play 
no role in platelet recruitment, but still drove core formation. We also observed a 
significant delay in core formation in the femoral artery and vein compared to the 
microvasculature. Measurements of tissue factor distribution showed that tissue factor, 
while plentiful in the femoral artery vessel wall, was ~10-fold further from the vessel 
lumen than in the cremaster arterioles. Thus, the increased core size and distance 
separating the tissue factor and lumen may make thrombin generation and thrombus 
architecture even more dependent upon platelet packing and molecular transport than 
our current model in the mouse microcirculation.  
 
In conclusion, this work demonstrates the importance of molecular transport in shaping 
the hemostatic process, and identifies several key events in thrombus formation that are 
responsible to regulating intrathrombus transport. These studies outline a regulatory 
mechanism that shapes agonist gradients in a biochemically independent manner, and 
identify novel effects of outside-in, and P2Y12 signaling in shaping the intrathrombus 
microenvironment and local transport properties. Future studies may also reveal how 
agonist transport is altered during pathological thrombus formation, and inform the 
design of novel therapies.    
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